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A B S T R A C T
Background
This review is an update of the first Cochrane publication on selenium for preventing cancer (Dennert 2011).
Selenium is a metalloid with both nutritional and toxicological properties. Higher selenium exposure and selenium supplements have
been suggested to protect against several types of cancers.
Objectives
Two research questions were addressed in this review: What is the evidence for:
1. an aetiological relation between selenium exposure and cancer risk in humans? and
2. the efficacy of selenium supplementation for cancer prevention in humans?
Search methods
We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 1), MEDLINE
(Ovid, 1966 to February 2013 week 1), EMBASE (1980 to 2013 week 6), CancerLit (February 2004) and CCMed (February 2011).
As MEDLINE now includes the journals indexed in CancerLit, no further searches were conducted in this database after 2004.
Selection criteria
We included prospective observational studies (cohort studies including sub-cohort controlled studies and nested case-control studies)
and randomised controlled trials (RCTs) with healthy adult participants (18 years of age and older).
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Data collection and analysis
For observational studies, we conducted random effects meta-analyses when five or more studies were retrieved for a specific outcome.
For RCTs, we performed random effects meta-analyses when two or more studies were available. The risk of bias in observational
studies was assessed using forms adapted from the Newcastle-Ottawa Quality Assessment Scale for cohort and case-control studies; the
criteria specified in the Cochrane Handbook for Systematic Reviews of Interventions were used to evaluate the risk of bias in RCTs.
Main results
We included 55 prospective observational studies (including more than 1,100,000 participants) and eight RCTs (with a total of 44,743
participants). For the observational studies, we found lower cancer incidence (summary odds ratio (OR) 0.69, 95% confidence interval
(CI) 0.53 to 0.91, N = 8) and cancer mortality (OR 0.60, 95% CI 0.39 to 0.93, N = 6) associated with higher selenium exposure.
Gender-specific subgroup analysis provided no clear evidence of different effects in men and women (P value 0.47), although cancer
incidence was lower in men (OR 0.66, 95% CI 0.42 to 1.05, N = 6) than in women (OR 0.90, 95% CI 0.45 to 1.77, N = 2). The
most pronounced decreases in risk of site-specific cancers were seen for stomach, bladder and prostate cancers. However, these findings
have limitations due to study design, quality and heterogeneity that complicate interpretation of the summary statistics. Some studies
suggested that genetic factors may modify the relation between selenium and cancer risk-a hypothesis that deserves further investigation.
In RCTs, we found no clear evidence that selenium supplementation reduced the risk of any cancer (risk ratio (RR) 0.90, 95% CI 0.70
to 1.17, two studies, N = 4765) or cancer-related mortality (RR 0.81, 95% CI 0.49 to 1.32, two studies, N = 18,698), and this finding
was confirmed when the analysis was restricted to studies with low risk of bias. The effect on prostate cancer was imprecise (RR 0.90,
95% CI 0.71 to 1.14, four studies, N = 19,110), and when the analysis was limited to trials with low risk of bias, the interventions
showed no effect (RR 1.02, 95% CI 0.90 to 1.14, three studies, N = 18,183). The risk of non-melanoma skin cancer was increased
(RR 1.44, 95% CI 0.95 to 1.17, three studies, N = 1900). Results of two trials-the Nutritional Prevention of Cancer Trial (NPCT) and
the Selenium and Vitamin E Cancer Trial (SELECT)-also raised concerns about possible increased risk of type 2 diabetes, alopecia and
dermatitis due to selenium supplements. An early hypothesis generated by NPCT that individuals with the lowest blood selenium levels
at baseline could reduce their risk of cancer, particularly of prostate cancer, by increasing selenium intake has not been confirmed by
subsequent trials. As the RCT participants were overwhelmingly male (94%), gender differences could not be systematically assessed.
Authors’ conclusions
Although an inverse association between selenium exposure and the risk of some types of cancer was found in some observational studies,
this cannot be taken as evidence of a causal relation, and these results should be interpreted with caution. These studies have many
limitations, including issues with assessment of exposure to selenium and to its various chemical forms, heterogeneity, confounding
and other biases. Conflicting results including inverse, null and direct associations have been reported for some cancer types.
RCTs assessing the effects of selenium supplementation on cancer risk have yielded inconsistent results, although the most recent
studies, characterised by a low risk of bias, found no beneficial effect on cancer risk, more specifically on risk of prostate cancer, as well
as little evidence of any influence of baseline selenium status. Rather, some trials suggest harmful effects of selenium exposure. To date,
no convincing evidence suggests that selenium supplements can prevent cancer in humans.
P L A I N L A N G U A G E S U M M A R Y
Selenium for preventing cancer
Review question
We reviewed the evidence suggesting that selenium can help to prevent cancer. This review updates the first Cochrane review on this
topic (Dennert 2011).
Background
Selenium is a naturally occurring element found in crops, animal products and water. Small amounts of selenium are needed for proper
human nutrition. Starting in the 1960s, numerous studies reported that people with high levels of selenium in their diet or in their
body tissues had lower rates of cancer. Some laboratory studies also suggested that selenium could inhibit the growth of cancer cells.
This led to widespread interest and claims that taking selenium supplements could prevent cancer. Over the next decades, many more
studies were conducted to compare cancer rates among individuals with high and low selenium levels, and several trials were conducted
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in which individuals were randomly assigned to receive selenium supplements or placebo and then were followed so their cancer rates
could be determined. Particular interest focused on whether selenium could prevent prostate, skin or other specific types of cancer.
Study characteristics
This review includes 55 studies in which adults observed to have high or low selenium levels were followed over time to determine
whether they developed cancer, along with eight trials in which adults were randomly assigned to receive selenium supplements or
placebo. The evidence is current to February 2013.
Key results
We found limited evidence suggesting that individuals observed to have higher selenium levels have a lower incidence of cancer.
However, it is not possible to conclude from these studies that seleniumwas the reason for the lower cancer risk, because a high selenium
level might be associated with other factors that reduce cancer risk, such as a healthier diet or lifestyle. Also, selenium comes in many
different chemical forms that have different biological activity, and these studies did not identify which chemical forms were being
measured. Selenium levels in body tissues in which people might develop cancer (e.g. the prostate) also were not examined.
The randomised controlled trials that assessed whether taking selenium supplements might prevent cancer differed considerably in
methodological quality and are not equally reliable. Several studies reported that individuals receiving selenium supplements decreased
their liver cancer risk, but these studies reported insufficient details about their randomisation process and participant follow-up to be
convincing. Recent trials that were judged to be well conducted and reliable have found no effects of selenium on reducing the overall
risk of cancer or on reducing the risk of particular cancers, including prostate cancer. In contrast, some trials suggest that selenium may
increase the risk of non-melanoma skin cancer, as well as of type 2 diabetes, raising concern about the safety of selenium supplements.
Overall, no convincing evidence suggests that selenium supplements can prevent cancer. However, for a full understanding of the role
of this metalloid in cancer development, more research is needed on how selenium may act differently in individuals with different
genetic backgrounds or nutritional status, and on the different biological activities of the various selenium compounds, which are still
largely unknown.
B A C K G R O U N D
This review is an update of the first Cochrane publication on
selenium for preventing cancer (Dennert 2011).
Description of the condition
Cancer is a leading cause of death worldwide (WHO 2008). Ac-
cording to World Health Organization (WHO) estimates, 14.1
million people developed and 8.2 million died of cancer in 2012,
with more than half of all new cases occurring in less developed
regions of the world (IARC 2012).
The role of diet and nutrition in carcinogenesis and cancer preven-
tion has been an area of active research for decades. A holy grail has
been the identification of nutritional supplements with cancer pre-
ventive properties. Such dietary factors would clearly have major
public health implications, but unfortunately, investigations into
supplementation of various vitamins, trace elements and other di-
etary constituents have generally yielded disappointing and even
troubling results (Ashar 2010; Bjelakovic 2012; Driscoll 2010;
Fortmann 2013;Guallar 2013; Jerome-Morais 2011;Marik 2012;
Martinez 2012; Mayne 2012; Rocourt 2013).
Description of the intervention
The metalloid selenium is one of the dietary elements that has
received considerable attention as a potential cancer preventive
agent. Selenium is nutritionally essential for humans but is toxic
at higher levels, with a narrow safe range of intake (Rayman
2012; Vinceti 2013a; Vinceti 2013b). Whether selenium pro-
vides various health benefits (including a cancer preventive ef-
fect) beyond its essential nutritional role is a matter of ongo-
ing debate (Bodnar 2012; Fortmann 2013; Karp 2013; Lippman
2009, in: SELECT 2009; Rayman 2012; Stranges 2010; Vinceti
2013a; Vinceti 2013b; Vinceti 2013d). Humans usually ingest
this trace element with crop and animal products and sometimes
in functional foods or supplements (Hurst 2013; Vinceti 2000a).
Chemical forms and concentrations of selenium in environmen-
tal matrices, foods, drinking water and other sources of exposure
vary considerably, depending on factors such as plant and animal
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metabolism and growth conditions or animal nutrition (Rayman
2008a; Rayman 2008b).
Selenium species can be classified into organically bound selenium
forms (e.g. selenomethionine, selenocysteine) and inorganic forms
(e.g. selenate, selenite) (Gammelgaard 2011;Weekley 2013). Sele-
nium yeast refers to a selenium-enriched yeastmedium that usually
contains nearly entirely organically bound selenium with a high
proportion of selenomethionine (Block 2004; Rayman 2004).
The recommended intake of selenium differs between regulatory
agencies (Hurst 2013; Vinceti 2009; Vinceti 2013a). For example,
the US Institute of Medicine recommends a daily intake of 55
µg/d for adults (Institute of Medicine 2009), whereas the WHO
recommends values ranging from 25 to 34 µg/d, depending on age
and sex (WHO 2004). These various standards do not take into
account the chemical forms of selenium, despite growing evidence
of the importance of selenium speciation (Vinceti 2013a; Vinceti
2013c; Weekley 2013).
To prevent adverse effects due to excessive selenium intake, the
US Institute of Medicine has set the tolerable upper intake level
to 400 µg/d for adults (Office of Dietary Supplements 2009);
however, recent epidemiological studies suggest toxicity at lower
intake levels (Lippman 2009, in: SELECT 2009; Stranges 2007;
Vinceti 2013a). In addition to the acute and chronic toxicity
of high selenium exposure, possible harmful effects of long-term
intake of lower dosages have been a matter of concern. How-
ever, such effects are still inadequately investigated (Vinceti 2001;
Vinceti 2009). Furthermore, strong evidence shows different bio-
logical activities of the various organic and inorganic forms of sele-
nium (Hazane-Puch 2013; Rayman 2008a; Vinceti 2009; Vinceti
2013c; Weekley 2013), suggesting the opportunity to better char-
acterise the specific toxicological and nutritional properties of each
selenium species in humans, in animals and in the environment.
Recent publications have questioned the adequacy of the current
upper ’safe’ limit of intake (Jerome-Morais 2011; Morris 2013;
Moyad 2012; Rocourt 2013; Sacco 2013; Vinceti 2009; Vinceti
2013b) and have espoused the need to set different limits for the
many different sources of organic and inorganic selenium.
Accurate estimation of selenium exposure in epidemiological stud-
ies presents several challenges. Individual exposure is typically as-
sessed by using peripheral biomarkers of exposure, such as blood
(generally plasma or serum) or nail concentrations, or by esti-
mating dietary intake (Ashton 2009). All of these methods have
strengths and limitations, and their validity has been questioned
(Ashton 2009; Haldimann 1996; Vinceti 2013b). However, levels
of selenium in peripheral biomarkers such as blood, toenail and
hair have been found to correlate to amoderate degree with dietary
intake as assessed through self reported consumption of supple-
ments, food frequency questionnaires and dietary records (Hurst
2013; Longnecker 1996; Ovaskainen 1993; Pestitschek 2013; van
den Brandt 1993a). )Stronger correlation has been seen at high in-
take levels (Morris 2013), although results of other studieswere not
consistent (Hunter 1990; Karita 2003; Satia 2006; Vinceti 2012).
Assessment of selenium levels in highly specific body tissues, is ex-
tremely complex, as these levels are not necessarily homogeneously
reflected by all biomarkers because overall selenium exposure, as
well as its chemical forms and other factors, influences distribution
of the metalloid into various body compartments (Behne 1996;
Behne 2010; Panter 1996; Vinceti 2000a; Vinceti 2013c). For
example, circulating levels of some selenium species and of total
selenium did not correlate with selenium content in the central
nervous system as assessed by cerebrospinal fluid concentrations
(Solovyev 2013; Vinceti 2013c), indicating not only the tissue-
specific significance of biomarkers but also the importance of se-
lenium speciation when the distribution of selenium in different
body compartments is assessed, representing target organs for dif-
ferent diseases.
Selenium levels found in human specimens (Rayman 2008b), as
well as the estimated intake of selenium (Fairweather-Tait 2011;
Haldimann 1996; Jablonska 2013), show high global variability
due to factors such as dietary habits, ethnicity, gender, age, indi-
vidual metabolism, occupational exposure, exposure to coal and
other sources of combustion and smoking. It is interesting to note
that smoking tends to lower selenium biomarker concentrations,
although it is a source of selenium exposure (Jossa 1991; Kafai
2003)-a phenomenon that might be related to altered metabolism
of the metalloid due to an interaction with cadmium. Globally,
inconsistencies have been noted as to how these factors are associ-
ated with selenium levels (Haldimann 1996; Vinceti 2000a). For
example, selenium levels increased with age in women, but not in
men, in the French SU.VI.M.AX cohort study (Arnaud 2007) and
decreased with age in a female population in Ohio (Smith 2000);
however, two studies in Switzerland and Austria could not find
an association between age and selenium status in either gender
(Burri 2008; Gundacker 2006). Gender-specific nutritional and
health behaviours, aswell as gender-specific differences in selenium
metabolism,may contribute to observed discrepancies in selenium
levels betweenmales and females (Combs 2012; Rodriguez 1995).
Gender might more generally influence the ability of selenium to
induce adverse metabolic effects, as suggested by the recent ob-
servation of a direct association between metabolic syndrome and
selenium in females but not in males in a European case-control
study (Arnaud 2012).
How the intervention might work
The ability of selenium to counteract cancer cell growth, as has
been observed in a large number of laboratory studies, may be
due to its effects on DNA stability, cell proliferation, necrotic and
apoptotic cell death in healthy and malignant cells, regulation of
oxidative stress and the immune system (for reviews, see: Davis
2012; Jackson 2008; Steinbrenner 2013; Weekley 2013). These
features have also suggested the possibility of using selenium com-
pounds in cancer therapy-a hypothesis that has been under inves-
tigation (Chintala 2012; Fan 2013; Kim 2012; Sonaa 2013). Se-
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lenium may be involved in these processes through several mech-
anisms as a source of selenometabolites and as a component of se-
lenium-containing enzymes (Davis 2012; Hatfield 2009; Jackson
2008; Steinbrenner 2013; Weekley 2013). The optimum level for
the retardation of carcinogenesis in human cells has been debated
and is thought to be higher than the level commonly achieved
through dietary changes (Whanger 2004). However, in laboratory
studies, selenium has been shown to promote malignant cell trans-
formation and progression (Chen 2000; Kandas 2009; National
Toxicology Program 2011;Novoselov 2005; Rose 2014; Su 2005),
thus confirming a ‘dual personality’ of this Janus-faced element
and of selenoproteins in both preventing and promoting cancer
(Hatfield 2014).
Numerous epidemiological studies have reported an inverse asso-
ciation between selenium exposure and cancer risk. The first such
studies had ecological study designs (Schrauzer 1977; Shamberger
1969). These were followed by case-control and cohort observa-
tional studies and randomised trials, some of which received sub-
stantial attention from both the general population and the scien-
tific community (Brinkman 2006; Fortmann 2013; Steinbrenner
2013; Vinceti 2013b). Gender-related differences regarding the
effects of selenium on cancer risk have also been suggested by some
observational and experimental human studies, and differences
in selenium tissue distribution, tumour biology and other factors
have been suggested to explain a possible greater beneficial effect
in males than in females (NPCT 2002; Waters 2004).
Why it is important to do this review
Selenium has been suggested to be involved in central anticarcino-
genic processes. This has led to wide marketing of selenium sup-
plements with associated health claims, particularly the preven-
tion of both cancer (Dennert 2011; Vinceti 2013b) and cardio-
vascular disease (Rees 2013). In recent decades, worldwide debate
has continued about the association between selenium exposure
and cancer risk, including whether selenium supplements are ef-
fective in decreasing the incidence of or mortality from cancer.
Epidemiological and other data have yielded conflicting results,
sometimes suggesting different effects in men and women, and it
has been suggested that selenium supplements might even have
harmful effects. This review is timely and important, as several
meta-analyses and systematic reviews have been published, but
an updated comprehensive summary synthesising evidence from
both observational studies and intervention trials that include all
types of cancer and look for gender-related differences has not
been conducted since the
time of the first Cochrane publication on the use of selenium for
preventing cancer (Dennert 2011).
O B J E C T I V E S
Two research questions were addressed in this review: What is the
evidence for:
1. an aetiological relation between selenium exposure and
cancer risk in humans? and
2. the efficacy of selenium supplementation for cancer
prevention in humans?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and prospective observa-
tional studies (cohort studies and nested case-control studies) were
included, irrespective of publication year, publication status or
language, provided they were published in extenso. We did not
include conference abstracts in this review.
Types of participants
All adult participants (18 years of age and older).
Types of interventions
We considered prospective observational studies (cohort studies
and cohort-nested and nested case-control studies) for inclusion if
they assessed baseline exposure to selenium in apparently cancer-
free individuals either as biochemical selenium status or as esti-
mated selenium intake at study entry.
We considered RCTs for inclusion if they used selenium supple-
mentation at any dose or route of administration for a minimum
of four weeks versus placebo or no intervention. We excluded tri-
als using selenium supplementation as part of a multi-component
preparation without a study arm using selenium monotherapy
supplementation.
Types of outcome measures
We analysed primary and secondary outcomes.
Primary outcomes
1. Incidence of any cancer and of site-specific cancers, assessed
as the proportion of participants developing cancers during the
study period.
2. Mortality from any cancer and from site-specific cancer,
assessed as the proportion of participants dying from cancers
during the study period.
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Secondary outcomes
1. Incidence of selected adverse effects, assessed as the
proportion of participants developing adverse health conditions.
These outcomes were assessed in RCTs only.
Search methods for identification of studies
We conducted electronic searches of the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL, 2013, Issue 1), MED-
LINE (Ovid, 1966 to February 2013 week 1), EMBASE (1980 to
2013 week 6), CancerLit (February 2004) and CCMed (Febru-
ary 2011). We conducted the initial search in 2004 and updates
in July 2007, January 2009, October 2009, February 2011 and
February 2013. AsMEDLINE now includes the journals indexed
in CancerLit, no further searches were conducted in this database
after 2004.
We also searched the following online clinical trials databases in
the previous review (Dennert 2011).
1. Clinical Trials of the American Cancer Society (http://
www.cancer.gov, February 2011).
2. The metaRegister of Controlled Trials (mRCT, http://
www.controlled-trials.com, February 2011).
3. The German Cancer Study Register (http://
www.studien.de, February 2011).
4. The System for Information on Grey Literature in Europe
(SIGLE) (February 2004, discontinued in 2005).
The search strategies are provided in Appendix 1.
Data collection and analysis
Selection of studies
Two review authors independently checked all electronic search
results for eligibility. When search results could not be rejected
with certainty on the basis of title, abstract or both, we obtained
full-text material.
We scanned bibliographies of papers retrieved using the described
search strategy to identify additional studies. If additional infor-
mation was needed, we contacted the correspondent authors of
the included studies; we also asked investigators for information
about unpublished trials.
Two review authors (MV and MH) independently applied the
inclusion and exclusion criteria, if necessary with the assistance of
a translator.We resolved disagreements by discussion and with the
involvement of a third review author.
Data extraction and management
We used piloted extraction forms for epidemiological studies and
RCTs to document data from the original material and to assess
the quality of studies. One review author (CDG) extracted data,
and a second review author (MV) checked extracted data for dis-
crepancies, which were discussed between the two review authors
(CDG and MV). In a small number of cases, we sought the opin-
ion of a third review author (GD or CMC) to reach a consensus. If
several reports from the same study were available, we considered
as primary publications studies reporting the entire period of fol-
low-up with active selenium supplementation, when available, but
study details available from other publications were also extracted
if not reported in the primary study reference.
For comparison of selenium exposure measured in serum and
plasma specimens, we converted all data into the unit µg/L. Re-
sults provided as ppm (parts per million) or µg/g were converted
using the factor 1.026 g/mL (density of blood plasma), and data
provided as µmol/L were converted using the factor 78.96 (molec-
ular weight of selenium).
To be included, prospective observational studies had to report
estimates of risk ratio (RR), for example, odds ratio (OR), for
various selenium exposure levels. Studies reporting only the RR
for a one-unit increase in selenium exposure were not included in
the analysis.
Assessment of risk of bias in included studies
Observational studies
The risk of bias in observational studies was assessed using as-
sessment forms adapted from the Newcastle-Ottawa Quality As-
sessment Scale (NOS) for cohort and case-control studies (Wells
2004). The NOS form for cohort studies was used for all included
observational studies, and the NOS case-control form was used
for nested case-control studies. Both forms must be adapted a pri-
ori for use in a systematic review according to the research ques-
tion and the review topic. The NOS uses a star system in which
studies are judged on key domains pertaining to the selection and
comparability of study groups, the ascertainment of exposure and
outcome, and the duration of follow-up. For each domain, either a
’star’ or ’no star’ is assigned, with a ’star’ indicating that that study
design element was considered adequate and less likely to intro-
duce bias. A study could receive a maximum of nine stars in the
cohort assessment (Appendix 2) and nine stars in the assessment
of the case-control portion (Appendix 3).
The risk of bias assessment was based on data provided in the
included publications. We did not check other publications for
details if they were not included in the review. If an included study
encompassed more than one publication with divergent ratings in
the NOS, we used the publication with the highest score.
Randomised controlled trials
We categorised generation of allocation sequence, allocation con-
cealment, blinding and completeness of outcome data as adequate
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(low risk of bias), inadequate (high risk of bias) or unclear, ac-
cording to the criteria specified in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011a) and suggested by
Higgins et al. (Higgins 2011b). We considered these four items
to be key domains for risk of bias assessment. Studies that were
categorised as “adequate” in all four domains were considered to
have a low risk of bias; studies with inadequate procedures in one
or more key domains were considered to have a high risk of bias.
Studies with unclear procedures in one or more key domains were
considered to have an unclear risk of bias.
We assessed the fulfilment of ethical standards as follows.
1. Was informed consent obtained from participants? (yes/no/
unclear).
2. Was approval obtained from an ethics board? (yes/no/
unclear).
Measures of treatment effect
This review includes only the binary outcome of cancer diagnosis
(i.e. cancer incidence) or death from cancer (i.e. cancer mortality),
or a combination of both. The term ’cancer risk’ is used in this
paper as a generic term and refers generally to cancer incidence,
cancer mortality and combined incidence/mortality data.
For observational studies, we used the odds ratio (OR) or the risk
ratio (RR) and its 95% confidence interval (95% CI) as mea-
sures of the association between cancer risk and selenium expo-
sure. When adjusted ORs were reported, we used the OR with the
most extensive covariate adjustment reported in the publication.
For RCTs, we used RRs and their 95% CIs. When hazard ratios
(HRs) rather than RRs were reported in the original study, we
reported the individual study results as HRs with their 95% CIs;
however, when data from such studies were included in meta-
analyses, we entered the RRs, and only RRs were pooled.
Dealing with missing data
When data were missing or when discrepancies in study publica-
tions were found, we tried to contact the study investigators to
request further information. Contacting study authors helped to
clarify discrepancies in several publications (e.g. differing data in
text and tables within the same report); however, we retrieved no
missing data or study details.
Assessment of heterogeneity
We performed a Chi2 test for heterogeneity of study results. Ad-
ditionally, we used I2 statistics (Higgins 2003) to quantify incon-
sistency.
Assessment of reporting biases
The possibility of reporting bias was evaluated by using funnel
plots.
Data synthesis
We performed data synthesis and analysis separately for RCTs and
observational studies.
For observational studies, we conducted randomeffectsmeta-anal-
yses for all cancers or for site-specific cancers for which at least
five studies were available. We applied this restriction for two rea-
sons. The first was practical: to limit the number of analyses to
be performed. The second was that we expected results to be het-
erogeneous, but heterogeneity cannot be described and quantified
well if too few studies are available (Higgins 2009). Although the
cutoff at five studies is somewhat arbitrary, this decision was made
very early in the review process; it was declared in the protocol
and confirmed in its update. RCTs were less numerous, but given
their fundamental importance in epidemiological research, we de-
cided in the current review update to perform meta-analyses for
all cancers or site-specific cancers when data from two or more
trials were available.
Observational studies
We conducted random effects meta-analyses of summary statistics
from observational studies if data were available from at least five
studies for all cancers or specific types of cancer. We used the
OR or RR comparing the highest and lowest selenium exposure
categories. Effect estimates were entered as the natural logarithm
of the OR or RR, and the squared standard error of the natural
logarithm of the OR or RR was used as a weight. The latter was
calculated from the reported upper and lower boundaries of the
95% CI of the OR or RR. If a 95% CI was not reported, we used
the total number of cases and the total number of controls, as
well as the number of categories of selenium exposure, to estimate
the numbers of cases and controls per exposure category. We then
used the standard normal approximation formula to calculate the
standard error of the OR (comparing the highest versus the lowest
exposure category (lnOR = (1/a + 1/b + 1/c + 1/d), where a, b, c
and d are the four counts needed to calculate the OR via (a*d)/
(b*c)).
Meta-analyses were conducted by using STATA (version 10 to 12)
statistical software. We repeated meta-analyses that were included
in this review publication using the Review Manager 5 statistical
tool; for this, logarithmic data for the OR and the standard error
were copied from STATA into ReviewManager 5, and results were
double-checked for errors.
Randomised controlled trials
We performed random effects meta-analyses of summary statistics
using RCT data if data were available from at least two studies
for all cancers or specific types of cancer. When more than one
publication from the same trial was available and reported different
periods of follow-up for the same cancer site, we included in the
meta-analysis only the longest period of follow-up, provided that
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the experimental protocol was still ongoing at the time of follow-
up (i.e. that selenium supplementation was still actively supplied).
RRs and 95% CIs were calculated on the basis of the numbers of
participants and cases when these were provided in the publica-
tion, using the meta-analysis tool provided by Review Manager 5;
otherwise, we used the RRs reported in the original publication.
When an adjusted measure was also reported, we reported both
the crude RR and the adjusted RR. We also calculated the RR of
adverse outcomes and 95% CIs if sufficient data were available.
Subgroup analysis and investigation of heterogeneity
For observational studies, we used gender-disaggregated data from
mixed-gender studies, together with data from single-gender co-
horts, for subgroup analyses by gender. We conducted the latter
subgroup analyses to account for potential gender differences in
selenium health effects (see Background).
Sensitivity analysis
For RCTs, we repeated analyses confining the included studies
versus those with low risk of bias. For observational studies, we
conducted sensitivity analyses to assess the effects of the different
methods used to assess selenium status/intake.
R E S U L T S
Description of studies
Citation style: Please note that we reference the sources of relevant
information in a certain way to enhance traceability of our results
for interested readers. When the source of information is not the
primary publication of an included study, the specific publication
of interest is also referenced. For example “Hakama 1990, in:
Knekt 1990” indicates that the cited paper is “Hakama 1990” as
part of the mentioned study.
Three full-text theses published in the US could not be accessed
(Coates 1987, in: Coates 1988; Menkes 1986a, in: Menkes 1986;
Schober 1986, in: Menkes 1986). However, later journal publica-
tions were available and were included in this review as main study
publications (Coates 1988, in: Coates 1988; Menkes 1986b, in:
Menkes 1986; Schober 1987, in: Menkes 1986). Thus retrieval of
the full-text theses was considered to be unnecessary.
Results of the search
In the previous Cochrane review, of 4082 hits of potential rele-
vance, 268 publications were retrieved in full text. Of these, 137
papers were considered as relevant (see the flow chart of the liter-
ature search in Dennert 2011).
In our updated search, after internal duplicates and duplicates
against the database of the literature search conducted in January
2011were excluded, 766 hits were retrieved.Of these, we excluded
744 references as being clearly irrelevant on the basis of title and
abstract (flow chart of literature search: Figure 1). The reasons for
exclusion were as follows.
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Figure 1. Flow chart.
1. Type of study: no prospective observational study or no
randomised controlled trial (n = 213).
2. Type of outcome measure: no cancer epidemiology/
prevention (n = 86).
3. Types of participants: no healthy adults (n = 397).
4. Type of exposure/intervention: no selenium exposure or no
selenium supplements (n = 48).
The remaining 22 publications were considered of possible rele-
vance and were reevaluated and retrieved in full text from this up-
dated search (268 were retrieved in full text from the previous re-
view). Upon further review, 11 of these publications were deemed
relevant.
Included studies
In total, from the previous Cochrane review and from our update,
148 papers were identified for inclusion in this review: 89 papers
referred to one ongoing and 55 completed observational studies,
and 59 papers referred to four ongoing and eight completedRCTs.
A detailed description of the studies included is given in the table
Characteristics of included studies.
1. Observational studies
Fifty-five completed observational studies were included in this re-
view. Forty-one studies were nested case-control studies, the others
were subcohort controlled or cohort studies, and one study used a
cohort together with a nested case-control design. Subcohort con-
trolled studies used (random) samples of the cohort as controls.
The original papers were published between 1983 and 2013. Six
9Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
studies were conducted in Asia (China, Japan and Taiwan), one
in Australia, 22 in Europe (including data from Belgium, Den-
mark, Germany, Greece, Italy, Netherlands, Norway, Spain, Swe-
den, Channel Islands, Finland, France and UK) and 25 in the US.
Overall, the studies included more than 1,100,000 participants.
European study populations made up 45%, US 45%, Asia 9.4%
and Australia 0.2% of all study participants. The median size of
the study populations was 8801. Twenty-eight studies included
men andwomen, one did not report gender, 21 included onlymen
and five only women. For a substantial proportion of the study
populations (38%), gender was not reported. Forty-three percent
of participants were men, and 23% were women. Six studies with
mixed-gender populations reported results stratified by gender.
The study populations were derived from 48 different cohorts.
Twenty-three cohorts were non-randomly recruited (e.g. included
volunteers), and 20 cohorts consisted of a random (or total) sam-
ple of the population of interest, which was either a specifically
exposed population such as male tin-miners in China or the gen-
eral population.
Forty-three studies specified the age range of their included par-
ticipants; most included adults older than 40 years of age.
Seven studies investigated nutritional and/or supplemental sele-
nium intake by using food frequency questionnaires or interviews.
Forty-eight studies assessed biochemical selenium status where:
1. 8 used toenail specimens,
2. 12 plasma specimens,
3. 27 serum specimens,
4. and one used both serum and plasma specimens.
One study measured both serum selenium levels and intake.
The mean follow-up period was up to three years in five studies
and longer than three years in the remaining studies. Generally,
study authors grouped the cases according to the International
Classification of Diseases (ICD) classification that was up-to-date
at the inception of the cohort observation. The level of disaggrega-
tion of data varied markedly between the studies. Although some
studies reported cancer risk according to organ system (e.g. urinary
tract, respiratory tract), others reported cancer risk for one or two
organs (e.g. female breast, urinary bladder). Only in the case of
skin cancer did studies also differentiate according to histological
type (e.g. melanoma, basal cell carcinoma).
For the following outcomes, five or more studies were included in
the review, and observational data were meta-analysed.
1. Any cancer (16 studies).
2. Female breast cancer (7 studies).
3. Urinary bladder cancer (6 studies).
4. Lung cancer (14 studies).
5. Prostate cancer (17 studies).
6. Stomach cancer (5 studies).
7. Colon/colorectal cancer (5 studies).
Bates 2011 was not included in the meta-analysis for any cancer,
as it provided only the HR associated with an increase of one
standard deviation of selenium exposure.
Table 1 provides an overview of the studies for each outcome. Five
studies gave data for the group of “other” cancers, which encom-
passed any type of cancer not reported separately in the study pub-
lications. The definition of “other” cancers varied between stud-
ies, including predominantly rare cancers but also cancers of un-
known origin. The results of the studies within the category “other
cancers” are mentioned for the sake of completeness; however, be-
cause of the diversity of outcomes, the results were not included
in further analysis or discussion of this review.
2. Randomised controlled trials
Eight randomised controlled trials with a total of 44,743 partic-
ipants (94% men) were included in this review. All used paral-
lel-group designs with two arms (Dreno 2007; Li 2000; Marshall
2011; NPCT 2002; Reid 2008; Yu 1991; Yu 1997), three arms
(Algotar 2013) or four arms (SELECT 2009). Three were con-
ducted in China (Li 2000; Yu 1991; Yu 1997), three in the US
(Marshall 2011; NPCT 2002; Reid 2008), one in the US/New
Zealand (Algotar 2013) and one in the US/Canada/Puerto Rico
(SELECT 2009).
Selenium supplements and placebos were administered daily. As
an active intervention, trials used 200 µg/d (Dreno 2007;Marshall
2011; NPCT 2002; Yu 1991; Yu 1997) or 400 µg/d (Reid 2008)
selenium in the form of selenised yeast tablets, composed nearly
entirely of organic selenium and particularly of selenomethionine
(Block 2004). Algotar 2013 used 200 µg and 400 µg as different
arms. Li 2000 used 500 µg sodium selenite, and SELECT 2009
used 200 µg/L selenomethionine.
Three Chinese trials investigated the preventive efficacy of sele-
nium supplementation against primary liver cancer in different
high-risk populations. Participants were carriers of the hepatitis
B surface antigen (HBs-Ag) with normal liver function or first-
degree relatives of liver cancer patients. Two trials used selenised
yeast (Yu 1991; Yu 1997), and one used sodium selenite (Li 2000).
The Nutritional Prevention of Cancer Trial (NPCT) investigated
the influence of selenium on the development of non-melanoma
skin cancer (basal and squamous cell carcinoma) in a population
considered at high risk of the disease, namely, patients with a his-
tory of non-melanoma skin cancer (NPCT 2002). Participants
were 1312 men and women from the eastern US 18 to 80 years of
age, with a history of two or more basal cell carcinomas or of one
squamous cell carcinoma. RR estimates for basal cell carcinoma,
squamous cell carcinoma and overall non-melanoma skin cancer
were reported for two periods of follow-up: an intermediate study
period (from 15 September 1983 to 31 December 1993: Clark
1996, in: NPCT 2002) and the entire blinded intervention period
(from 15 September 1983 to 31 January 1996: Duffield-Lillico
2002 for the secondary outcomes; Duffield-Lillico 2003 for the
primary outcome, i.e. non-melanoma skin cancer; and Duffield-
Lillico 2003 for an in-depth analysis of prostate cancer risk; see
NPCT 2002). In the present analysis, only the final reports con-
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cerning the entire period of blinded follow-up, also characterised
by active administration of selenium supplements, were used.
In 1990, additional secondary endpoints were identified post hoc
in NPCT 2002 (total cancer mortality, total cancer incidence,
incidence of lung, prostate and colorectal cancers). The inci-
dences of female breast cancer, bladder cancer, oesophageal can-
cer, melanoma, haematological cancer and cancers of the head and
neck were also reported in trial publications (NPCT 2002).
A substudy of the NPCT (Reid 2008) investigated the efficacy of a
higher selenium dose, supplied as selenised yeast orally, in the pre-
vention of non-melanoma skin cancer at one of the NPCT study
sites. Study design was similar to theNPCT study, except that 423
participants at this site were randomly assigned to placebo or in-
tervention with higher selenium content. Reid 2008 also reported
the incidence of internal cancers.
The incidence of skin cancer was evaluated as a secondary out-
come by Dreno 2007 in a group of 184 organ transplant recipi-
ents who received 200 µg/d of selenium for three years and then
were followed up for an additional two years. In this multi-centre,
randomised, placebo-controlled trial, 91 selenium-supplemented
participants and 93 non-supplemented participants were moni-
tored for the development of both non-malignant (warts and var-
ious keratoses) and malignant skin lesions.
The Selenium and Vitamin E Cancer Prevention Trial (SELECT
2009) investigated the effect of selenium as L-selenomethionine
and/or vitamin E supplementation in men of diverse ethnic back-
grounds against the development of prostate cancer and other ’sec-
ondary’ outcomes (i.e. the risk of all cancers, lung cancer, colorec-
tal cancer, and bladder cancer). This study was a very large phase
3 randomised, placebo-controlled trial, activated in June 2001
and originally designed for a seven- to 12-year period of follow-
up, carried out at 427 sites in the US, Canada and Puerto Rico.
However, the independent Data and Safety Monitoring Commi-
tee recommended in September 15, 2008, the discontinuation of
study supplements based on the absence of benefit from vitamin
E or selenium and no possibility of a benefit to the planned de-
gree with additional follow-up (SELECT 2009). The committee
also expressed concern about increased prostate cancer risk among
vitamin E-treated participants and increased diabetes risk among
selenium-supplemented participants (SELECT 2009). Adminis-
tration of these supplements was therefore discontinued on Oc-
tober 23, 2008, in spite of the planned supplementation period
of 12 years. The results of SELECT are based on the follow-up
provided at the end of the blinded supplementation period, which
included 117,660 person-years of follow-up, and not on an ex-
tended period of follow-up, which encompassed an additional 32
months of surveillance (144,846 person-years in total) after the
end of the supplementation period. The endpoints were prostate
cancer (the ’primary’ endpoint) and colorectal cancer, lung cancer,
all the other cancers and all cancers overall. A subsequent study
from SELECT also evaluated the risk of bladder cancer, adding to
the standard follow-up an additional post supplementation period
of 32 months (SELECT 2009).
The effect of selenium supplementation on prostate cancer was
also evaluated in two phase 3 trials published in 2011 (Marshall
2011) and in 2013 (Algotar 2013). In Marshall 2011, 423 men
with high-grade prostatic intraepithelial neoplasia, and therefore
considered to be at very high risk of prostate cancer, were randomly
assigned to selenium (200 µg/d as selenomethionine) or placebo.
Algotar 2013 evaluated whether supplementation with 200 or 400
µg/d of selenium as selenised yeast reduced the risk of prostate
cancer among men at high risk of the disease, based on a prostate-
specific antigen (PSA) level exceeding 4 ng/L, suspicious digital
rectal examination and PSA velocity greater than 0.75 ng/mL/y.
The trial, called ’The Negative Biopsy Trial’, followed the study
participants for five years in the US (where both supplementation
and follow-up were complete for such period) and for no longer
than three years in New Zealand, and was discontinued after a
recommendation to stop the trial was issued by an external Data
and Safety Monitoring Committee.
Excluded studies
Of 22 potentially relevant papers retrieved in the updated search,
11 papers did not fulfil the inclusion criteria. Nine of these pub-
lications were rejected as including duplication of data from al-
ready included studies or posters/abstracts at meetings; two pa-
pers were excluded because cancer was not a study endpoint. The
table Characteristics of excluded studies describes the reasons for
exclusion from the previous Cochrane review (see Dennert 2011
for the main reasons for exclusion) and from this update.
Risk of bias in included studies
Observational studies
A summary of study ratings according to the Newcastle-Ottawa
Scale (NOS) is presented in Table 2. The median number of as-
signed stars was eight for the (nested) case-control study assess-
ments and seven for the cohort study assessments, out of a maxi-
mum of nine stars each (Figure 2 and Figure 3).
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Figure 2. Newcastle-Ottawa Scale: number of studies by number of “stars” assigned in the case-control
portion of studies.
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Figure 3. Newcastle-Ottawa Scale: number of studies by number of “stars” assigned in the cohort portion
of studies.
All but one cohort study received five to nine stars on the NOS.
The exception (two stars) was an early investigation, which was
available only in abstract form for assessment (Clark 1985). For
three items on the NOS cohort assessment, 85% of the included
studies were considered adequate: representativeness of the cohort
for the target population (58% of the studies received a star),
demonstration that cancer was not present at study commence-
ment (85%) and completeness of follow-up data (58%).
The representativeness of the cohort for the target population is a
matter of external validity and generalisability of study results, but
a systematic deviation of participants from the target population
might also introduce bias into study results. The target population
of included studies depended on the study objectives and could
have been the general population, as well as special occupational
groups. Studies that did not identify their target population or
recruited volunteers were not assigned a star for this question. Dif-
ferential selection of study participants (e.g. volunteers) from the
target population can lead to confounding by factors associated
with selenium status and cancer incidence (e.g. nutritional be-
haviour, socioeconomic position). All included studies chose com-
parison groups (cases/controls or exposed/non-exposed) from the
same study population. This approach enhanced comparability
between groups.
Follow-up data were considered as complete or as missing data
unlikely to introduce bias to study results in 45% of included ob-
servational studies. In the other cohorts, losses to follow-up were
greater than 5% and a description of losses to follow-up was not
provided. A high attrition rate may alter the characteristics of the
population under investigation and may impede the generalisabil-
ity of study results to the intended target population (external va-
lidity). The presence of attrition does not necessarily mean that
the study results are biased. However, given the possibility that
selenium status may be linked to sociodemographic variables and
socioeconomic position, whichmay also influence participation in
follow-up procedures, a differential effect of attrition may intro-
duce bias towards underestimation or overestimation of the true
exposure effect.
Forty-one included observational studies were nested case-control
studies and therefore were assessed using the NOS case-control
form. The number of stars in the NOS assessment of the case-
control studies ranged from five to nine, with 89% receiving eight
or nine stars. Although the included prospective case-control stud-
ies were generally assessed as having a low risk of bias, in some
studies concern arose regarding case definition and the question
of representativeness of the cases.
The definition of cases was considered inadequate in 44% of the
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nested case-control studies, as cases were identified by self report-
ing; linkage to databases with unclear validity or procedures was
not described. The magnitude and direction of bias that might
have been introduced to the study results remain unclear.
In 22% of studies, not all identified cases (or an appropriate sam-
ple of them) were included in the trial analyses, or selection proce-
dures for analysed cases were not reported. In some studies, blood
specimens were lost as the result of technical problems (e.g. cooler
breakdown at one study centre); in other studies, material available
for analysis was insufficient; and in others, cases for analysis were
selected in a non-random manner. This might bias the estimates
of association in either direction.
No obvious asymmetry (as an indicator of publication bias) was
noted in the funnel plots of the studies on total and prostate cancer
risk (Figure 4 and Figure 5).
Figure 4. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 1.17 Total
cancer incidence and mortality.
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Figure 5. Funnel plot of comparison: 1 Highest versus lowest selenium exposure, outcome: 1.7 Prostate
cancer risk.
Randomised controlled trials
An overview of the risk of bias in the included randomised con-
trolled trials, performed according to Cochrane criteria for bias
assessment (Higgins 2011a; Higgins 2011b), is presented in Table
3.
All three trials on liver cancer risk (Li 2000; Yu 1991; Yu 1997)
were considered to have an unclear risk of bias. In these trials,
generation of allocation sequence and allocation concealment were
not reported. One study mentioned that the dropout rate was
similar in the intervention and control groups; the remaining two
studies did not report the completeness of outcome data. Blinding
was judged as adequate in all three studies, as the use of placebo
supplements was reported. We inferred from this procedure that
at least the study participants and the physicians directly involved
were blinded towards treatment status.
It is unclear whether Li 2000 was an individually randomised con-
trolled trial. Study investigators used the phrase ’randomisation
based on the residence area’ and did not describe the randomisa-
tion procedure any further. As participants were recruited from
17 villages, the villages, not the individual participants, may have
been randomly assigned to the intervention and control groups.
However, we could not make contact with the study investiga-
tors to clarify these questions. Randomisation of villages instead
of individuals could have introduced bias to the study results, as
the incidence of liver cancer is known to differ between areas as a
result of environmental factors.
RCTs with inadequate or unclear allocation concealment have
been found to overestimate the benefit of interventions, especially
trials with subjective outcomes (Pildal 2007; Wood 2008). In all
three liver cancer RCTs, follow-up and case detection procedures
were not reported, so the influence of subjective factors on case
detection, such as interpretation of bodily symptoms as triggers of
further diagnostic tests, is unknown. Although we judged blinding
as ’adequate’ in all three liver cancer trials, we do not knowwhether
it was successful in practice for participants, healthcare providers
and outcome assessors.
These uncertainties about study methods seriously weaken our
confidence in reported RCT results on liver cancer risk.
SELECT 2009, Algotar 2013 andMarshall 2011 were considered
to have a low risk of bias because they reported adequate genera-
tion of allocation sequence, allocation concealment, blinding and
completeness of outcome data.
Dreno 2007 and Duffield-Lillico 2002 to 2003, in: NPCT 2002
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were judged to have unclear risk of bias. Dreno 2007 provided
unclear generation of allocation sequence, allocation concealment
and blinding; only completeness of outcome data was adequate.
NPCT was considered to be at unclear risk of bias because of ex-
posure-related detection bias for its primary outcome, as the per-
centage of study participants with an abnormal PSA (> 4 ng/mL)
who underwent biopsy varied according to selenium treatment
group, with 35% in the placebo group and 14% in the selenium-
treated group (Duffield-Lillico 2003, in: NPCT 2002; Marshall
2011). In analyses stratified by baseline selenium concentration,
the difference was greatest among participants in the lowest ter-
tile, in whom the inverse association between selenium adminis-
tration and prostate cancer risk was strongest. The difference in
biopsy rates could not be accounted for by factors such as PSA
concentration, age at which abnormal PSA was detected and al-
ternative diagnostic procedures. Although a difference this large
could have occurred by chance, this finding raises concerns about
possible disruption of blinding. No information was provided as
to the prostate biopsy rate among participants with lower PSA
levels or biopsy rates for the primary outcome of non-melanoma
skin cancer, which also requires pathological confirmation, nor for
the other secondary outcomes examined in this trial.
Ethical criteria
Informed consent and ethics board approval were fulfilled by all
trials (Algotar 2013; Dreno 2007; Marshall 2011; NPCT 2002;
Reid 2008; SELECT 2009), except for Li 2000, Yu 1997, and Yu
1991, in which they were not mentioned.
Effects of interventions
1. Observational studies
When the risk of cancer for higher and lower levels of selenium
exposure is compared, a summary risk estimate of one suggests
that there is no association between selenium exposure and cancer,
a summary risk estimate below one suggests a possible protective
effect of higher selenium exposure and a summary risk estimate
above one suggests a possible harmful effect of higher selenium
exposure.
1.1. Aetiological association: results from meta-analyses
1.1.1. Any cancer
Results of 16 prospective observational studies on total cancer risk,
including data on more than 144,000 participants, were meta-
analysed. The cohorts of Salonen 1984 and Salonen 1985 over-
lapped. Hence, only data from Salonen 1985 were included in the
meta-analysis. Fex 1987 had to be omitted, as the CI value was
not reported and could not be calculated from the available data.
For participants in the highest category of prediagnostic selenium
exposure, the summary risk estimate was OR 0.69 (95% CI 0.53
to 0.91) for cancer incidence and OR 0.60 (95% CI 0.39 to 0.93)
for cancer mortality for both genders combined (Analysis 1.1)
when compared with participants in the lowest exposure category.
Heterogeneity was observed for both incidence (I² = 49%) and
mortality (I² = 62%).
Analyses by gender found lower point estimates for men (inci-
dence: OR 0.66, 95% CI 0.42 to 1.05; mortality: OR 0.56, 95%
CI 0.38 to 0.81) (Analysis 1.2) than for women (incidence: OR
0.90, 95% CI 0.45 to 1.77; mortality: OR 0.92, 95% CI 0.79
to 1.07) (Analysis 1.3), However, a test for subgroup differences
found no clear evidence of different effects in men and women (P
value 0.47).
All studies used either serumor serum and plasma biomarker levels
for assessment of selenium status. Analysis 1.4 shows the results in
ascending order of baseline exposure for those studies that reported
category borders. The graph does not reveal a clear pattern of a
relation between baseline biomarker level and cancer risk.
1.1.2. Female breast cancer
Eight studies were included in the meta-analysis. No association
was seen between baseline selenium levels and breast cancer risk,
with overall OR 0.91 (95% CI 0.69 to 1.20) (Analysis 1.5). The
heterogeneity of results (I² = 38%) was low.
1.1.3. Bladder cancer
Meta-analysis of bladder cancer incidence in five observational
studies found an inverse association, with an overall risk estimate
of 0.67 (95% CI 0.46 to 0.97), suggesting a protective effect of
higher selenium levels against bladder cancer (Analysis 1.6) (overall
heterogeneity: I² = 30%).
Gender-disaggregated data were available only from Michaud
2005, indicating a protective effect in women, but not in men in
this study. However, two studies (Michaud 2002; Nomura 1987)
included only male participants, and both found a reduced but
statistically very imprecise bladder cancer risk for higher selenium
exposure (Analysis 1.6). Heterogeneity was not reduced by gender
stratification (I² = 40% in study results for men).
1.1.4. Lung cancer
Twelve studies were included in this meta-analysis. Data from
Menkes 1986 and Knekt 1990 were not meta-analysed, as the
study population of the former overlapped with that of another
meta-analysed study (Comstock 1997) and results of the latter
were presented in insufficient detail.
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The summary risk estimate for lung cancer incidence for both
genders combined was 0.75 (95% CI 0.54 to 1.03) (Analysis 1.7).
Moderate heterogeneity was seen between study results (I² = 54%).
In the meta-analysis according to gender using gender-stratified
study results (Analysis 1.8), the summary risk estimate for women
wasOR0.83 (95%CI0.43 to 1.61) and formenOR0.98 (95%CI
0.68 to 1.39). Heterogeneity among study results was not reduced
by stratification. However, we expected the results for gender-
combined data to be more or less a combination of the separate
results for women and men. This was not the case here, with
’gender-neutral’ data suggesting a greater protective effect thanwas
seen with gender-stratified data. This discrepancy might be related
to differences in study design or in study populations. In Knekt
1998, 95% of lung cancer cases occurred in men. We repeated
the meta-analysis of gender-disaggregated data categorising Knekt
1998 as a ’men-only’ study and found a slightly changed summary
relative risk estimate for men (OR 0.81, 95% CI 0.56 to 1.18).
The only study that used nutritional intake assessment for expo-
sure classification (Kromhout 1987) found no association with
lung cancer risk (Analysis 1.9). Two studies measured selenium
content in toenails, with inconsistent results: participants (all
women) in the Nurses’ Health Study (Garland 1995) showed in-
creased lung cancer risk with higher selenium toenail levels, al-
though an inverse association was observed in the Netherlands co-
hort study (van den Brandt 1993a). The remaining nine studies
used serum or plasma selenium levels. The summary ORwas 0.91
(95% CI 0.70 to 1.018) with low heterogeneity (I² = 33%).
We plotted the studies using serum/plasma in ascending order of
baseline exposure level (Analysis 1.10). No clear pattern of a rela-
tion between baseline exposure levels and lung cancer risk could be
seen on this graph. The two studies suggesting the greatest protec-
tive effect of higher selenium levels were Knekt 1998 and Kabuto
1994. However, two other studies with similar biomarker levels
reported discrepant results (Nomura 1987; Ratnasinghe 2000).
A recent Danish study also found a direct association between
baseline selenium exposure and subsequent lung cancer incidence,
whichwas considerably enhanced in smokers characterised by high
serum cotinine levels (Suadicani 2012),
1.1.5. Prostate cancer
Seventeen epidemiological studies on prostate cancer incidence
were included in the meta-analysis. The summary risk estimate
for higher selenium exposure was OR 0.79 (95% CI 0.69 to 0.90)
(heterogeneity: I² = 23%) (Analysis 1.11).
Stratification by method of selenium assessment showed a reduc-
tion in prostate cancer risk for higher baseline biochemical mark-
ers (OR 0.76, 95% CI 0.67 to 0.88) but not for higher estimated
selenium intake (OR 1.00, 95% CI 0.73 to 1.36) (Analysis 1.12).
The inverse association between selenium biomarkers and prostate
cancer incidence was stronger for toenail levels (OR 0.53, 95%
CI 0.35 to 0.81) than for blood levels (OR 0.82, 95% CI 0.72
to 0.93) (Analysis 1.13). Heterogeneity among study results was
slightly reduced by these stratifications.
Stratification by country and by continent found the risk reduc-
tion more pronounced in the US than in Europe (Analysis 1.14;
Analysis 1.15).
Overall, the strongest inverse associations were seen in studies
from the US published before 2001. These findings cannot be ex-
plained by differences in baseline selenium levels alone. Analysis
1.16 shows the results of studies using serum or plasma mea-
surements in ascending order of selenium levels. For similar cat-
egories of selenium concentration, studies indicated different ef-
fects (Goodman 2001 versus Clark 1985; Nomura 2000 versus
Peters 2007 and Gill 2009, see Epplein 2009).
1.1.6. Stomach cancer
Five observational studies were included in the meta-analysis of
gastric cancer incidence. The summary risk estimate for both gen-
ders combined was OR 0.66 (95% CI 0.43 to 1.01) in the high-
est exposure category when compared with the lowest (I² = 51%)
(Analysis 1.17). However, in this meta-analysis, one cohort (Mark
2000, in: Wei 2004) is included twice because the results were re-
ported stratified according to cardia and non-cardia gastric cancer.
We repeated the meta-analyses and included the results of Mark
2000 (see: Wei 2004) for cardia and non-cardia gastric cancer
separately. The summary OR was 0.75 (95% CI 0.47 to 1.21)
when data for non-cardia cancer were included andOR0.59 (95%
CI 0.38 to 0.93) when data for cardia cancer were included.
Using the available gender-stratified results for meta-analysis, the
risk estimate for men was OR 0.43 (95% CI 0.14 to 1.32) (I² =
56%) and for women OR 0.73 (95% CI 0.12 to 4.35) (I² = 62%)
(Analysis 1.18).
1.1.7. Colon/colorectal cancer
Five observational studies reported data on colon or colorectal
cancer incidence. The summary risk estimate was OR 0.89 (95%
CI 0.65 to 1.23) for both genders combined (I² = 3.8%) (Analysis
1.19), OR 0.69 (95% CI 0.42 to 1.12) for men and OR 1.06
(95% CI 0.57 to 2.00) for women (Analysis 1.20).
1.2. Aetiological association: other results
For all other types of cancer, data were available from fewer than
five epidemiological studies; thus results were not meta-analysed.
Results of observational studies not included in meta-analyses are
reported in Table 4. None of the study results supported an as-
sociation between selenium exposure and gynaecological cancer
risk, and results for cancers of the gastrointestinal, respiratory or
urological tract were inconsistent. For respiratory and urological
cancers, studies reported either no association or increased risk for
participants with a higher selenium exposure. For gastrointestinal
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cancers, studies found either no association or reduced risk with a
higher selenium exposure.
2. Randomised controlled trials
We report results fromDuffield-Lillico 2002 for all evaluated out-
comes in the NPCT study (NPCT 2002) (prostate, lung, bladder,
colorectal and breast cancer; any cancer; and death from cancer),
except for prostate cancer, for which we also used Duffield-Lillico
2003BJU, and for the primary outcome, non-melanoma skin can-
cer, whose results were reported in Duffield-Lillico 2003 JNCI.
For the SELECT study (SELECT 2009), we included only the
results from Lippman 2009, which reported on the blinded pe-
riod of follow-up with continuing selenium supplementation, not
fromKlein 2011, which reported a longer period of follow-up, in-
cluding a subsequent period without selenium supplementation,
discontinued in 2008 in compliance with the recommendation of
the trial’s independent Data and Safety Monitoring Committee.
This second report by Klein et al. included an additional period of
32 months (23% person-time increase) along with the first follow-
up period, and results were essentially similar to those of Lipp-
man et al. 2009. For bladder cancer risk in SELECT, we used data
from Lotan 2012, which encompassed the same extended period
of follow-up as Klein 2011 but was the only available report from
the SELECT trial on this cancer type.
2.1. Preventive efficacy outcomes
2.1.1. Any cancer incidence and mortality
The outcomes of any cancer incidence and any cancer mortality
were evaluated by pooling the data from two studies-NPCT 2002
and SELECT 2009. For RCTs, we repeated analyses confined to
trials with low risk of bias; for any cancer incidence and mortality
outcomes, analysis was limited to SELECT alone. We observed
no evidence of reduced incident cancer risk (RR 0.90, 95% CI
0.70 to 1.17) (Analysis 2.1) or cancer mortality (RR 0.81, 95%
CI 0.49 to 1.32) (Analysis 2.2) in the selenium group compared
with the placebo group. When analysis was limited to SELECT,
no evidence was found of an effect on all cancers (RR 1.01, 95%
CI 0.92 to 1.11) or on death from cancer (RR 1.02, 95% CI 0.80
to 1.30).
2.1.2. Primary liver cancer
Three RCTs investigated the efficacy of selenium supplementation
for liver cancer prevention. All three were conducted inChinawith
participants of different high-risk groups in Qidong province.
Yu 1991 reported on a trial with 2474 male and female first-degree
relatives of liver cancer patients. During the study period of two
years, 10 participants in the selenium group, who received 200 µg
selenium yeast/d, and 13 participants in the placebo group were
observed (RR 0.55, 95% CI 0.24 to 1.25).
Yu 1997 investigated a four-year supplementation periodwith 200
µg selenium yeast/d in 226 male and female hepatitis B-surface
antigen (HBs-Ag) carriers. Eleven cases (person-time incidence
rate: 1573.03/100,000) were detected in the placebo group and
four cases in the selenium group (RR 0.36, 95% CI 0.12 to 1.11)
during the eight-year follow-up period. The mean blood selenium
level during the intervention period was 152 ng/mL in the inter-
vention group and 107 ng/mL in the control group.
Li 2000 randomly assigned 2065 male HBs-Ag carriers to receive
0.5mg sodium selenite or placebo daily for three years. Thirty-four
cases of liver cancer occurred among 1112 participants receiving
selenium and 57 cases among 953 placebo participants (RR 0.51,
95% CI 0.34 to 0.77).
The pooled risk ratio of the three studies was 0.50, with 95% CI
0.35 to 0.77, corresponding to a strong reduction in the incidence
of liver cancer in participants assigned to selenium compared with
those assigned to placebo (Analysis 2.3). However, all three trials
were considered to have an unclear risk of bias, caused by lack
of clear reporting of generation of allocation sequence, allocation
concealment and/or completeness of outcome data.
2.1.3. Non-melanoma skin cancer
2.1.3.1. Total non-melanoma skin cancer
Higher risk for non-melanoma skin cancer was seen in the se-
lenium supplementation group (200 µg/d) of the NPCT com-
pared with the placebo group (unadjusted RR 1.27, 95% CI 1.11
to 1.45) (Duffield-Lillico 2003a, in: NPCT 2002). This increase
was confirmed by multivariate analysis after adjustment for con-
founders (HR 1.17, 95% CI 1.02 to 1.34) and was concentrated
among participants in the highest two tertiles of baseline plasma
selenium (≥ 105.6 ng/mL). No variation in this effect appeared
to be induced by age, gender or smoking habits. Eliminating cases
that occurred during the first period of selenium supplementation
(one to two years) induced a slight decline in RRs. The mean se-
lenium plasma concentration of participants was 114 ng/mL at
the time of randomisation. Increased risk for total non-melanoma
skin cancer was seen in all tertiles of baseline plasma selenium lev-
els (Reid 2008).
In this NPCT substudy carried out in Macon, which included
both 200 and 400 µg/d selenium supplementation (Reid 2008),
after adjustment for age, gender and smoking, non-melanoma skin
cancer risk increased in the 200 µg/d arm (unadjusted RR 1.49,
95% CI 1.10 to 2.03; adjusted HR 1.5, 95% CI 1.13 to 2.04)
but not in the 400 µg/d arm (unadjusted RR 0.88, 95% CI 0.66
to 1.16; adjusted HR 0.9, 95% CI 0.7 to 1.2). At the remaining
sites, where only 200 µg/d of supplemental seleniumwas used, the
RR was 1.24 (95% CI 1.07 to 1.45) and the HR was 1.2 (95%
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CI 1.0 to 1.4). Distribution of baseline plasma selenium levels
was similar in this substudy to that in the NPCT main study, and
no evidence of effect modification according to baseline selenium
exposure emerged.
Overall, NPCT did not support preventive efficacy of selenium
yeast supplementation against non-melanoma skin cancer in these
populations; on the contrary, it indicated a cancer-promoting ef-
fect of selenium on this cancer type, which was the primary trial
endpoint, raising concern about potential harmful effects of such
selenium supplementation.
Unfortunately, non-melanoma skin cancer incidence thus far has
not been investigated in SELECT, which is the largest selenium
supplementation trial conducted to date (Lippman 2009, Klein
2011, in: SELECT 2009). This endpoint was investigated in a
small trial in a French population of 184 organ graft recipients who
were considered to be at high risk of pre-malignant and malignant
epithelial lesions (Dreno 2007). This trial detected a higher in-
cidence of skin cancer in 91 selenium-supplemented participants
(six cases; 6.6%) compared with 93 placebo-supplemented partic-
ipants (two cases; 2.2%; P value 0.15) during a five-year follow-
up, which comprised in its first three years daily supplementation
with selenised yeast containing 200 µg selenium.
A small trial among participants at high risk for prostate cancer
also investigated the effect on risk of non-melanoma skin cancer of
using selenium supplements of 200 and 400 µg/d, with a median
follow-up of three years (Algotar 2013). Results for non-melanoma
skin cancer from this study showed an occurrence of three cases
among 232 placebo-treated participants and 11 cases among 467
selenium-supplemented participants (eight cases among 234 in-
dividuals receiving 200 µg/d of selenium, and three cases among
233 receiving 400 µg/d), with increased risk after overall selenium
supplementation (incidence rate ratio from our calculation 1.8,
95% CI 0.5 to 10.2) but no evidence of a dose-response relation.
We computed a summary RR for non-melanoma skin cancer in
selenium-supplemented participants by pooling the RRs from the
above three trials (Algotar 2013; Dreno 2007; NPCT 2002; N =
1900), rather than by using numbers of participants and cases, be-
cause the number of skin cancer cases diagnosed in the NPCTwas
not reported in the relevant publication (Duffield-Lillico 2003).
The estimated risk ratio (Analysis 2.4) indicated an increased risk
of non-melanoma skin cancer associated with selenium supple-
mentation of 200 µg/d (RR 1.44, 95% CI 0.95 to 2.17). When
the analysis for non-melanoma skin cancer was limited to Algotar
2013-the only study with low risk of bias-the risk ratio was still
well over unity but was statistically very unstable as the result of
the very low number of cases (RR 2.64, 95% CI 0.71 to 9.84).
2.1.3.2. Basal cell carcinoma (BCC)
At the end of the blinded treatment period in NPCT 2002, the
unadjusted RR for basal cell carcinoma in the 200 µg/d selenium
group was 1.17 (95% CI 1.02 to 1.35). Computation of the ad-
justed HR in multivariate analysis yielded a value of 1.09 (95%
CI 0.94 to 1.26). Eliminating cases that occurred within the first
two years of supplementation had no further effect on the RR.
Variables such as age, gender and smoking status had little effect
on this estimate. In another, much smaller trial in which investi-
gators administered 200 µg/d selenium and no RR estimates were
reported (Dreno 2007), three cases of BCC occurred among 91
selenium-supplemented participants, along with one case among
93 placebo-receiving participants.
Reid 2008 found a crude RR of 0.90 (95% CI 0.65 to 1.24) and
an adjusted HR of 0.95 (95%CI 0.69 to 1.29) for this cancer type
in the 400 µg/d selenium substudy.
2.1.3.3. Squamous cell carcinoma (SCC)
In NPCT 2002, selenium supplementation increased the risk of
squamous cell carcinoma, both in the unadjusted analysis (RR
1.32, 95% CI 1.09 to 1.60) and in the adjusted one (HR 1.25,
95%CI 1.03 to 1.51). After exclusion of cases that occurredwithin
the first two years, a slight decline in the effect of selenium sup-
plementation was seen. Little influence on the point estimates of
age, gender and smoking status was noted. The adverse effects of
selenium supplementation on SCC risk appeared to increase with
increasing plasma selenium levels at baseline. A higher risk of non-
melanoma skin cancer incidence was seen only in participants with
baseline plasma levels in the highest two tertiles of baseline levels
(≥ 105.6 ng/mL), suggesting an interaction between supplemen-
tation and baseline exposure.
In the 400 µg/d selenium substudy (Reid 2008), no alteration of
SCC risk by selenium supplementation was reported (crude RR
1.20, 95% CI 0.85 to 1.68; adjusted HR 1.05, 95% CI 0.71 to
1.56). The smaller trial by Dreno et al. (Dreno 2007) reported
that two among 91 selenium-supplemented individuals were diag-
nosed with SCC, whereas no cases were described among placebo
participants.
2.1.4. Prostate cancer
The meta-analysis for prostate cancer, which is provided in
Analysis 2.5, found an RR of 0.90 for participants supplemented
with selenium compared with placebo (95% CI 0.71 to 1.14).
When the analysis was limited to low-bias trials, no evidence of any
beneficial effect of selenium supplementation emerged (Analysis
2.6).
The trial that first investigated the relation between selenium ex-
posure and prostate cancer risk-NPCT 2002 (see Duffield-Lillico
2002 and Duffield-Lillico 2003)-reported a reduction in prostate
cancer incidence in the selenium-treated group, which was par-
ticularly strong in a first period of follow-up (1983 to 1993; ad-
justed HR 0.35, 95% CI 0.16 to 0.65) and was slightly higher
but still much lower than unity during the entire period of fol-
low-up (1983 to 1996; HR 0.48, 95% CI 0.28 to 0.80). Analyses
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stratified by baseline plasma selenium category showed a greatly
reduced risk associated with active treatment in participants with
plasma selenium ≤ 106.4 µg/L (HR 0.14, 95% CI 0.03 to 0.61),
but in the intermediate category (106.8 to 123.2 µg/L) and in
the upper category (> 123.2 µg/L), HRs were 0.33 (95% CI 0.13
to 0.82) and 1.14 (95% CI 0.51 to 2.59), respectively. Selenium
supplementation in participants with baseline PSA ≤ 4 ng/mL
was associated with considerably reduced risk (HR 0.33, 95% CI
0.14 to -0.79) compared with risk in individuals with PSA > 4 ng/
mL (HR 0.95, 95% CI 0.42 to -2.14).
Interpretation of NPCT findings is complicated by a potentially
severe source of bias. As reported by the study authors, a consid-
erably higher percentage of participants with elevated PSA levels
underwent prostatic biopsy in the placebo group as compared with
the selenium group (35% vs 14%; P < 0.05; NPCT 2002, see
Duffield-Lillico 2003). Differences in biopsy rates were greatest
among participants with the lowest baseline selenium concentra-
tions, which was the subgroup that appeared to derive the great-
est beneficial effects of selenium administration. This may have
contributed to an overestimation in the NPCT of the effects of
selenium supplementation.
The SELECT trial found no evidence of benefit derived from
selenium supplementation (comparedwith placebo) over amedian
of 5.5 years in terms of prostate cancer incidence (HR 1.03, 95%
CI 0.90 to 1.18, 99% CI 0.87 to 1.24) (SELECT 2009). The
adjusted HR for prostate cancer in the selenium plus vitamin E
group compared with the placebo group was 1.05 (95% CI 0.91
to 1.20, 99% CI 0.88 to 1.25). No specific RR estimate according
to disease severity was reported in the original report of the trial,
but during an extended follow-up of this cohort after selenium
supplementation had ceased (Klein 2011), an increased risk of
Gleason 7 or greater disease was found (HR 1.21, 99% CI 0.90
to 1.63). It is interesting to note that the SELECT trial included
only participants with PSA≤ 4 ng/mL-the group that showed the
greatest apparent benefit in the NPCT.
The SELECT trial was discontinued in 2008 in compliance with
the recommendation of the Data and Safety Monitoring Com-
mittee, which expressed some concern regarding an increase in
prostate cancer in the vitamin E-alone group (HR 1.13, 99% CI
0.95 to 1.35) and an increase in type 2 diabetes in the selenium
group (RR 1.07, 99% CI 0.94 to -1.22).
In Marshall 2011, the prostate cancer incidence was 35.6% versus
36.6% in selenium-supplemented compared with placebo-treated
participants after three years of follow-up, respectively. The overall
RR was 0.91, with a 95% CI of 0.55 to 1.52 (courtesy of James
Marshall, unpublished data). Analysis of RRs according to baseline
plasma selenium levels showed no dose-response effect, with point
estimates of 0.82 (0.40 to 1.69), 1.38 (0.68 to 2.78), 0.98 (0.58
to -1.68) and 0.91 (0.45 to 1.84), by increasing the quartile of
selenium status at baseline (Marshall 2011).
Algotar 2013 reported an HR of prostate cancer of 0.94 (95% CI
0.52 to -1.7) for participants receiving the 200 µg/d dose and 0.90
(0.48 to -1.7) for those receiving 400µg/d, comparedwith placebo.
Although average baseline selenium status, as assessed through
plasma selenium, was higher than in the NPCT (median value
126.1 versus 115.0 µg/L), the lowest tertile of plasma selenium
levels had a median value (101.1. µg/L) well below the apparent
threshold of 120 µg/L, at which a beneficial effect of selenium
seemed to occur in the NPCT. Furthermore, as noted by the study
authors, 45% of participants enrolled in this study had baseline
plasma selenium levels < 123 µg/L, which is the upper threshold
for a protective effect of selenium supplementation according to
the results of the NPCT. Moreover, the trial authors stated in
the paper that ’None of the baseline variables modified the effect
of selenium on the primary endpoint’;these variables were age,
plasma seleniumconcentration and serumPSA at baseline (Algotar
2013).
We also investigated the risk of prostate cancer associated with
selenium supplementation after limiting the analysis to the three
trials at low risk of bias (Algotar 2013; Marshall 2011; SELECT
2009). This restriction had limited effects on the statistical preci-
sion of the estimates and yielded an overall RR of 1.02 (95% CI
0.90 to 1.14), indicating no effect of intervention (supplemen-
tation of organic selenium at 200 µg/d) on prostate cancer risk.
These three studies were generally characterised by higher mean
baseline selenium values than were seen in the excluded NPCT,
but such differences were generally limited; also, analyses strati-
fied according to baseline selenium exposure offered little evidence
of a beneficial effect of supplementation even at lower exposure
(Algotar 2013; Marshall 2011) (Analysis 2.6).
2.1.5. Lung, bladder and colorectal cancer
Lung, bladder and colorectal cancer outcomes were evaluated by
pooling the data from NPCT 2002 and SELECT 2009.
Slight to moderate RR departures from unity, which statistically
were very unstable, were observed in the selenium group compared
with the placebo group for lung cancer (RR 0.94, 95% CI 0.62
to 1.42) (Analysis 2.7), bladder cancer (RR 1.14, 95% CI 0.81
to 1.61) (Analysis 2.8) and colorectal cancer (RR 0.77, 95% CI
0.37 to 1.62) (Analysis 2.9).When analysis was limited to the trial
with low risk of bias (SELECT), evidence showed no effect on risk
for colorectal cancer (RR 1.04, 95% CI 0.73 to 1.98) or for lung
cancer (RR 1.11, 95% CI 0.80 to -1.54).
2.2. Adverse effects
InNPCT 2002 and SELECT 2009, adverse effects associatedwith
selenium supplements were unexpectedly observed. In NPCT, 35
participants withdrew from the study because of adverse effects,
mainly gastrointestinal upset. The RR for adverse events in the
selenium group was 1.51 (95% CI 0.74 to 3.11) (our calculation,
based on the number of randomly assignedparticipants). Increased
risk of glaucoma was also reported (Marshall 2011; NPCT 2002
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), which prompted additional studies on this issue (Bruhn 2009)
and likely led to the inclusion of cataract and glaucoma among
the several potential adverse events monitored in subsequent trials
in which selenium was administered (Algotar 2013).
A secondary analysis of participants who did not have diabetes
at the start of the study revealed an excess risk of type 2 diabetes
mellitus in the selenium group (adjusted HR 1.55, 95% CI 1.03
to 2.33) (Stranges 2007). In that study, increased risk of devel-
oping type 2 diabetes associated with selenium supplementation
was found across all tertiles of baseline plasma selenium levels,
although the excess was much greater for the upper category of >
121.6 ng/mL (RR 2.70, 95% CI 1.30 to 5.61) than for the lower
(RR 1.13, 95% CI 0.58 to 2.18) and intermediate (RR 1.36, 95%
CI 0.60 to 3.09) subgroups. The increased risk of diabetes associ-
ated with selenium supplementation was independent of baseline
age, sex, smoking status and body mass index (BMI), with the
exception of participants in the top tertile of BMI. In SELECT,
men in the selenium group had an increased risk of alopecia (RR
1.28, 99% CI 1.01 to 1.62), dermatitis (grade 1 to 2, RR 1.17,
99% CI 1.00 to 1.35; grade 3 to 4, RR 1.74, 99% CI 0.56 to
5.44) and halitosis (RR 1.17, 99%CI 0.99 to 1.38). An increase in
diabetes mellitus type 2 was seen in the selenium-alone group (RR
1.07, 99% CI 0.94 to 1.22). Such excess risk decreased over time
after selenium supplementation ceased, as shown by the results of
the Klein study, which expanded by 32 months the follow-up of
SELECT participants in the absence of further supplementation
(Klein 2011, in: SELECT 2009). In this study, the RR of diabetes
was 1.04 (99% CI 0.93 to -1.17), thus supporting a short-term
effect of selenium supplementation on diabetes risk. Thus, both
NPCT and SELECT results suggest that supplementation with
selenium may increase the risk for type 2 diabetes.
The three trials on liver cancer and the Reid 2008 study did not
mention the occurrence of adverse effects. One paper stated that
no case of selenosis had been observed during the trial. Two re-
cent phase 3 trials have investigated the occurrence of diabetes af-
ter selenium supplementation for cancer prevention. During five
years of follow-up of 699 participants at high risk for prostate can-
cer supplemented with 200 or 400 µg/d of selenium or placebo,
Algotar 2013 reported the occurrence of diabetes in 12, 12 and
seven subjects, respectively. This allowed us to compute an inci-
dence rate ratio of 1.70 (95% CI 0.62 to -5.10) and 1.71 (0.62
to -5.12) among the 200 and 400 µg/d selenium-supplemented
participants, respectively, compared with those given placebo. No
assessment of diabetes incidence was reported for the Dreno 2007
or the Marshall 2011 trial.
In a recent phase 3 trial carried out in 1561 participants with re-
sected stage I non-small-cell lung cancer, which was discontinued
for futility in compliance with the recommendation of the Data
and Safety Monitoring Committee, and which showed a slightly
higher risk of lung second primary tumors and overall second pri-
mary tumors among selenium-supplemented participants (Karp
2013), the RR of diabetes during follow-up was not reported by
the trial authors. However, occurrence during four years of fol-
low-up (2007 to 2011) was stated as 26 new diagnoses of dia-
betes in the selenium arm (1040 participants at baseline, of whom
865 underwent toxicity assessment) and 12 new diagnoses among
placebo-treated participants (521/477). These numbers allowed
us to compute an RR of 1.09 (95% CI 0.53 to 2.36) or, in par-
ticipants with toxicity assessment, 1.19 (95% CI 0.58 to 2.60)-
figures similar to the HRs observed in SELECT (SELECT 2009).
D I S C U S S I O N
Summary of main results
The aims of this review were to examine the efficacy of selenium
supplements in preventing cancer and the association between
selenium exposure and risk of cancer incidence and mortality,
overall and separately, in men and women.
Observational studies and aetiological association
From our meta-analyses of 16 prospective observational studies
on total cancer risk, we found reduced cancer incidence and mor-
tality with higher selenium exposure. The risk of cancer was 31%
(95% CI 9% to 47%) lower in the highest category of selenium
exposure compared with the lowest; the risk of death from cancer
was 36% (95%CI 13% to 54%) lower. Subgroup analyses by gen-
der, however, yielded no convincing evidence of different effects
of selenium exposure in men versus women.
The risk of developing bladder cancer was reduced by 33% (95%
CI 3% to 54%) and that of prostate cancer by 21% (95% CI
10% to 31%). The risk of lung, gastric or colorectal cancer was
also found to be reduced with higher selenium exposure; however,
the confidence intervals of the summary risk estimates overlapped
unity. No association was seen between selenium and risk of breast
cancer.
As is the case with all meta-analyses of epidemiological data, our
findings have potential limitations resulting from study design, as
well as from quality and heterogeneity of the data. These limita-
tions complicate interpretation of the summary statistics.
RCTs and preventive efficacy
We identified eight RCTs that investigated mono-selenium sup-
plements in prevention of non-melanoma skin cancer, liver can-
cer and prostate cancer, as well as many secondary outcomes, in-
cluding incidence and mortality of overall cancer and other site-
specific cancers. Overall, no convincing evidence suggests that se-
lenium supplementation prevented the primary outcomes (non-
melanoma skin cancer, liver cancer and prostate cancer) or the sec-
ondary outcomes. The results of two trials-NPCT and SELECT-
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also raised concerns about possible harmful effects of selenium sup-
plements, including increased incidence of non-melanoma skin
cancer, type 2 diabetes and dermatological effects.
Of the three liver cancer prevention trials, one reported a strongly
reduced risk of liver cancer for male carriers of the HBs-Ag taking
inorganic selenium supplements (sodium selenite) for three years,
while the other two studies reported little effect of organic sele-
nium supplements (selenium yeast) for the same cancer site. As the
result of several methodological concerns related to randomisation
and completeness of outcome data, the risk of bias was judged
as unclear for all three of these RCTs. Therefore, we could not
conclude that there is strong support for selenium supplements
as agents for the prevention of liver cancer. Unfortunately, liver
cancer was not included among the secondary outcomes in the
other trials.
The NPCT (NPCT 2002), which was considered to have an un-
clear risk of bias related to different prostate biopsy rates in the
two arms, found an increase in the incidence of non-melanoma
skin cancer in selenium-supplemented participants, and analysis
of secondary outcomes indicated lower total cancer incidence and
mortality in the selenium group in men but not in women. Anal-
yses stratified according to cancer type found a strongly reduced
risk for prostate cancer, as well as oesophageal, colorectal and lung
cancers, while some increase in other cancers such as breast cancer
emerged. When participants were categorised into three tertiles
according to baseline serum selenium,HR for all cancers increased
from 0.51 (95% CI 0.32 to 0.81) in the bottom category to 0.70
(95% CI 0.44 to 1.09) and 1.20 (95% CI 0.77 to 1.86) in the
two upper categories, respectively.
The SELECT trial (SELECT 2009) was a low-bias and powerful
prostate cancer prevention trial carried out in the male general
population of North America not at high risk of prostate cancer
(≤ 4 ng/mL of serum PSA and a digital rectal examination not
suspicious for cancer). This trial found no difference in prostate
cancer incidence for L-selenomethionine-supplemented partici-
pants as compared with placebo participants after a median fol-
low-up of 5.5 years (HR 1.04, 95% CI 0.90 to 1.18), and analysis
of secondary outcomes showed no effect of selenium on risk of
overall cancers or on risk of other cancers. Median selenium at
baseline (135 µg/L in serum in the selenium arm vs 137.6 µg/
L in the placebo arm) was higher than in the NPC trial (average
plasma selenium114µg/L); unfortunately, no analysis stratified by
baseline selenium status has so far been reported in SELECT, nor
was non-melanoma skin cancer among the secondary outcomes
investigated. This trial used an intervention different from that
used in NPCT (selenomethionine in SELECT and selenised yeast
in the former), although this is unlikely to have been responsible
for the observed differences (Waters 2013), and in both cases, the
intervention comprised organic selenium species (Block 2004).
In a small study of organ transplant recipients (Dreno 2007),
an unexpected increase in non-melanoma skin cancer incidence
emerged, which was of concern in the light of results of theNPCT.
In two recent well-conducted phase 3 trials in participants at high
risk for prostate cancer, 200 µg/d of selenium (as selenomethio-
nine in one study (Marshall 2011) and as selenised yeast in the
other (Algotar 2013)) did not decrease subsequent cancer inci-
dence compared with placebo. In these latter studies, selenium
exposure at baseline did not modify the effects of selenium sup-
plementation (i.e. no evidence indicated that a lower baseline se-
lenium status as reflected by plasma selenium levels was associated
with a more beneficial effect of subsequent selenium treatment).
Overall completeness and applicability of
evidence
Observational studies and aetiological association
We reviewed data from prospective observational studies in which
selenium exposure was measured in populations without evidence
of cancer, who were then followed up for a specified period of
time. This approach minimised the risk of reverse causality.
The included studies differed in terms of selenium exposure mea-
surement, types of outcomes, study designs and study popula-
tions. The low number of studies for most of the meta-analysed
types of cancers prevented a thorough investigation of sources of
heterogeneity between study results. In particular, we could not
explore the influence of specific sources of bias or themethodolog-
ical quality of epidemiological studies on heterogeneity.
The investigations included more than 1,100,000 individuals
from diverse study populations, predominantly from Europe and
the US, and to a lesser extent, Asia and Australia (also see:
Dennert 2008). No prospective observational study on selenium
and cancer risk could be identified from Africa or South America.
This regional distribution reflects the underrepresentation of non-
Western and resource-poor countries in epidemiological research
(Pearce 2004). Differential regional representation in epidemio-
logical studies is of special interest for this review, as selenium lev-
els in humans around the world vary significantly. Selenium levels
measured in the included cohorts reflect a broad range of naturally
occurring selenium exposure, as documented by several epidemi-
ological studies worldwide. However, some of the lowest and the
highest selenium levels in humans were reported in populations
in South America (Jaffé 1992)-a region not investigated in any of
the reviewed observational studies.
More than half of the studies included mixed-gender populations,
but most reported no gender-disaggregated results. In the available
gender-specific results, men are overrepresented-a fact that could
hamper the potential assessment of the relation between selenium
exposure and cancer risk in females.
RCTs and preventive efficacy
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This review investigated a diverse range of cancers, but cancer is
not a uniform condition, andmalignant neoplasms show great dif-
ferences in tumour biology. Only non-melanoma skin cancer, liver
cancer and prostate cancer were investigated as primary outcomes
in the included prevention trials, and regarding these main out-
comes, specific characteristics of the study populations may also
limit the generalisability of results. Participants in the included
RCTs on skin and liver cancer belonged to populations at high
risk for the outcome under investigation, and participants in the
three prostate cancer trials were at average risk (SELECT 2009) or
at high risk (Algotar 2013; Marshall 2011) for this disease. Most
participants in the NPCT were older and white, predominantly
male inhabitants of the US, and themost recent trials were limited
to the US male population. Average baseline selenium exposure in
theNPCTwas lower than that characterising subsequent trials car-
ried out in the US, in which selenium intake was generally higher
that that characterising most European populations. Although the
NPCT suggested that selenium supplementation was highly ben-
eficial only in the lowest range of baseline selenium exposure, the
most recent studies, carried out in populations generally charac-
terised by higher average selenium exposure, did not suggest such
an interaction. An indication of strong effect modification was
also found for gender in the NPCT study, as demonstrated, for
example, by the HR for all cancers associated with selenium sup-
plementation, which was 0.67 (95%CI 0.50 to 0.89) in males and
1.20 (95% CI 0.66 to 2.20) in females (NPCT 2002).
Participants in the SELECT study on prostate cancer prevention
were apparently healthy men over 50 years of age from the general
population of North America (SELECT 2009). The large sample
size and the inclusion of non-white participants from different so-
cioeconomic backgrounds supported the generalisability of study
findings to other adequately nourished populations.
Selenium supplements contain either organic or inorganic species
of selenium or a mixture of both (e.g. in the form of selenised
yeast). Different species of selenium may exhibit differential ef-
fects on human health. RCTs using selenised yeast supplements,
nearly entirely comprising organic selenium forms (Block 2004;
Waters 2013), found either a harmful effect or no effect of supple-
mentation on the main study outcome. The SELECT trial used
supplements of L-selenomethionine, which is the major compo-
nent of selenised yeast, and also found no preventive efficacy. The
only RCT investigating sodium selenite supplements found a pro-
tective effect against liver cancer but was considered to have an
unclear risk of bias. It is also unclear how applicable these results
are in other settings and in populations with a different nutritional
status. Interpretation of the results of clinical trials using selenium
supplements should consider the different chemical forms of sele-
nium, as well as their potentially different health effects when used
as supplements (Weekley 2013). Inmost studies, possibly for safety
reasons, organic selenium as selenised yeast (Algotar 2013; NPCT
2002) or selenomethionine (Marshall 2011; SELECT 2009) was
used. However, the chemical form used is unlikely to explain the
different results betweenNPCTand the other trials (Waters 2013).
With reference to this issue, of interest also are the results of a ’nat-
ural experiment’ that occurred in Northern Italy, wherein a small
population unintentionally consumed for several years drinking
water with unusually high content of selenium in its inorganic
hexavalent form, selenate. Follow-up of that population revealed
a slightly increased risk of cancer, mainly due to an excess risk
of melanoma, kidney cancer and lymphoid malignancies (Vinceti
1998; Vinceti 2000b); the latter observation was of particular in-
terest in view of the recently reported association between expo-
sure to atmospheric selenium and risk of childhood acute lym-
phoblastic leukaemia in California (Heck 2014).
An important unresolved issue is the possibility that participants
with a ’low’ baseline selenium status may experience an inverse
association between selenium exposure and cancer risk. NPCT
found a strong beneficial effect of selenium supplementation
amongparticipants in the lowest tertiles of baseline selenium levels;
however, the risk of cancer changed abruptly from an apparently
protective effect in the two lower tertiles (HR 0.51 and 0.70) to an
excess risk (HR 1.20, 95%CI 0.77 to 1.86) in the highest tertile of
plasma selenium, despite a difference of only 16.4 µg/L between
the lower and upper tertiles. This would imply that a change in di-
etary intake of around 10 µgwould change a strongly protective ef-
fect of seleniumon cancer risk into a possibly detrimental effect-an
implausible scenario given the wide range of selenium intake(from
about 20 to several hundred micrograms)characterising Western
populations. Moreover, the intermediate tertile of baseline plasma
selenium in theNPCT (105.6 to 122.0 µg/L) appeared to be asso-
ciated not only with reduced overall cancer risk but alsowith an ex-
cess risk of squamous cell skin carcinoma (HR 1.49, 95% CI 1.05
to 2.12) and overall non-melanoma skin cancer (NPCT 2002), as
well as diabetes (RR 1.36, 95% CI 0.60 to 3.09) (Stranges 2007);
this occurrence of both adverse and beneficial effects is unlikely if
the selenium supplementation was serving to remedy a selenium
deficiency. In addition, the strongest effect of selenium on over-
all cancer risk at the lower levels of baseline selenium status was
due to a considerable decrease in prostate cancer, but this finding
was subject to detection bias because of a decreased biopsy rate
in selenium-supplemented participants, particularly in those with
the lowest baseline selenium status, as recognised by the authors
of the NPCT (NPCT 2002). Little evidence of a beneficial effect
of selenium supplementation was noted among participants with
the lowest baseline selenium exposure (plasma selenium < 106 µg/
L) in either the prostate cancer trial of Marshall et al. (Marshall
2011) or the prostate cancer trial of Algotar et al. (Algotar 2013),
despite the fact that 45% of the participants in that study had
baseline plasma selenium levels < 123 µg/L-the suggested thresh-
old for beneficial effects of selenium supplementation according
to the NPCT (NPCT 2002). SELECT was unable to find any
beneficial effect of selenium despite its large size and therefore
the almost certain inclusion of participants with low baseline sele-
nium levels. However, analyses stratified by baseline selenium sta-
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tus are not available for SELECT: Such analyses would greatly help
to elucidate this issue. It is hoped that future work on SELECT
will include follow-up for non-melanoma skin cancer, whose risk
increased after selenium supplementation in three trials (Algotar
2013; Dreno 2007; NPCT 2002); this represents one of the most
troublesome effects of selenium supplementation so far identified
(Vinceti 2013b).
Quality of the evidence
Observational studies and aetiological association
The 55 observational studies were heterogenous, not only in
methodology, but also in the quality and level of detail of report-
ing.
Confounding and other biases
Selenium measurement and categorical exposure
classification
Six observational studies measured nutritional or supplemental se-
lenium intake using questionnaires or interviews. Most studies,
however, relied on selenium biomarkers such as toenail, serum or
plasma selenium levels. Percentile borders, for example, quartiles
or quintiles, were usually applied as cut points for exposure cate-
gories. Our analyses were based on the comparison of highest ver-
sus lowest baseline exposure category. In our meta-analyses, dif-
ferent methods of selenium measurement and different numbers
of exposure categories covering different absolute selenium levels
were combined.
Adequate assessment of total selenium intake with food frequency
questionnaires (FFQs) or interviews may be hampered by lack
of adequate food composition data reflecting regional and sea-
sonal variations in selenium concentration. The Duffield 1999
trial compared duplicate diet collections, dietary logs, FFQs and
biomarkers asmeasurements for selenium intake and status among
New Zealandmen and women. The FFQ overestimated the mean
selenium intake in study participants when compared with lab-
oratory analyses of duplicate meals. Correlation between dietary
measurements and seleniumbiomarkers (whole blood and plasma)
weremodest (r = 0.1 to 0.4) at best. Karita 2003 did not find a cor-
relation between estimates of dietary intake and biomarker levels
of selenium in a Japanese population, as was observed by other in-
vestigators (Hunter 1990; Satia 2006; Vinceti 2012). On the other
hand, other studies have found a clear correlation between dietary
intake of selenium, assessed through different methodologies and
questionnaires, and blood or toenail selenium levels, indicating
the adequacy of both approaches for assessing selenium exposure
in different contexts characterised by low or high selenium intake
(Haldimann 1996; Longnecker 1996; Pestitschek 2013; Swanson
1990; van den Brandt 1993b). Validity problems, possibly leading
to exposure misclassification, have been generally reported when
questionnaires were used to assess supplement use (Murphy 2002).
Regarding biomarkers for selenium measurement, Ashton 2009
showed in a systematic review that plasma and whole-blood se-
lenium concentrations increased with higher selenium intake in
supplementation studies. Although Ashton 2009 could not iden-
tify serum studies for this systematic review, plasma, whole-blood
and presumably serum selenium levels were considered by the au-
thors to adequately reflect a short-term increase in supplemental
selenium intake in healthy adults. However, the review authors
also found unexplained heterogeneity in the reaction of partici-
pants’ plasma selenium levels to selenium supplementation.
Regarding the estimation of long-term nutritional intake with
biomarkers, Longnecker 1996 demonstrated a high correlation
between long-term selenium intake as estimated from duplicate
food portions and single measurements from whole blood, serum
and toenail specimens.
These findings support the concern that ranking of selenium expo-
sure differs according to the instruments used to assess intake and
differences between intake assessment and biomarkers. Exposure
misclassification may have biased the results of individual studies,
and a meta-analysis of observational data is likely to reflect these
biases. Non-differential exposure misclassification might have oc-
curred in all included studies as the result of measurement errors or
of the gap between the theoretical definition of selenium exposure
and the measurement thereof, which served as a proxy. Non-dif-
ferential misclassification might lead to an underestimation as well
as an overestimation of an effect in the presence of more than two
exposure categories. Our approach of performing a meta-analysis
that covered different methods of selenium assessment might have
introduced additional heterogeneity into our review results.
Exposure misclassification may have occurred in the great major-
ity of observational studies because of failure to take into consid-
eration the different selenium compounds, each of which has dis-
tinctive biochemical properties and toxicological and nutritional
activities (Weekley 2013). This failure is likely due to the fact that
speciation of different selenium compounds is very complex and
expensive and requires sophisticated professional expertise and an-
alytical equipment. The possibility of major biases associated with
misclassification of selenium exposure due to different concentra-
tions of inorganic and selenium species is demonstrated by a recent
study in amyotrophic lateral sclerosis, which showed a very dif-
ferent distribution of the various forms in the cerebrospinal fluid
of participants newly diagnosed with amyotrophic lateral sclerosis
compared with controls (Vinceti 2013c). In that selenium speci-
ation study, relative risk calculations carried out on the different
selenium species yielded markedly different results, which were
even opposite in some cases (e.g. for organic selenium vs selen-
ite). This and other investigations indicate an asymmetrical dis-
tribution of the various chemical species of selenium in differ-
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ent body compartments (Behne 1996; Behne 2010; Panter 1996;
Solovyev 2013; Vinceti 2013c), suggesting another major source
of exposure misclassification (i.e. differential storage of selenium
compounds in various body tissues, including target ones for the
diseases under investigation). These studies thus indicate the po-
tential for exposure misclassification in observational studies and
the pitfalls associated with an approach based on assessment of
total selenium content in peripheral biomarkers.
One concern, which we cannot clarify to date, is that biomark-
ers differentially reflect intake of organic and inorganic selenium
species. Animal studies indicate that selenium from inorganic
sources is not retained so well in the body as organic selenium.
Selenium from organic sources led to higher blood selenium levels
and higher activity of glutathione peroxidase than equal doses of
inorganic supplements in veterinary studies (Slavik 2008; Steen
2008). However, symptoms of acute toxicity were observed in an-
imals with lower intake of inorganic than organic selenium species
(Kim 2001; Tiwary 2006). Panter et al. administered equivalent
amounts of selenium to swine in organic and inorganic forms and
found higher toxicity despite lower body selenium levels after ad-
ministration of inorganic forms (Panter 1996). Hall 2008 found
an increased genotoxic effect in human cell lines of sodium selenite
in comparison with organic selenium. When the possibly differ-
ential effects of selenium species on human health are considered,
adequate interpretation of the biomarkers representing selenium
exposure would require knowledge of the selenium compounds to
which the individual was exposed.
In our review we found that in observational studies, cancer risks
frequently showed an inverse association with biomarker levels
but not with nutritional intake. This might be a consequence of
an invalid measurement of nutritional intake, thus biasing results
towards the null, but it might likewise reflect that there truly was
no association, and that findings from the biomarker studies were
the result of inadequate exposure assessment. In some instances,
measurements of nutritional intake might provide better exposure
estimates thandobiomarkers, whichmay considerablymis-classify
the exposure to inorganic and organic selenium sources.
Furthermore, it must be outlined that comparison of risks between
the highest and the lowest exposure categories is most suitable for
identifying an effect when a consistent decrease or increase is seen
across absolute exposure levels. Other associations (e.g. threshold
effects, U-shaped relations) may have been missed by this method
of meta-analysis, or the true effect might have been diminished.
Comparability of cases and controls and detection of cancer
All included studies recruited participants pre-diagnostically, and
cases and control participants were drawn from the same popula-
tion. This approach decreased potential differences between com-
parison groups, which could have influenced cancer disease or
death due to factors other than selenium exposure. We included
the results from each study in meta-analyses, which were adjusted
for the highest numbers of additional variables.
Any cancer
All studies on total cancer risk identified cases by using registry
links or a combination of several methods, and losses to follow-up
were generally very low. Two studies on cancer incidence and two
studies on cancer mortality analysed less than 80% of all identified
cases (incidence: Coates 1988: 79%; mortality: Kok 1987a: 71%;
Kornitzer 2004: 57%; Persson 2000: 76%). The main reason for
this loss of sample was missing selenium measurements. Not all
studies that assessed mortality as a measure of cancer risk excluded
participants with cancer disease at study inception. This might
have led to overestimation of a protective effect if selenium levels
were lowered by the presence of cancer. We therefore consider
the results for cancer incidence to be more valid than the cancer
mortality results.
Prostate cancer
All but two of the studies on prostate cancer risk identified cases
by using links to cancer registries or a combination of personal
follow-up interviews with PSA screening. Two studies with health
professionals used self reporting for case identification, followed
by confirmation through medical records. The number of peo-
ple lost to follow-up was low in all included studies. Two studies,
however, included less than 80% of all identified cases in their
analyses (Brooks 2001: 39%; van den Brandt 2003, in: van den
Brandt 1993a: 77%) because samples were not available for se-
lenium measurement or diagnosis was not confirmed. In Brooks
2001, bias might have been introduced to the results to some ex-
tent, as the demographic variables differed between identified and
analysed cases.
Bladder cancer
Losses to follow-up were low in three studies (Michaud 2002;
Nomura 1987; Zeegers 2002 in: van den Brandt 1993a) and un-
clear in two studies on bladder cancer risk (Helzlsouer 1986, in:
Menkes 1986; Michaud 2005). Endpoints were ascertained in
elaborate ways in four studies that included linkages to registries
and regional andnational databases; one study relied on self report-
ing of study participants (Michaud 2005). The latter investigation
compared bladder cancer in the Nurses’ Health Study (women)
versus the Health Professionals Follow-Up Study (men) and was
the only study to report gender-disaggregated data. A gender-dif-
ferential association between selenium exposure and bladder can-
cer risk was found, but the role of potential biases due to possibly
different self reporting behaviour in these two distinct cohorts re-
mained unclear.
The second study, which found an inverse association between
selenium exposure and bladder cancer risk, was Zeegers 2002 (van
den Brandt 1993a), which could analyse only 70% of identified
bladder cancer cases, as specimens for seleniummeasurement were
not available for the remainder.
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Residual confounding and effect modification
Most of the studies included controls for smoking and age by
matching or by using multivariate techniques. However, only a
few considered the potential effects of other factors. Possible con-
founding factors could be another food nutrient or a certain be-
haviour that exhibits cancer protective effects and is associated
with higher intake of selenium-rich foods. Furthermore, intake of
heavymetals and other dietary factorsmaymodify seleniumhealth
effects or the relations between selenium exposure and biomarkers
(overview, in: Vinceti 2000a). Metabolic interactions, for exam-
ple, are known for arsenic, cadmium and other elements (Zeng
2005; Zwolak 2012).
Even in studies that considered the influence of a specific factor,
the validity of assessment of the potential confounder can be chal-
lenging and is not commonly reported. For example, control for
smoke exposure as a known risk factor for several types of cancer
is an important issue in epidemiological studies on cancer risk.
Cigarette smokers tend to have lower selenium biomarker levels,
although cigarette smoking is a source of selenium exposure it-
self. Therefore, an inverse association between selenium and lung
cancer risk might be the result of residual confounding and effect
modification by smoking. Exposure to environmental and house-
hold smoking, which has been shown to be associated with in-
creased risk of cancer (Gorlova 2006; Nishino 2001), might also
be associated with selenium status due to differential nutritional
behaviours or other mechanisms. We are not aware of any study
that investigated this issue.
Some potential confounders cluster in population groups accord-
ing to socioeconomic position (SEP).Only a few studies attempted
to control for indicators of adult SEP as potential confounders
(e.g. education, occupation, income). None used a composite in-
dex of indicators or considered childhood SEP. Some studies re-
stricted their cohorts to certain subgroups of a population, such
as occupational groups, and were likely to include only people of
a similar adult socioeconomic background.
It has been claimed that associations between vitamins and dis-
eases are the result of confounding by social and behavioural fac-
tors acting over the course of a lifetime (Lawlor 2004). Lawlor
2004 argued that divergent results from epidemiological and ran-
domised controlled studies on the prevention of cardiovascular
diseases can be explained by unmeasured confounding due to SEP.
Risk of most cancers-like cardiovascular morbidity-isknown to de-
crease with higher SEP. Research also indicated a positive associa-
tion between higher SEP and selenium biomarkers (Barany 2002;
Niskar 2003). However, other investigations have not confirmed
these findings: Kant 2007, for example, did not find an association
between a measure of household poverty and selenium status.
The hypothesis of possible confounding due to SEP leading to an
indirect association between selenium and cancer would be consis-
tent with the results for all types of cancers in this review for the ob-
servational studies-including the null association with breast can-
cer-with the exception of prostate cancer findings. Prostate cancer
has been found to be diagnosed more often in men of a higher
SEP (Dalton 2008), although we saw a protective association with
higher selenium exposure. It remains unclear whether the more
frequent diagnosis of prostate cancer in men with a higher SEP
reflects an excess of prostate cancer incidence in this population. It
might also result from differential health and screening behaviours
leading to detection of otherwise symptom-free cases, while men
with a lower SEP tend to be overrepresented in diagnoses of ad-
vanced stages of the disease (Rapiti 2009). More information on
screening and diagnostic behaviours of male cohort participants
would be necessary to further elucidate these findings.
For prostate cancer, studies published before 2000, especially those
from the US, found a greater protective effect with higher sele-
nium levels than did later studies. We consistently observed this
in the studies on lung cancer. This might be attributable to dif-
ferences in study design or populations (with later studies being
the larger studies including the general population) or to changing
health and screening behaviours over time in the case of prostate
cancer studies. It could also reflect publication bias in earlier years
favouring positive results. An alternative explanation could be a
’threshold’ effect for a possible protective effect of selenium against
prostate cancer, which has been diminishing because of increas-
ing use of selenium supplements in the US. Brooks 2001 report-
edly observed results consistent with a threshold effect at a level
of 108 µg/L serum selenium. Conversely, a threshold effect was
not seen in another study with almost the same percentile limits
(Goodman 2001) in a population of asbestos workers, who may
have had other sources of selenium exposure than were noted in
the participants in Brooks 2001 from the general population. It
has been frequently suggested that an increase in selenium intake
might be beneficial only for men with lower selenium levels, as
glutathione peroxidase activity reaches a plateau above approxi-
mately 95 (range 89 to 114) µg/L (Rayman 2000).
We found no clear indication of a threshold effect in lung or
prostate cancer in the overview of study results. Heterogeneity
between studies therefore might reflect not a consistent biological
threshold effect of baseline selenium exposure levels, but rather
a cluster of known and unknown influences of factors related to
study design, study population and potential biases.
Another consideration is the role of genetic factors. Some recent
observational studies examining selenoprotein-related single-nu-
cleotide polymorphisms have suggested a role for genetic variants
in genes coding for selenoproteins in modifying cancer risk, or the
relation between selenium exposure and subsequent cancer risk,
although not all results have been consistent (Geybels 2013; Me-
plan PLOSone 2012; Penney 2010; Penney 2013; Slattery 2012;
Takata CEBP 2011). Moreover, the null results of the most recent
low-bias RCTs (Algotar 2013; Marshall 2011; SELECT 2009) do
not suggest that at least the most frequent genotypes may strongly
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influence the selenium and cancer relation, although such hy-
potheses cannot be ruled out for more rare genetic variants of se-
lenoprotein or other proteins. In addition, and entirely hypotheti-
cally, different genetic factors might both increase and decrease the
risk of cancer associated with selenium exposure; therefore oppo-
site effects with final null results in the overall general population
might occur. Additional data from SELECT based on genotyping
of study participants, if available, might be extremely useful for
assessing hypotheses regarding genetic variants of selenoenzymes
and their interaction with selenium status.
The role of chance
Large epidemiological studies often investigate a large number of
possible associations. In general, when a multiplicity of compar-
isons is performed, some associations can occur by chance. Thus
the possibility that some associations between selenium exposure
and cancer endpoints occurred by chance cannot be ruled out.
Summary
Factors that seemed to account in part for interstudy heterogeneity
were type of outcomemeasure (incidence ormortality), assessment
of exposure and gender.
Given the possible influences of bias, particularly residual con-
founding and exposure misclassification, and of modifying factors
on the selenium-cancer relation, the summary estimates from our
meta-analysis and more generally from all meta-analyses of obser-
vational studies on the selenium and cancer relationmust be inter-
preted with caution. Meta-analyses of spurious findings in obser-
vational studies enhance the precision of a summary risk estimate,
which does not itself get nearer to the true value and may suggest
a non-existent association (Egger 1998).
RCTs and preventive efficacy
SELECT (SELECT 2009), Marshall (Marshall 2011) and Algotar
(Algotar 2013) were the only trials considered to have a low risk of
bias with adequate sequence generation, allocation concealment,
blinding and reporting of findings, and the consistency of their
findings for prostate cancer as well as the strong statistical power
of the only study investigating other cancer types-SELECT-makes
their results highly reliable.
In the three trials on liver cancer prevention, quality of reporting
was an issue, and these trials were considered to have an unknown
risk of bias. The individual trials were reported-in some cases, dis-
crepantly-in several papers, and essential questions regarding se-
quence generation, allocation concealment, handling of dropouts
and withdrawals and detection of outcomes remain unanswered.
This might be due to inadequate reporting but might also hint
of flaws in trial design and implementation. We were uncertain
whether the only trial that reported positive results for selenium
supplements in liver cancer prevention randomly assigned partic-
ipants individually. A cluster randomisation of participants who
lived in the same area/village, which may have been the procedure
in this investigation, might have introduced additional bias to the
study results (e.g. as the result of different environmental factors
contributing to liver cancer development or detection) and might
have led to an overestimation of the protective efficacy of sele-
nium. Duplication of results with a rigorous study design would
be necessary to assess the effects of sodium selenite on liver can-
cer incidence. With regard to the NPCT (NPCT 2002) and the
Dreno et al. trial (Dreno 2007), indications of a potentially seri-
ous detection bias for the US study and of unclear methodological
details (such as blinding) for the French investigation led us to
consider those experimental studies to be at unclear risk of bias,
as discussed in greater detail elsewhere in this review.
Potential biases in the review process
RCTs and preventive efficacy and observational
studies and aetiological association
The literature search included the major international databases
in the English and German languages, and we applied a broad
search strategy supplemented by handsearching for references.We
assume that we identified all randomised controlled studies and
prospective observational studies relevant to our review questions.
As we did not search databases in other languages (e.g. Chinese,
Russian), we cannot rule out that we missed smaller studies that
were not published in international journals. We also might have
missed observational studies whose results on selenium exposure
and cancer were reported in the body of a paper but were not
mentioned in the paper’s title or abstract, even if the paper is
indexed in the searched databases.
We contacted all investigators to ask for missing or additional data
on their studies. Sometimes we were unable to obtain answers to
questions we had regarding methodology or outcomes, and some-
times investigators gave us the information we needed. We were
unable to obtain answers particularly for earlier epidemiological
studies, for which primary investigators may have relocated or
died, or for which data were not available in a current electronic
format. Similarly, we could not make contact with primary inves-
tigators of Chinese RCTs.
The risk of bias assessment was based on the included publications.
The risk of bias of studies that did not adequately describe the
study design in the included publication but gave a reference to
another paper might therefore have been overestimated in this
review.
Another concern, especially with the epidemiological studies, is
publication bias. Cohort and nested case-control studies often are
not exclusively designed to test for a specific exposure-outcome
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association but enable researchers to investigate a range of ques-
tions. It is conceivable that unfavourable results were less likely to
be published.
We decided a priori to conduct meta-analyses for observational
studies only when five or more studies were available for a study
outcome. As a result of this cutoff, we did not conduct meta-
analyses for a number of observational study outcomes with two
to four studies available (Table 1). Our primary intention was to
facilitate the investigation of heterogeneity between studies that
were included in meta-analyses, to avoid producing more precise,
but still unexplainably biased, results. On the converse, the choice
of reporting meta-analysis of RCTs when at least two studies were
available and of emphasising the analysis conducted for RCTs at
low risk of bias was made to highlight the most reliable and recent
evidence on selenium and cancer relation, which comes fromwell-
designed experimental studies.
The authors of this review came from different disciplines and
have different focuses (e.g. epidemiology, biostatistics, clinical
medicine, nutrition). We consider this internal variety of exper-
tise to be a strength of this review and made use of it by apply-
ing double-checking procedures during the entire review process
when possible.
Agreements and disagreements with other
studies or reviews
The idea of selenium supplementation for cancer prevention re-
ceived broad support after the first report was received from the
NPCT and after publication of several observational studies that
supported the hypothesis of an aetiological relation between low
selenium status and cancer development. Combs 2005 stated that
“the hypothesis that selenium can affect cancer risk is supported
by a remarkably consistent body of scientific evidence” (Combs
2005). These ideas stimulated the largest ever cancer prevention
trial, SELECT, which failed to provide support for this hypothesis,
and two additional prostate cancer trials (Algotar 2013; Marshall
2011), whose results were in line with the SELECTfindings in fail-
ing to find a beneficial effect of selenium. Disagreement between
results of this systematic review and those of other publications
may be explained in part by the differentiation between aetiology
and efficacy in the research questions of this review, and by the
possibility in the present study of reporting the most recent and
sound evidence coming from experimental studies. An additional
relevant RCT, which could not be meta-analysed in this review,
since it was released in PubMed in September 2013, also appears
to confirm our conclusions (Karp 2013).
Observational studies and aetiological association
A number of systematic reviews on selenium and the risk of differ-
ent types of cancer have been conducted with and without meta-
analyses. Overall, our combined risk estimates are consistent with
these results, and slight discrepancies in numbers are attributable
at least in part to different inclusion criteria. However, some of
the previous publications arrived at more favourable conclusions
regarding a possible protective association of higher selenium ex-
posure against cancer.
Our meta-analyses of observational studies suggest an inverse as-
sociation between selenium exposure and risk of several cancers
in men, which was reflected in reduced overall cancer incidence
and mortality. Associations with toenail selenium levels tended to
be greater than with serum or plasma levels, and in general no
associations with selenium intake were noted. These findings were
consistent with secondary outcomes of the NPCT, particularly in
its first report (Clark 1996, in: NPCT 2002), which suggested
preventive efficacy of selenium supplements against several types
of cancer inmen, the strongest of which was prostate cancer. How-
ever, the large-scale SELECT trial and two subsequent RCTs failed
to confirm any beneficial effects of supplemental selenium intake
on prostate cancer risk (Algotar 2013; Marshall 2011; SELECT
2009). An earlier ecological analysis of a nationwide programme
to increase selenium intake with fortification in Finland also found
no evidence of a protective effect against prostate cancer (Vinceti
2000a).
Overall, little evidence suggests an association between selenium
exposure and cancer risk in women; if existent, it is likely to be
small. Our meta-analyses do not support a protective association
between higher selenium exposure and breast or colorectal cancer
in women.
It has been argued that gender-related outcomes may reflect dif-
ferent exposure levels at baseline possibly related to gender-spe-
cific nutritional behaviour, which might be true for comparisons
of distinct women-only and men-only cohorts (Michaud 2005).
However, comparisons by gender within studies also point to a
differential effect at similar exposure levels. We cannot rule out
that sex or gender differences may be observed by chance only, but
laboratory and animal research has suggested sex differences in se-
lenium metabolism and biology. Also sex-specific tumour biology
and a predominance of specific cancer types may contribute to dif-
ferential health outcomes in women and men. However, we can-
not estimate the magnitude that sex or gender differences possibly
contribute to observed differential health outcomes in men and
women. These considerations are of special interest, as selenium
supplements are aggressively marketed, especially to women, with
regard to breast cancer prevention and treatment, and this is not
supported by data from observational or clinical investigations.
Heterogeneity between studies was not much reduced by gender
stratification in our meta-analyses. Furthermore, we expected that
non-gender-stratified data from observational studies would more
or less reflect a combination of gender-stratified results for a spe-
cific tumour type, but this was not always the case. In lung cancer
meta-analysis, for example, risk reduction by higher selenium lev-
els seems to be greater in data for both genders combined than in
data for women and men separately. This underlines the influence
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of other sources of heterogeneity on study outcomes. Reporting
of gender-stratified results in mixed-gender cohort studies, which
has become increasingly common over the years, might therefore
reflect other factors related to study design, such as better evalu-
ation of possible confounders in more recently published studies.
Socioeconomic position could be one such possible confounder,
leading to an overestimation of a protective effect of selenium.
Several studies have found selenium levels to be positively associ-
ated with adult socioeconomic position in both men and women
(Gundacker 2006; Niskar 2003).
Therefore, doubts about whether observed associations point to a
real causal relation between selenium biomarker levels and cancer
risk are fully justified.
RCTs and preventive efficacy-specific cancer types
Non-melanoma skin cancer
The increase in risk of non-melanoma skin cancer associated with
selenium supplements found in theNPCT (NPCT 2002), and ap-
parently confirmed in Dreno 2007 and in Algotar 2013 (although
in the latter case without evidence of a dose-response relation),
raises strong concern about the safety of selenium yeast supple-
mentation in both men and women with reference to this cancer
type. Increased risk of non-melanoma skin cancer could be more
pronounced in or restricted to high-risk populations, or could be
observable only above certain selenium levels, which the NPCT
suggested to be around 105 µg/L (Duffield 2003, see: SELECT
2009).Uncertainty over the size andprecision of the risk associated
with selenium supplementation from our analysis makes relevant
data for this cancer type from the SELECT trial, in the light of
its power and its low risk of bias, of fundamental importance for
elucidating the hypothesis of an excess skin cancer risk associated
with selenium exposure.
Liver and other gastrointestinal cancers
Bjelakovic 2008 conducted a systematic review of antioxidant sup-
plements for prevention of gastrointestinal (GIT) cancers. Review
authors meta-analysed RCT data for liver cancer prevention with
selenium-containing supplements and reported a protective effect
in both genders (RR 0.56, 95% CI 0.42 to 0.76). Three of the
four trials in their meta-analysis were also included in this system-
atic review (Li 2000; Yu 1991; Yu 1997). The remaining RCT
(Li 2004b) used a combination of selenium with allitridum, a
synthetic garlic extract, in the intervention and therefore did not
meet our inclusion criteria. Li 2004b found a preventive efficacy
of high-dose allitridum/100 µg sodium selenite supplementation
on total and gastric cancer incidence in men but not in women.
No effect on liver cancer was seen in participants of either gen-
der. Allitridum was considered the main intervention by Li and
colleagues in their paper, and the contribution of selenium to the
overall effect remained unclear. Themore recent RCT byQu2007
found no effect of 50 µg selenium yeast in combination with beta-
carotene and alpha-tocopherol on liver cancer mortality.
We calculated a summary risk estimate for theRCTs on liver cancer
included in this review, but limitations of these trials, particularly
with reference to their risk of bias, strongly hamper evaluation
of their results and suggest extreme caution in interpreting the
findings concerning liver cancer. An additional analysis from the
SELECTtrial with reference to liver cancerwould help to assess the
potential relation of this site-specific cancer to antecedent selenium
exposure.
We could not identify RCTs that investigated otherGIT cancers as
primary outcomes. The NPCT reported reduced risk of colorectal
and oesophageal cancer as a secondary outcome in the selenium
group. Other studies using multi-component selenium-contain-
ing supplements found divergent results, which also indicated po-
tential sex or gender differences (Blot 1993; Hercberg 2004)
The SELECT trial included colorectal cancer but no other gas-
trointestinal cancers or overall gastrointestinal cancers among the
secondary outcomes investigated (Lippman 2009, see: SELECT
2009). Trial results showed no change whatsoever in colorectal
cancer risk in selenium-supplemented participants compared with
placebo-receiving individuals. Because no reduction in overall can-
cer risk was seen among this selenium-supplemented male popu-
lation, a major effect on other frequent cancer types such as differ-
ent gastrointestinal cancers seems unlikely to have occurred. Un-
fortunately, no low-bias trials have been carried out in females.
We consider that the availability of supplemental results from the
SELECT study regarding liver cancer and other gastrointestinal
neoplasms, as well as other outcomes, would be of major impor-
tance for an adequate assessment of the relation between risk of
these cancers and antecedent selenium exposure.
Other cancers and diseases
Data on a variety of other cancers were reported in NPCT and in
SELECT. It is worthy of note that results for the primary outcome
of the NPCT (i.e. the incidence of non-melanoma skin cancer)
received less attention in the public debate than those for secondary
outcomes, especially those in favour of selenium supplementation.
Underrepresentation of women in theNPCT decreased the power
to detect sex-/gender-specific effects (Duffield-Lillico 2002, see:
NPCT 2002) and is a matter of concern, as a high but statistically
imprecise risk of breast cancer was detected in the selenium group
(HR 1.89, 95% CI 0.69 to 5.14). All possible beneficial effects on
cancer incidence were confined to men in this study.
The SELECT trial investigated as secondary outcomes a variety
of cancers in addition to prostate cancer (the primary outcome):
lung cancer, colorectal cancer, other cancers, overall cancer and
cardiovascular events (haemorrhagic stroke and other cardiovas-
cular disease) (SELECT 2009). No evidence of a beneficial effect
of selenium supplementation on any of these outcomes emerged,
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with the partial exception of a slight and statistically very unsta-
ble decrease in cardiovascular events (HR 0.91, 99% CI 0.66 to
1.24); for this issue, we refer to a recent Cochrane review (Rees
2013) and a trial sequential analysis (Brigo 2014). Estimates for
lung cancer (HR 1.10, 99% CI 0.63 to 1.61) were also very im-
precise and suggested higher risk, mirroring the results of a recent
trial in participants with a history of lung cancer (Karp 2013),
which investigated the efficacy of selenium supplementation (200
µg/selenium/d as selenised yeast vs placebo) for the prevention of
second primary tumor and second primary lung cancer in par-
ticipants with resected non-small-cell lung cancer (Karp 2013;
RCT˙ECOG 2002). Results of this trial could not be included in
the present meta-analyses because of its late publication date, but
they appear to be consistent with results of the most recent RCTs
(Algotar 2013;Marshall 2011; SELECT2009) and therefore seem
to confirm the findings of this review.
SELECT also reported a slightly elevated risk for type 2 diabetes
in the selenium group (RR 1.07, 99% CI 0.94 to 1.22), which
decreased in the longer, unblinded follow-up study of the same
study population after cessation of selenium supplementation (RR
1.04, 99%CI 0.93 to 1.17; Klein 2011, see: SELECT 2009). This
increase was amatter of concern, especially in the light of detection
in 2007 of an excess risk of diabetes associated with selenium
supplementation in a secondary analysis ofNPCTresults (Stranges
2007). Based on our computations using data provided in the
reports, two subsequent smaller trials (Algotar 2013; Karp 2013)
had an increased (although statistically very unstable) diabetes risk
among selenium-supplemented participants (incidence rate ratio
1.7, 95%CI0.6 to 5.1 and1.2, 0.6 to 2.6, respectively). Therefore,
the possibility that selenium supplementation represents a risk
factor for diabetes deserves to be considered carefullyand appears
to be under active investigation (Pounis 2014; Rocourt 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Observational studies have provided some evidence that intake of
the metalloid seleniummay influence cancer risk in humans, both
in men and in women, but a role of bias, and of confounding in
particular, cannot not be ruled out in these investigations because
of methodological shortcomings. Results from the most recent
randomised controlled trials, which were carried out in men and
had a low risk of bias, have failed to provide evidence of any
beneficial effect of selenium supplementation on risk of all cancers,
prostate cancer or other site-specific cancers. Additionally, RCTs
have raised concern about possible toxicities from long-term intake
of supplemental selenium, such as excess risk of non-melanoma
skin cancer and type 2 diabetes. The findings of our review do
not provide evidence to support supplementation with selenium
to prevent cancer.
Implications for research
Some questions regarding selenium, such as whether selenium
might influence cancer risk in individuals with very low or very
high baseline exposure to this element, or in individuals with dif-
ferent genotypes, have not been fully resolved, although currently
available evidence from randomised trials offers little support for
such hypotheses. For ethical reasons, in the light of potential tox-
icity of selenium supplementation and failure of the most recent
and well-conducted experimental cohort studies to find beneficial
effects, new randomised trials on the selenium and cancer relation
are unlikely to be undertaken in the future. Therefore expanding
the results of the SELECT trial to examine additional outcomes
(liver cancer and non-melanoma skin cancer) and subgroups with
specific characteristics (baseline selenium exposure levels and ge-
netic factors) may be the best available option to clarify these is-
sues. Unfortunately, SELECT results cannot address the possible
occurrence of gender differences because this trial enrolled only
males.
It is definitively known from a number of studies that the various
chemical forms of selenium have very different nutritional and
toxicological properties. However, for themost part, observational
studies have assessed only total selenium exposure. Future observa-
tional studies would contribute greatly to a better understanding
of the selenium and cancer relation by including selenium specia-
tion in their exposure assessment methodology in evaluating can-
cer risk associated with intake or tissue levels of specific inorganic
and organic species of this metalloid.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agalliu 2011
Methods Nested case-cohort study
Country: Canada
Participants Name of parent cohort: Canadian Study of Diet, Lifestyle and Health (CSDLH)
Participants: 22.975 participants (alumni associations of the University of Western Ontario,
67% of 34.291)
Recruitment: between 1995 and 1998
Outcome assessment: December 2003
Number of cases:
Prostate cancer: 661
Case definition: incidence
Years of follow-up: 4.3 to 7.7 years mean
Type of selenium marker: supplementation
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age at baseline, race, BMI, exercise activity, and education
Risk estimates [95% CI] Reference category: zero
Results:
Prostate cancer
highest quartile: HR 0.76 (95% CI 0.43 to 1.33)
Selenium levels in exposure categories lowest quartile (median value): 15.7 µg
highest quartile (median value): 105.0 µg
Notes
Akbaraly 2005
Methods Cohort/sub-cohort controlled cohort study
Country: France
Participants Name of parent cohort: Etude du Vieillissement Antériel Study (EVA study)
Participants: 1389 participants (41% male, 59% female)
Inclusion criteria: 59 to 71 years of age; residents of Nantes; able to undergo examination at
study centre
Recruitment: 1991 to 1993
Outcome assessment: December 2001
Number of cases:
Any cancer: 45 (male/female: n.r.)
Case definition:mortality
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Akbaraly 2005 (Continued)
Years of follow-up: 9.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: gender, smoking, alcohol intake, medication use, obesity,
diabetes mellitus, hypertension, CVD, age, education, dyslipidaemia, low cognitive function
Risk estimates [95% CI] Reference category: highest quartile
Results:
Any cancer
both genders: lowest quartile: RR 4.06 (95% CI 1.51 to 10.92)
Selenium levels in exposure categories lowest quartile: 0.18 to 0.95 µmol/l
highest quartile: 1.22 to 1.97 µmol/l
Notes
Algotar 2013
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear
Concealment: The study agent (two doses) and matched placebo caplets were coated with
titanium oxide to ensure identical appearance, weight, taste, and smell
Blinding: only described as double-blinded
Dropouts/withdrawals: study dropouts percentage was 34.1%, 41.9%, and 40.8% for placebo,
200 mg/ day selenium group and 400 mg/day selenium group respectively (P=0.173)
Intention-to-treat-analysis: yes
Recruitment period: not specified
Treatment duration: not specified
Observation period/dermatologic follow-up:
Subjects were followed every 6 months for up to 5 years
Detection of cases: Tissue samples from the subject’s qualifying biopsy were requested from
the subject’s physician and compiled in a biospecimen repository
Informed consent: An external Data and Safety Monitoring Committee (DSMC) was estab-
lished before study initiation.This committee was responsible for reviewing protocol amend-
ments, consent forms, accrual and retention rates, adverse events, and data analysis reports
Participants 699 male participants with a negative prostate biopsy
Country: US and NZ
Number of patients: 699 (randomised to selenium 200 ug/day group: 234, to selenium 400
ug/day group: 233; to placebo group: 233)
Condition: male patients at high risk for prostate cancer (prostate specific antigen (PSA) >4
ng/ml and/or suspicious digital rectal examination and/or PSA velocity >0.75 ng/ml/year),
but with a negative prostate biopsy
Demographics:mean age 65.2± SD 8 years (selenium 200ug/day), 65.5±7.7 years (selenium
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Algotar 2013 (Continued)
400ug/day), 65.5±7.4 years (placebo);
Recruitment and setting: from urology offices at 20 sites in theUnited States andNewZealand
Interventions Intervention:
200 µg/day selenium supplied as selenium yeast
400 µg/day selenium supplied as selenium yeast
Control: placebo
Recruitment: not reported
End of the blinded treatment period: For subjects in the US, participation was complete at
5 years, whereas subjects in New Zealand received intervention for no more than 3 years
Outcomes Primary outcome measure:
the incidence of biopsyproven prostate cancer over the course of the study
Other reported outcomes:
The secondary endpoint was the rate of change of PSA over time (i.e., PSA velocity) using
biannual PSA measurements
Risk estimates [95% CI] Primary outcomes:
The hazard ratios [95% confidence intervals] for risk of developing prostate cancer in the
selenium 200 mg/day or the selenium 400 mg/day group were 0.94 [0.52, 1.7] and 0.90 [0.
48, 1.7], respectively
Other reported outcomes:
PSA velocity in the selenium arms was not significantly different from that observed in the
placebo group (P= 0.18 and P = 0.17, respectively)
Selenium levels in exposure categories d.n.a.
Notes The DSMC recommended that the trial be stopped before all participants completed the
full intervention duration
Adverse effects: No significant differences were seen in the incidences of cataract/glaucoma
or in hair/nail changes in the three treatment groups
HR: adjusted for: age at baseline, baseline PSA, baseline selenium concentrations
Allen 2008
Methods Matched, nested case-control study
Countries: Denmark, Germany, Greece, Italy, the Netherlands, Spain, Sweden, the UK
Participants Participants: approximately 130,000 men
Inclusion criteria: male participants of the EPIC study
Name of parent cohort: European Prospective Investigation into Cancer andNutrition (EPIC)
Recruitment: 1992 to 2000
Outcome assessment: at each country’s study closure date (between June 1999 and January
2003)
Number of cases:
Prostate cancer: 959 (male/female: 959/0)
Case definition: incidence
Years of follow-up: median 2.6 years (Greece) to 9.2 years (Sweden)
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Allen 2008 (Continued)
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis:BMI, smoking, alcohol consumption, physical activity,marital
status, education
Variables controlled by matching: age, study centre, time of day of blood collection, time
between blood collection and last meal, sex
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
highest quintile: OR 0.96 (95% CI 0.70 to 1.31)
Selenium levels in exposure categories lowest quintile < 62.0 µg/l
highest quintile ≥ 84.1 µg/l
Notes
Bates 2011
Methods Cohort Study
Country: UK
Participants Participants: 1,054 men and women
Inclusion criteria: people aged 65 years and over
Name of parent cohort: British National Diet and Nutrition Survey
Recruitment: 1994 to 1995
Outcome assessment: September 2008
Number of cases:
Cancer deaths: 140
Case definition:mortality
Type of selenium marker: plasma concentration
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, a1-antichymotrypsin (an acute-phase indicator),
plasma creatinine (a renal status indicator), plasma total andHDL-cholesterol concentrations
and plasma albumin concentration
Risk estimates [95% CI] Cancer deaths
HR 0.72; 95 % CI 0.58 to 0.89
Selenium levels in exposure categories plasma concentrations
Notes
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Bleys 2008
Methods Cohort Study
Country: US
Participants Participants: 13,887 men and women
Inclusion criteria:male and female adults, aged 20 to 90 years, participating in the NHANES
III: “stratified, multistage probability cluster to provide data representing the noninstitution-
alized US population” (Bleys 2008, p. 404)
Name of parent cohort:ThirdNational Health andNutrition Examination Survey (NHANES
III)
Recruitment: 1988 to 1994
Outcome assessment: 15 December 2000
Number of cases:
Cancer deaths: 457 (male/female: n.r.)
Case definition:mortality
Years of follow-up: 6 to 12 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, race, education, annual family income, post-
menopausal status (women), cigarette smoking, serum cotinine level, alcohol consumption
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Cancer deaths
both genders: highest tertile: HR 0.69 (95% CI 0.53 to 0.90)
both genders: highest tertile:HR 0.68 (95%CI 0.48 to 0.97); cases at baseline were excluded
Selenium levels in exposure categories lowest tertile < 117.31 ng/ml
highest tertile ≥ 130.39 ng/ml
Notes
Brooks 2001
Methods Matched, nested case-control study
Country: US
Participants Name of parent cohort: Baltimore Longitudinal Study of Aging
Participants: 1555 men
Inclusion criteria: n.r.
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
prostate cancer: 52 (male/female: 52/0)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: plasma
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Brooks 2001 (Continued)
Interventions d.n.a.
Outcomes Analysed cases: analysis for 52 of 133 cases (reason for non-inclusion: plasma and/or histo-
logical confirmation of diagnosis not available)
Statistical methods: logistic regression
Variables controlled in analysis: years between blood donation and diagnosis/follow-up, age,
age by years before diagnosis interaction, BMI, smoking history, alcohol use
Variables controlled by matching: age
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
highest quartile: OR 0.24 (95% CI 0.07 to 0.77)
Selenium levels in exposure categories lowest quartile: 8.20 to 10.70 µg/dl
highest quartile: 13.30 to 18.20 µg/dl
Notes
Clark 1985
Methods Cohort/sub-cohort-controlled cohort study
Country: US
Participants Participants: 177 participants; no information on gender
Inclusion criteria: persons at high risk of non-melanoma skin cancer
Recruitment: n.r.
Outcome assessment: n.r.
Number of cases:
skin (non-melanoma): 19 (male/female: n.r.)
Case definition: incidence
Years of follow-up: mean: 3.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Risk estimates [95% CI] Reference category: lower half
Results:
Skin (non-melanoma)
gender n.r.: higher half: RR 0.77 (CI not reported)
Selenium levels in exposure categories n.r.
Notes
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Coates 1988
Methods Matched, nested case-control study
Country: US
Participants Participants: number of participants n.r.; both genders
Inclusion criteria: employees of two Seattle companies
Recruitment: 1972 to 1973 and 1976
Outcome assessment: not stated
Number of cases:
Any cancer: 154 (male/female: n.r.)
Gastrointestinal cancer: 28 (male/female: n.r.)
Breast cancer: 20 (male/female: 0/20)
Prostate cancer: 13 (male/female: 13/0)
Haematological cancers: 12 (male/female: n.r.)
Cervical cancer: 12 (male/female: 0/12)
Lung cancer: 11 (male/female: n.r.)
Other: 58 (male/female: n.r.)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum and plasma
Interventions d.n.a.
Outcomes Analysed cases: 154 (133 serum, 21 plasma) of 195 cases analysed (reason for non-inclusion:
no sample available for analysis or no control available)
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection,
employer, plasma or serum sample
Risk estimates [95% CI] Reference category: lowest
Results:
Any cancer
both genders: highest quintile: OR 1.0 (95% CI 0.5 to 1.8)
Gastrointestinal cancer
both genders: highest tertile: OR 1.0 (CI not reported)
Breast cancer
highest tertile: OR 3.4 (CI not reported)
Prostate cancer
highest tertile: OR 0.3 (CI not reported)
Haematological cancers
both genders: highest tertile: OR 0.6 (CI not reported)
Cervical cancer
highest tertile: OR 1.1 (CI not reported)
Lung cancer
both genders: highest tertile: OR 0.8 (CI not reported)
Other cancers
both genders: highest tertile: OR 0.9 (CI not reported)
Selenium levels in exposure categories serum:
lowest quintile: 98 to 142 µg/l
highest quintile: 181 to 240 µg/l
52Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Coates 1988 (Continued)
lowest tertile: 98 to 148 µg/l
highest tertile: 171 to 240 µg/l
plasma:
lowest quintile: 115 to 129 µg/l
highest quintile: 157 to 207 µg/l
lowest tertile: 115 to 137 µg/l
highest tertile: 151 to 207 µg/l
Notes Primary publication: Coates 1988
Secondary publication: Coates 1987
Combs 1993
Methods Cohort/sub-cohort-controlled cohort study
Country: US
Participants Participants: 1239 men and women
Inclusion criteria: participants of the NPCT with valid selenium measurement at baseline
Name of parent cohort: Nutritional Prevention of Cancer Trial (NPCT)
Recruitment: see: Nutritional Prevention of Cancer Trial
Outcome assessment: not stated
Number of cases:
Squamous cell cancer: 204 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 2.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, gender, current smoking, alcohol drinking
Risk estimates [95% CI] Reference category (unadjusted RR): lower half
Results:
Squamous cell cancer
both genders: higher half: unadjusted RR 0.69 (95% CI 0.51 to 0.92)
both genders: “interquartile contrast” (high versus low), adjusted RR 0.79 (95% CI 0.67 to
0.94)
Selenium levels in exposure categories lower half: ≤ 114.00 µg/l
higher half: ≥ 114.10 µg/l
Notes
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Comstock 1997
Methods Matched, nested case-control study
Country: US
Participants Participants: number of participants n.r.; both genders
Inclusion criteria: residents of Washington County
Name of parent cohort: CLUE I and II Cohort
Recruitment: 1974/75 or 1989
Outcome assessment: n.r.
Number of cases:
Lung cancer: 258 (male/female: 157/101)
Case definition: incidence
Years of follow-up: n.r.
Type of selenium marker: serum/plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, participant of Clue I or Clue II cohort
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Lung cancer
both genders: highest quintile: OR 0.65 (CI not reported)
Selenium levels in exposure categories n.r.
Notes
Dong 2008
Methods Cohort study
Country: US
Participants Participants: 339 participants (275 men; 64 women)
Inclusion criteria: participants of a surveillance programme formen and women with Barrett’s
oesophagus, no prior history of oesophageal cancer or diagnosis of cancer within first three
months of baseline
Name of parent cohort: Seattle Barrett’s Esophagus Program
Recruitment: 1983 to 2004, baseline assessment for this study: 1 February 1995 to 1 July
2004
Outcome assessment: n.r.
Number of cases: oesophageal adenocarcinoma: 37 (32 men, 5 women)
Case definition: incidence
Years of follow-up: mean: 5 years
Type of selenium marker: intake of selenium supplements (self administered food frequency
questionnaire)
Interventions d.n.a.
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Dong 2008 (Continued)
Outcomes Statistical methods: Cox proportional hazards regression
Variables controlled in analysis: age, sex, fruit and vegetable consumption, percent energy
from fat, waist-hip ratio, cigarette smoking, non-steroidal anti-inflammatory drug use
Risk estimates [95% CI] Reference category: no supplemental selenium intake (lowest exposure category)
Results:
both genders: supplement intake ≥ 50 µg/day: HR 0.27 (95% CI 0.03 to 2.21)
Selenium levels in exposure categories lowest category: no supplemental selenium intake
middle category: supplemental selenium intake < 50 µg/day
highest category: supplemental intake ≥ 50 µg/day
Notes
Dorgan 1998
Methods Matched, nested case-control study
Country: US
Participants Participants: 6426 women
Inclusion criteria: female volunteers with serum available at the Breast Cancer Serum Bank
in Columbia (Missouri)/U.S.A; no history of cancer at baseline; missing serum sample for
analysis excluded
Recruitment: 1987 to 1997
Outcome assessment: 1982 to 1983, 1989
Number of cases:
Breast cancer: 105 (male/female: 0/105)
Case definition: incidence
Years of follow-up: median: 2.7 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: serum cholesterol, packs of cigarettes / day, BMI
Variables controlled bymatching: age, year andmonth of sample collection, diagnosis of benign
breast disease within two years prior to study enrolment, “sequence number of blood draw”
for women who donate blood more than one time
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Breast cancer
highest quartile: OR 0.9 (95% CI 0.4 to 1.8)
Selenium levels in exposure categories lowest quartile: ≤ 1.43 µmol/l
highest quartile: 1.67 to 1.98 µmol/l
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Dorgan 1998 (Continued)
Notes
Dreno 2007
Methods Multicentre, randomised, placebo-controlled, parallel-group trial
Allocation: random
Sequence generation: unclear
Concealment: unclear
Blinding: only described as double-blinded
Dropouts/withdrawals: During the treatment phase, 38 in the selenium group and 37 in the
placebo group withdrew from the study. This distribution was similar in both treatment
groups
Intention-to-treat-analysis: unclear
Recruitment period: not specified
Treatment duration: 3 years of treatment
Observation period/dermatologic follow-up:
Subjects were followed for 2 years more after treatment
Detection of cases: Patients were seen by a dermatologist before grafting; and any patients
presenting with a non-malignant or malignant skin keratosis or viral warts that had been
present for less than 3 months were not selected. Within 10 weeks following the graft, a
second visit was performed by a dermatologist to check that no new cutaneous lesion had
appeared
Informed consent:The protocol and consent form had been approved by a National Ethics
Committee prior to starting the study. Written informed consent was mandatory
Participants 184 participants
Number of patients: 184 (randomised to selenium 200 ug/day group: 91, to placebo group:
93)
Condition: organ transplant recipient population
Demographics:mean age 44.3± SD13 years (selenium200ug/day), 44.4± 10.7 years (placebo)
;
Interventions Intervention:
200 µg/day selenium supplied as selenium yeast
Control: placebo
Outcomes Primary outcome measure:
Occurrence rates of warts and various keratoses
Other reported outcomes:
skin cancers
Risk estimates [95% CI] Primary outcome: events in selenium group=33 (36.3%), events in placebo group=31 (33.
3%); odds-ratio 1.09, P = 0.72
Secondary outcome: events in selenium group=6 (6.6%), events in placebo group=2 (2.2%)
; odds-ratio 3.08, P = 0.15
Selenium levels in exposure categories
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Dreno 2007 (Continued)
Notes
Epplein 2009
Methods Matched, nested case-control study (Epplein 2009, Gill 2009)
Country: US
Participants Inclusion criteria: participants of theMultiethnic Cohort, aged 45 to 75 years (native Hawai-
ians: aged 42 years and older), blood sample provided before cancer diagnosis between 1997
and 2006
Name of parent cohort: Multiethnic Cohort
Recruitment: 1993 to 1996
Case definition: incidence
Type of selenium marker: serum
Epplein 2009:
Participants: 67,594 (male: 29,009 / female: 38,585) men and women
Outcome assessment: 2006
Number of cases:
Lung cancer: 207 (male/female: 136/71)
Years of follow-up: 0 to 10 years
Gill 2009:
Participants: 29,009 men
Outcome assessment: n.r.
Number of cases:
Prostate cancer: 467 (male/female: 467/0)
Years of follow-up: n.r.
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Epplein 2009:
Variables controlled in analysis: age, fasting hours, pack-years, pack-years squared, years of
schooling, family history of lung cancer
Variables controlled by matching: age, sex, race/ethnicity, date of sample collection, time of
day of sample collection, fasting status, smoking
Gill 2009:
Analysed cases: 450 of 467 cases analysed
Variables controlled in analysis: age, fasting hours, BMI, family history of prostate cancer,
education
Variables controlled by matching: age, race/ethnicity, date of sample collection, geographic
site (California, Hawaii), time of day of sample collection, fasting status
Risk estimates [95% CI] Epplein 2009:
Reference category: lowest tertile
Results:
Lung cancer
male:
highest tertile: OR 0.70 (95% CI 0.37 to 1.33)
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Epplein 2009 (Continued)
female:
highest tertile: OR 0.98 (95% CI 0.42 to 2.29)
Gill 2009:
Reference category: lowest quartile
Results:
Prostate cancer
highest quartile: OR 0.82 (95% CI 0.59 to 1.14)
Selenium levels in exposure categories Epplein 2009:
lowest tertile: median 0.12 µg/g of sodium
highest tertile: median 0.15 µg/g of sodium
Gill 2009:
lowest quartile: median 0.12 µg/g
highest quartile: median 0.16 µg/g
Notes Primary publication: Epplein 2009
Other publications: Gill 2009
Fex 1987
Methods Matched, nested case-control study
Country: Sweden
Participants Participants: 7935 men
Inclusion criteria: 46 to 48 years of age; residents of Malmo/Sweden; no restriction regarding
malignant disease at baseline (11 of 35 cases were diagnosed with cancer at baseline screening
examination and/or died during first year of follow-up)
Name of parent cohort: Malmo Preventive Programme
Recruitment: 1975 to 1979
Outcome assessment: June 1981
Number of cases:
Any cancer: 35 (male/female: 35/0)
Case definition:mortality
Years of follow-up: 3.5 to 8.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 35 of 61 cases analysed (reason for non-inclusion: no plasma sample available)
Statistical methods: logistic regression, Mantel-Haenszel
Variables controlled by matching: age, month of sample collection
Risk estimates [95% CI] Reference category: highest quintile
Results:
Any cancer
male: lowest quintiles: OR 3.8 (CI not reported)
Selenium levels in exposure categories n.r.
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Fex 1987 (Continued)
Notes
Fujishima 2011
Methods Prospective cohort study
Country: northern part of Japan
Participants Participants: 1,041 men and women
Inclusion criteria: adult haemodialysis patients
Name of parent cohort: ‘Kaleidoscopic Approaches to patients with end-stage RENal disease
Study’ (the KAREN Study)
Recruitment: June 2003 to March 2004
Number of cases:
malignant disease-related death: 17
Case definition:mortality
Years of follow-up: 5-year
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: Cox logistic regression
Variables controlled by matching: age, male gender, BMI, hypertension, dyslipidaemia, dia-
betes mellitus, serum albumin levels, high-sensitivity CRPlevels, history of myocardial in-
farction, history of stroke, history of malignant disease, smoking status and regular drinking
habit
Risk estimates [95% CI] Reference category: lowest quartile
Results:
malignant disease-related death
highest quartile: HR 2.98 (95% CI 0.62 to 14.35)
Selenium levels in exposure categories lowest quartile: 18.4-85.3 pg/L
highest quartile: 114.2-226.2 pg/L
Notes
Garland 1995
Methods Matched, nested case-control study
Country: US
Participants Participants: 62,641 women
Inclusion criteria: female registered nurses in 11 U.S. states; aged 30 to 55 years at baseline;
completed questionnaire in 1976 and provision of toenail sample in 1982; no history of
cancer at baseline
Name of parent cohort: Nurses’ Health Study (NHS)
Recruitment: 1976 (toenail sample collection in 1982)
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Garland 1995 (Continued)
Outcome assessment: 1 June 1986
Garland 1995:
Number of cases:
Any cancer (without breast): 503 (male/female: 0/503)
Colon and rectal cancer: 89 (male/female: 0/89)
Melanoma: 63 (male/female: 0/63)
Ovarian cancer: 58 (male/female: 0/58)
Lung cancer: 47 (male/female: 0/47)
Other: 155 (male/female: 0/155)
Uterine cancer: 91 (male/female: 0/91)
Hunter 1990:
Number of cases:
Breast cancer: 434 (0/434)
Case definition: incidence
Years of follow-up: 2.0 to 4.4 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistic regression, conditional logistic regression
Variables controlled in analysis: smoking status
Variables controlled by matching: age, year and month of sample collection
Hunter 1990 additionally controlled in analysis for: age at first birth, age atmenarche, alcohol
use, history of benign breast disease, menopausal status, maternal breast cancer, breast cancer
in sister(s), oral contraceptive use, parity, relative weight
Risk estimates [95% CI] Reference category: lowest quintile, lowest tertile
Results:
Garland 1995:
Any cancer (without breast)
female: highest quintile: OR 1.44 (95% CI 0.97 to 2.13)
Colon and rectal cancer
female: highest tertile: OR 2.04 (95% CI 0.88 to 4.75)
Melanoma
female: highest tertile: OR 1.66 (95% CI 0.71 to 3.85)
Ovarian cancer
highest tertile: OR 1.22 (95% CI 0.44 to 3.38)
Lung cancer
female: highest tertile: OR 4.33 (95% CI 0.54 to 34.60)
Other cancer
female: highest tertile: OR 0.97 (95% CI 0.55 to 1.71)
Uterine cancer
highest tertile: OR 1.38 (95% CI 0.62 to 3.08)
Hunter 1990:
Breast cancer
highest quintile: OR 1.10 (95% CI 0.70 to 1.72)
Selenium levels in exposure categories Garland 1995:
lowest quintile: ≤ 0.71 µg/g
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Garland 1995 (Continued)
highest quintile: ≥ 0.95 µg/g
Hunter 1990:
lowest quintile: ≤ 0.705 µg/g
highest quintile: ≥ 0.906 µg/g
Notes Primary publication: Garland 1995
Other publications: Hunter 1990
Glattre 1989
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 100,000 men and women
Inclusion criteria: serum available at Janus serum bank (Norwegian serum bank which is
consolidated from several sources and maintained by the Norwegian Cancer Society for
research purposes)
Recruitment: 1972 to 1985
Outcome assessment: end of 1985
Number of cases:
thyroid cancer: 43 (male/female: 12/31)
Case definition: incidence
Years of follow-up: 0.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, year of sample collection, county of residence
Risk estimates [95% CI] Reference category: highest tertile
Results:
Thyroid cancer
both genders: lowest tertiles: OR 7.7 (95% CI 1.3 to 44.7)
men: lowest tertiles: OR 6.5 (95% CI 0.2 to 201.9)
women: lowest tertiles: OR 8.3 (95% CI 0.9 to 78.5)
Selenium levels in exposure categories lowest tertile: ≤ 1.25 µmol/l
highest tertile: ≥ 1.65 µmol/l
Notes
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Goodman 2001
Methods Matched, nested case-control study
Country: US
Participants Participants: 18,314 men and women
Inclusion criteria: asbestos workers: 45 to 74 years of age; smokers > 20 pack-years: 50 to 69
years of age; cohort of a RCT for lung cancer prevention in high risk populations
Name of parent cohort: Caret (Carotene and Retinol Efficacy Trial)
Recruitment: 1988 to 1994
Outcome assessment: April 1999
Number of cases:
Lung cancer: 235 (male/female: n.r.)
Prostate cancer: 356 (male/female: 356/0)
Case definition: incidence
Years of follow-up: 6.0 to 12.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 235 of 236 prostate cancer cases analysed (reason for non-inclusion: no sample
available for analysis or no control available); 356 of 385 lung cancer cases analysed (reason
for non-inclusion: missing selenium values for case-control pairs)
Statistical methods: conditional logistic regression
Variables controlled bymatching: age, smoking status at randomisation, year of randomisation,
year of sample collection, treatment arm, exposure population
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Lung cancer
both genders: highest quartile: OR 1.20 (95% CI 0.77 to 1.88)
male: highest quartile: OR 1.53 (95% CI 0.83 to 2.82)
female: highest quartile: OR 0.76 (95% CI 0.29 to 2.01)
Prostate cancer
highest quartile: OR 1.02 (95% CI 0.65 to 1.60)
Selenium levels in exposure categories Lung cancer:
lowest quartile: 6.39 to 10.55 µg/dl
highest quartile: 12.94 to 17.23 µg/dl
Prostate cancer:
lowest quartile: 5.07 to 10.12 µg/dl
highest quartile: 12.60 to 21.96 µg/dl
Notes
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Grundmark 2011
Methods Cohort study
Country: Swedish
Participants Participants: 2322 males
Inclusion criteria: male residents in Uppsala county in January 1970, born in 1920-24
Name of parent cohort: Uppsala Longitudinal Study of Adult Men (ULSAM).
Recruitment: 1991 to 1995
Outcome assessment: 31/12/2003
Number of cases:
Prostate cancer: 208
Case definition: incidence
Years of follow-up: 26.5-years (median)
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: proportional hazard model
Risk estimates [95% CI] Reference category: lowest level
Results:
Prostate cancer:
highest level: RR 0.83 (95% CI 0.60 to 1.16)
Selenium levels in exposure categories lowest level: <=70 µg/l
highest level: >81 µg/l
Notes
Hartman 1998
Methods Cohort/sub-cohort-controlled cohort study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-
melanoma skin cancer) at baseline; no severe physical or psychiatric illness; intake of vitamin
E/A/beta-carotene supplements in excess of defined amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
Prostate cancer: 302 (male/female: 302/0)
Case definition: incidence
Years of follow-up: 5.0 to 8.0 years
Type of selenium marker: intake(food use questionnaire)
Interventions d.n.a.
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Hartman 1998 (Continued)
Outcomes Analysed cases: 302 of 317 cases included in analysis (reason for non-inclusion: no dietary
information available)
analysis stratified by randomisation status according to active interventions or placebo in-
terventions in the RCT
results reported separately for total selenium intake and non-supplemental selenium intake
Statistical methods: Cox regression
Variables controlled in analysis: age, living in urban area, beta-carotene intervention, total
energy, BPH
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer:
Total (nutritional and supplemental) selenium intake in participants without active alpha-
tocopherol intervention:
highest quartile: RR 1.27 (95% CI 0.70 to 2.20)
Total (nutritional and supplemental) selenium intake in participants with alpha-tocopherol
intervention:
highest quartile: RR 0.84 (95% CI 0.43 to 1.67)
Nutritional selenium intake in participants without active alpha-tocopherol intervention:
highest quartile: RR 1.32 (95% CI 0.70 to 2.47)
Nutritional selenium intake in participants with alpha-tocopherol intervention:
highest quartile: RR 0.72 (95% CI 0.33 to 1.55)
Selenium levels in exposure categories Total nutritional and supplemental selenium intake:
lowest quartile: ≤ 71.51 µg/day
highest quartile: ≥ 111.06 µg/day
Nutritional selenium intake:
lowest quartile: ≤ 70.10 µg/day
highest quartile: ≥ 105.65 µg/day
Notes
Helzlsouer 2000
Methods Matched, nested case-control study
Country: US
Participants Participants: 10,456 men
Inclusion criteria: residents of Washington county; cases with second malignancy or missing
pathologic confirmation excluded
Name of parent cohort: CLUE II Cohort
Recruitment: 1989
Outcome assessment: September 1996
Number of cases:
prostate cancer: 117 (male/female: 117/0)
Case definition: incidence
Years of follow-up: 6.8 to 7.8 years
Type of selenium marker: toenail
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Helzlsouer 2000 (Continued)
Interventions d.n.a.
Outcomes Analysed cases: 117 of 145 cases analysed (reason for non-inclusion: no toenail clipping
available)
Statistical methods: conditional logistic regression
Variables controlled in analysis: BMI at age 21, education, hours since last meal
Variables controlled by matching: age, race/ethnicity, year and month of sample collection,
size of toenail clipping
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
highest quintile: OR 0.38 (95% CI 0.17 to 0.85)
Selenium levels in exposure categories lowest quintile: ≤ 0.69 ppm
highest quintile: ≥ 0.92 ppm
Notes
Hotaling 2011
Methods Cohort study
Country: US
Participants Participants: 77,050 men and women,
aged 50 to 76 years, participants recruited from subscribers of commercial mailing list,
residents of westernWashington state, non-whites excluded, no malignant disease at baseline
Name of parent cohort: Vitamins and lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Outcome assessment: 31/12/2007
Number of cases:
Urothelial carcinoma: 330
Case definition: incidence
Years of follow-up: 6 years (median)
Type of selenium marker: supplemental intake (questionnaire: use of supplements over the
last 10 years, mean supplemental intake / day calculated)
Interventions d.n.a.
Outcomes Statistical methods: cox proportional hazards regression,
Variables controlled in analysis: age, gender, race (white, black, other), education, family
history of bladder cancer, smoking (never; former, quit more than 10 years before start of
VITAL; former, quit less than 10 years before start of VITAL; current), pack-years (never
smoker and tertiles), and fruit and vegetable intake
Risk estimates [95% CI] Reference category: nonuse
Results:
highest level: HR 0.97 (95% CI 0.72 to 1.31)
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Hotaling 2011 (Continued)
Selenium levels in exposure categories lowest level: nonuse
highest quartile: 20 mcg
Notes
Kabuto 1994
Methods Matched, nested case-control study
Country: Japan
Participants Participants: 20,000 men and women
Inclusion criteria: survivors of the atomic bomb in Hiroshima or Nagasaki; serum available
for analysis
Name of parent cohort: Adult Health Study Hiroshima and Nagasaki
Recruitment: 1960 (blood samples drawn in 1970 to 1972)
Outcome assessment: 1983
Number of cases:
Stomach cancer: 201 (male/female: 113/88)
Lung cancer: 77 (male/female: 43/34)
Case definition: incidence
Years of follow-up: 12.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: radiation dose, smoking, age, gender
Variables controlled by matching: age, gender, year/month of sample collection, city
Risk estimates [95% CI] Reference category: highest quartile
Results:
Stomach
both genders: lowest quartile: OR 1.0 (95% CI 0.5 to 1.9)
Lung cancer
both genders: lowest quartile: OR 1.8 (95% CI 0.7 to 5.0)
Selenium levels in exposure categories lowest quartile ≤ 98.90 ng/ml
highest quartile ≥ 128.10 ng/ml
Notes
66Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Karagas 1997
Methods Matched, nested case-control study
Country: US
Participants Participants: 1805 men and women
Inclusion criteria: at least one basal cell or squamous cell cancer before study entry; partici-
pants of an RCT for non-melanoma skin cancer prevention with oral beta-carotene supple-
mentation
Name of parent cohort: Skin Cancer Prevention Study
Recruitment: February 1983 to February 1986
Outcome assessment: 30 September 1989
Number of cases:
Squamous cell cancer: 131 (89% male/11% female)
Case definition: incidence
Years of follow-up: 3.0 to 5.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: cigarette smoking
Variables controlled by matching: age, gender, study centre of RCT, time in study (diagnosis
date)
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Squamous cell cancer
both genders: highest quartile: OR 0.86 (95% CI 0.47 to 1.58)
Selenium levels in exposure categories lowest quartile: ≤ 0.12 ppm
highest quartile: ≥ 0.14 ppm;
Notes
Knekt 1990
Methods Matched, nested case-control study (Knekt 1990, Hakama 1990, Knekt 1988, Knekt 1996)
Cohort study (Knekt 1991)
Country: Finland
Participants Inclusion criteria: no history of cancer at baseline
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination
Survey
Recruitment: 1968 to 1972
Knekt 1990:
Participants: 39,268: 21,172 men and 18,096 women
Outcome assessment: 31 December 1980
Number of cases:
Any cancer: 1096 (male/female: 597/499)
Stomach cancer: 95 (male/female: 58/37)
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Knekt 1990 (Continued)
Colon and rectal cancer: 91 (male/female: 32/59)
Lung cancer: 198 (male/female: 189/9)
Prostate cancer: 51 (male/female: 51/0)
Urinary tract cancer: 47 (male/female: 34/13)
Pancreatic cancer: 45 (male/female: 22/23)
Breast cancer: 90 (male/female: 0/90)
Gynaecological cancer (without breast): 86 (male/female: 0/86)
Basal cell carcinoma (skin): 126 (male/female: 64/62)
Other: 267 (male/female: 147/120)
Hakama 1990:
Participants: number of participants n.r.; both genders
Inclusion criteria: aged 15 years and older
Outcome assessment: 1977
Number of cases:
Any cancer: 766 (male/female: n.r.)
Lung cancer: 151 (male/female: 151/0)
Breast cancer: 67 (male/female: 0/67)
Stomach cancer: 76 (male/female: n.r.)
Prostate cancer: 37 (male/female: 37/0)
Knekt 1988:
Participants: 36,265: 21,172 men and 15,093 women
Outcome assessment: 31 December 1977
Number of cases:
Oesophageal and stomach cancer: 86 (male/female: 51/35)
Colon and rectal cancer: 57 (male/female: 21/36)
Knekt 1991:
Participants: 4538 men
Inclusion criteria: aged 20 to 69 years, with dietary history taken
Outcome assessment: 1986
Number of cases:
Lung cancer: 117 (male/female: 117/0)
Knekt 1996:
Participants: 1896 women
Outcome assessment: 1980
Number of cases:
Ovarian cancer: 24 (male/female: 0/24)
Case definition: incidence
Years of follow-up: 9 to 20 years
Type of selenium marker: serum (Knekt 1990, Hakama 1990, Knekt 1988, Knekt 1996),
intake (Knekt 1991: dietary history)
Interventions d.n.a.
Outcomes Knekt 1990:
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking
Variables additionally controlled in analysis of highest four quintiles versus lowest quintile: occu-
pation, BMI, parity, cholesterol, haematocrit
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
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Knekt 1990 (Continued)
Hakama 1990:
Analysed cases: 766 of 864 cases analysed (reason for non-inclusion: no serum sample)
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking
Variables additionally controlled in analysis of highest four quintiles versus lowest quintile: retinol
level, alpha-tocopherol level
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Knekt 1988:
Statistical methods: n.r.
Variables controlled in analysis: smoking, serum cholesterol
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Knekt 1991:
Statistical methods: Cox-proportional hazards model
Variables controlled in analysis: age, smoking (data stratified according to smoking status)
Knekt 1996:
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, municipality, time of baseline examination,
duration of storage of sample
Risk estimates [95% CI] Knekt 1990:
Reference category: lowest quintile
Results:
Any cancer
male:
highest quintile: OR 0.41 (CI not reported)
above 20th percentile: OR 0.67 (CI not reported); cases during first 2 years of follow-up
excluded: 476 cases: OR 0.65 (95% CI 0.48 to 0.89)
female:
highest quintile: OR 0.86 (CI not reported)
above 20th percentile: OR 0.93 (CI not reported); cases during first 2 years of follow-up
excluded: 423 cases: OR 0.97 (95% CI 0.68 to 1.39)
Stomach cancer
male:
highest quintile: OR 0.09 (CI not reported)
above 20th percentile: OR 0.26 (CI not reported); cases during first 2 years of follow-up
excluded: 43 cases: OR 0.24 (95% CI 0.09 to 0.69)
female:
highest quintile: OR 0.27 (CI not reported)
above 20th percentile: OR 0.59 (CI not reported); cases during first 2 years of follow-up
excluded: 30 cases: OR 0.48 (95% CI 0.14 to 1.66)
Colon and rectal cancer
male:
highest quintile: OR 0.53 (CI not reported)
above 20th percentile: OR 0.69 (CI not reported); cases during first 2 years of follow-up
excluded: 29 cases: OR 1.01 (95% CI 0.18 to 5.65)
female:
highest quintile: OR 0.80 (CI not reported)
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Knekt 1990 (Continued)
above 20th percentile: OR 1.26 (CI not reported); cases during first 2 years of follow-up
excluded: 48 cases: OR 1.10 (95% CI 0.42 to 2.92)
Lung cancer
male:
highest quintile: OR 0.30 (CI not reported)
above 20th percentile: OR 0.60 (CI not reported); cases during first 2 years of follow-up
excluded: 153 cases: OR 0.66 (95% CI 0.37 to 1.19)
female:
third highest quintile: OR 4.62 (CI not reported) (quintile 4 and 5 did not contain any
cases)
Prostate cancer
highest quintile: OR 1.15 (CI not reported)
above 20th percentile: OR 1.13 (CI not reported); cases during first 2 years of follow-up
excluded: 46 cases: OR 1.00 (95% CI 0.42 to 2.40)
Urinary tract cancer
male:
highest quintile: OR 0.81 (CI not reported)
above 20th percentile: OR 0.89 (CI not reported); cases during first 2 years of follow-up
excluded: 26 cases: OR 0.34 (95% CI 0.06 to 2.06)
female:
highest quintile: OR 4.12 (CI not reported)
above 20th percentile: not reported; cases during first 2 years of follow-up excluded: 9 cases:
OR 2.51 (95% CI 0.13 to 47.9)
Pancreatic cancer
male:
fourth quintile versus lowest: OR 0.58 (CI not reported) (highest quintile did not contain
any cases)
above 20th percentile: OR 0.11 (CI not reported); cases during first 2 years of follow-up
excluded: not reported
female:
highest quintile: OR 3.49 (CI not reported)
above 20th percentile: not reported; cases during first 2 years of follow-up excluded: 22 cases:
OR 0.86 (95% CI 0.21 to 3.52)
Breast cancer
highest quintile: OR 0.64 (CI not reported)
above 20th percentile: OR 0.52 (CI not reported); cases during first 2 years of follow-up
excluded: 74 cases: OR 0.57 (95% CI 0.18 to 1.81)
Gynaecological cancer (without breast)
highest quintile: OR 0.96 (CI not reported)
above 20th percentile: OR 0.91 (CI not reported); cases during first 2 years of follow-up
excluded: 70 cases: OR 1.03 (95% CI 0.43 to 2.50)
Basal cell carcinoma (skin)
male:
highest quintile: OR 0.54 (CI not reported)
above 20th percentile: OR 0.65 (CI not reported); cases during first 2 years of follow-up
excluded: 54 cases: OR 0.86 (95% CI 0.35 to 2.12)
female:
highest quintile: OR 1.55 (CI not reported)
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Knekt 1990 (Continued)
above 20th percentile: OR 1.73 (CI not reported); cases during first 2 years of follow-up
excluded: 52 cases: OR 1.54 (95% CI 0.64 to 3.73)
Other or unspecified cancer:
male:
highest quintile: OR 0.42 (CI not reported)
above 20th percentile: OR 0.72 (CI not reported); cases during first 2 years of follow-up
excluded: 110 cases: OR 0.70 (95% CI 0.36 to 1.36)
female:
highest quintile: OR 0.71 (CI not reported)
above 20th percentile: OR 0.87 (CI not reported); cases during first 2 years of follow-up
excluded: 111 cases: OR 0.92 (95% CI 0.44 to 1.92)
Hakama 1990:
Reference category: highest quintile
Results:
Any cancer
male:
lowest quintile: OR 2.40 (CI not reported)
lowest quintile vs. four highest quintiles: OR 1.60 (CI not reported)
female:
lowest quintile: OR 1.20 (CI not reported)
lowest quintile vs. four highest quintiles:0.90 (CI not reported)
Lung cancer
male:
lowest quintile vs. four highest quintiles: OR 1.80 (CI not reported)
Breast cancer
lowest quintile vs. four highest quintiles: OR 3.10 (CI not reported)
Stomach cancer
male:
lowest quintile vs. four highest quintiles: OR 6.70 (CI not reported)
female:
lowest quintile vs. four highest quintiles: OR 2.00 (CI not reported)
Prostate cancer
lowest quintile vs. four highest quintiles: OR 0.80 (CI not reported)
Knekt 1988:
Reference category: highest quintile
Results:
Oesophageal and stomach cancer
male:
lowest tertile: OR 2.20 (CI not reported)
lowest quintile vs. four highest quintiles: OR 3.3 (95% CI 1.3 to 9.1)
female:
lowest tertile: OR 1.50 (CI not reported)
lowest quintile vs. four highest quintiles: OR 2.4 (95% CI 0.7 to 8.3)
Colon and rectal cancer
male:
lowest tertile: OR 0.90 (CI not reported)
lowest quintile vs. four highest quintiles: OR 1.7 (95% CI 0.4 to 7.7)
female:
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Knekt 1990 (Continued)
lowest tertile: OR 0.60 (CI not reported)
lowest quintile vs. four highest quintiles: OR 0.8 (95% CI 0.2 to 2.4)
Knekt 1991:
Reference category: highest tertile
Results:
Lung cancer
male non-smokers: lowest tertile: OR 1.03 (CI not reported)
male smokers: lowest tertile: OR 0.83 (CI not reported)
Knekt 1996:
Reference category: highest tertile
Results:
Ovarian cancer
lowest tertile: OR 1.15 (95% CI 0.19 to 4.06)
Selenium levels in exposure categories Knekt 1990:
lowest quintile: ≤ 48.90 µg/l; highest quintile ≥ 78.00 µg/l
Hakama 1990:
quintiles: not specified
Knekt 1988:
both genders:
lowest tertile: ≤ 56.90 µg/l; highest tertile ≥ 70.10 µg/l
lowest quintile: ≤ 50 µg/l; highest four quintiles > 50 µg/l
Knekt 1991:
tertiles: n.r.
Knekt 1996:
lowest tertile: ≤ 56.90 µg/l; highest tertile: ≥ 68.10 µg/l
Notes Primary publication: Knekt 1990
Other publications: Hakama 1990, Knekt 1988, Knekt 1991, Knekt 1996
Knekt 1998
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 9101 men and women
Inclusion criteria: 19 years or older; no history of cancer at baseline; serum sample available
for analysis
Name of parent cohort: Social Insurance Institution’s Mobile Clinic Health Examination
Survey
Recruitment: 1973 to 1976
Outcome assessment: end of 1991
Number of cases:
Lung cancer: 91 (male/female: approximately 95%/5%)
Case definition: incidence
Years of follow-up: 16.0 to 19.0 years
Type of selenium marker: serum
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Knekt 1998 (Continued)
Interventions d.n.a.
Outcomes Analysed cases: 91 of 95 (male/female: 90/5) cases analysed
Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking, alpha-tocopherol, serum cholesterol, copper, oro-
somucoid, BMI
Variables controlled bymatching: age, gender, municipality, season of sample collection, length
of storage of sample
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Lung cancer
analysis adjusted for smoking only: both genders: highest tertiles: OR 0.44 (95% CI 0.21
to 0.89)
analysis adjusted for all variables (number of cases: 77): highest tertiles: OR 0.41 (95% CI
0.17 to 0.94)
Selenium levels in exposure categories lowest tertile: ≤ 45.49 µg/l
highest tertile: ≥ 60.60 µg/l
Notes
Kok 1987a
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 10,532 men and women
Inclusion criteria: inhabitants of Zoetermeer; 5 years or older
Name of parent cohort: EPOZ Cohort (Epidemiologisch onderzoek naar risico-indicatoren
voor hart- en vaatziekten)
Recruitment: 1975 to 1978
Outcome assessment: 31 December 1983
Number of cases:
Any cancer: 69 (male/female: 40/29)
Case definition:mortality
Years of follow-up: 6.0 to 9.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 69 of 114 cases analysed (reason for non-inclusion: serum or baseline data not
available, deaths in first year of follow-up excluded)
Statistical methods: not specified
Variables controlled in analysis: age, smoking, serum cholesterol, serum vitamin A and E,
systolic and diastolic blood pressure, BMI, week of blood collection, years of education,
gender (in group of both genders)
Variables controlled by matching: age, gender, smoking status
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Kok 1987a (Continued)
Risk estimates [95% CI] Reference category: highest four quintiles
Results:
Any cancer
both genders: lowest quintile: OR 1.9 (90% CI 1.0 to 3.5)
male: lowest quintile: OR 2.7 (90% CI 1.2 to 6.2)
female: lowest quintile: OR 1.5 (90% CI 0.5 to 4.5)
Selenium levels in exposure categories both genders:
lowest quintile: ≤ 102.79 µg/l
highest four quintiles: ≥ 102.80 µg/l
men:
lowest quintile: ≤ 100.79 µg/l
highest four quintiles: ≥ 100.80 µg/l
women:
lowest quintile: ≤ 107.29 µg/l
highest four quintiles: ≥ 107.30 µg/l
Notes Primary publication: Kok 1987b
Other publication: Kok 1987a
Kornitzer 2004
Methods Matched, nested case-control study
Country: Belgium
Participants Participants: cohort size not reported; men and women
Inclusion criteria: 25 to 74 years of age
Name of parent cohort: Belgian Interuniversity Study on Nutrition and Health
Recruitment: 1980 to 1984
Outcome assessment: n.r.
Number of cases:
Any cancer: 193 (male/female: 143/50)
Case definition:mortality
Years of follow-up: 10.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 143 male/50 female cases analysed from 252 male/91 female cases (reason for
non-inclusion: no selenium measurement available)
Statistical methods: not specified
Variables controlled in analysis: BMI, total energy, total fat, saturated fat, alcohol intake, fibre,
retinol, vitamin C, smoking, beta-carotene
Variables controlled by matching: age, gender
Risk estimates [95% CI] Reference category: highest tertile
Results:
Any cancer
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Kornitzer 2004 (Continued)
male: lowest tertile: OR 2.2 (95% CI 1.3 to 3.7)
female: lowest tertile: OR 0.7 (95% CI 0.3 to 1.6)
Selenium levels in exposure categories lowest tertile ≤ 72.00 µg/l
highest tertile ≥ 85.00 µg/l
Notes
Kromhout 1987
Methods Cohort/sub-cohort-controlled cohort study
Country: the Netherlands
Participants Participants: 878 men
Inclusion criteria: 40 to 59 years of age; random sample of general male population at specific
age in Zutphen
Name of parent cohort: Zutphen Study
Recruitment: 1960
Outcome assessment: 1985
Number of cases:
lung cancer: 63 (male/female: 63/0)
Case definition:mortality
Years of follow-up: 25.0 years
Type of selenium marker: intake (interview)
Interventions d.n.a.
Outcomes Statistical methods: Cox proportional hazard model
Variables controlled in analysis: age, pack years of smoking
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Lung cancer
male: highest quartile: RR 0.98 (95% CI 0.41 to 2.36)
Selenium levels in exposure categories lowest quartile: ≤ 55.00 µg/day
highest quartile: ≥ 72.10 µg/day
Notes
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Li 2000
Methods Randomised controlled trial
Allocation: randomised, “based on their residence area”
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo), of investigators and doctors: unclear, not described
Dropouts/withdrawals: no significant difference between percentage of drop-outs in interven-
tion and control group (absolute numbers not reported)
Intention-to-treat-analysis: unclear
Recruitment period: unclear, not described
Observation period: 3 years, started in 1996
Study period: unclear, not described
Detection of cases: unclear, the study followed the diagnostic menu published by the National
Cancer Control and Prevention Center, follow-up procedures not described
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2065 (selenium group: 1112; placebo group: 953)
Condition: HBsAg carriers with negative AFP and normal ALT living in Qidong, Jiangsu
province
Demographics:men only; aged 20 to 65 years (screening group)
Recruitment and setting: recruitment of 2065 HBsAg carriers from 17 villages out of a screen-
ing group of 18,000 men
Interventions Intervention: 0.5 mg sodium selenite p.o. daily for 3 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer
Other: blood selenium levels, activity of glutathione peroxidase
Results: person-year incidence rate (number of cases/total number of persons) in intervention
and control group:
1st year of follow-up: selenium group 899.25/100,000 (10/1112); placebo group: 1,888.77/
100,000 (18/953)
2nd year of follow-up: selenium group 1,708.60/100,000 (19/1112); placebo group: 4,302.
20/100,000 (41/953)
3rd year of follow-up: selenium group 3,057.55/100,000 (34/1112); placebo group: 5,981.
11/100,000 (57/953)
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes adverse effects were not mentioned
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Li 2004a
Methods Matched, nested case-control study
Country: US
Participants Participants: 14,916 men
Inclusion criteria: participants of Physicians’ Health Study who provided blood sample
(healthy male physicians); no history of cancer at baseline; several physical conditions ex-
cluded at baseline: chronic renal failure, unstable angina pectoris, liver disease, peptic ulcer,
history of TIA/stroke/myocardial infarction/gout; no use of vitamin A or beta-carotene sup-
plements
Name of parent cohort: Physicians’ Health Study
Recruitment: 1982
Outcome assessment: 1995
Number of cases:
Prostate cancer: 586 (male/female: 586/0)
Case definition: incidence
Years of follow-up: 13.0 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Statistical methods: logistic regression
Variables controlled in analysis: age at baseline, smoking status, duration of follow-up
Variables controlled by matching: age, smoking status
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer
highest quintile: OR 0.78 (95% CI 0.54 to 1.13)
Selenium levels in exposure categories lowest quintile: 0.060 to 0.090 ppm
highest quintile: 0.121 to 0.190 ppm
Notes
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Marshall 2011
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear
Concealment: unclear
Blinding: only described as double-blinded. The central pathologist was also blinded to study
assignment
Dropouts/withdrawals: 13/227 in the selenium arm and 12/225 in the placebo arm were lost
to follow-up
Intention-to-treat-analysis: yes
Recruitment period: not specified
Treatment duration: not specified
Observation period/dermatologic follow-up:
Subjects were followed for three years. They were seen in clinic at baseline and every six
months thereafter
Detection of cases: Tissue blocks and corresponding pathology reports for all prostate proce-
dures were to be submitted to the central study pathologist for review
Informed consent: All patients gave oral and written informed consent in accordance with
institutional and federal guidelines. The protocol was approved by the Institutional Review
Boards at participating institutions, and was monitored by the Data and Safety Monitoring
Committee of SWOG
Participants Country: US
Number of patients: 452 (randomised to selenium 200 ug/day group: 227, to placebo group:
225)
Condition: 40 years of age or older; digital rectal examination; biopsy- confirmed diagnosis
of HGPIN with no evidence of cancer; upper limit of prostate-specific antigen (PSA) of 10
ng/mL (as measured locally); American Urological Association (AUA) symptom score of less
than 20 (41), signifying no debilitating urinary problems; ambulatory and able to carry out
work of a light or sedentary nature
Demographics: Selenium and placebo patients were well balanced with respect to age, race,
ethnicity, pre-study PSA category, vitamin E supplements, and number of cores in the
initial biopsy. They also were well balanced in body mass index, baseline blood selenium,
performance status, and number of cores revealing HGPIN
Interventions Subjects were randomised in fashion to placebo or 200 mcg/day of selenium, with daily
treatment scheduled for three years or until a PC diagnosis
Recruitment: not reported
End of the blinded treatment period: at 3 years
Outcomes Primary outcome measure:
progression of HGPIN to PC over a three-year period
Risk estimates [95% CI] Primary outcomes:
Adjusted OR=0.913, P= 0.727, 95%CI= 0.55-1.52 for risk of prostate cancer as a function
of treatment group (with placebo as referent group) is: adj OR=
Selenium levels in exposure categories d.n.a.
Notes The OR estimate was given from the author
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McNaughton 2005
Methods Matched, nested case-control study (McNaughton 2005b)
Cohort study (Heinen 2007, van der Pols 2009)
Country: Australia
Participants Name of parent cohort: Nambour Skin Cancer Study
Recruitment: 1992 to 1996
Case definition: incidence
McNaughton 2005b:
Participants: approximately 1000 men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation in
a randomised controlled trial for skin cancer prevention with beta-carotene supplements and
sunscreen application in 1992; living in the Nambour community; free of SCC at baseline;
with blood sample and FFQ provided in 1996; participants with extreme energy intakes in
FFQ excluded
Outcome assessment:December 2001
Number of cases:
Basal cell carcinoma of the skin: 90 (male/female: 39/51)
Years of follow-up: 5.5 years
Type of selenium marker: serum and nutritional intake (FFQ)
Heinen 2007:
Participants: 1001 men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation
in randomised controlled trial for skin cancer prevention with beta-carotene supplements
and sunscreen application in 1992; living in the Nambour community; with blood sample
and FFQ provided in 1996; participants with extreme energy intakes in FFQ and missing
consumption frequencies for more than 10% of food items excluded
Outcome assessment: 31 December 2004
Number of cases:
Basal cell carcinoma of the skin: 149 (male/female: 87/62) participants with 321 BCC
tumours
Squamous cell carcinoma of the skin: 116 (male/female: 70/46) participants with 221 SCC
tumours,
Case definition: incidence (tumour-based incidence and person-based incidence)
Years of follow-up: 8 years
Type of selenium marker: nutritional intake (FFQ)
van der Pols 2009:
Participants: 485 (male/female: 223/262) men and women
Inclusion criteria: randomly selected adults, aged 20 to 69 years; recruited for participation
in randomised controlled trial for skin cancer prevention with beta-carotene supplements
and sunscreen application in 1992; randomised to placebo in the intervention trial; living
in the Nambour community; free of SCC at baseline; with blood sample and FFQ provided
in 1996; participants with extreme energy intakes in FFQ excluded
Outcome assessment: 31 December 2004
Number of cases:
Basal cell carcinomaof the skin: 77 (male/female: 46/31) participantswith 173BCC tumours
Squamous cell carcinoma of the skin: 59 (male/female: 38/21) participants with 124 SCC
tumours,
Years of follow-up: 8 years
Type of selenium marker: serum
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McNaughton 2005 (Continued)
Interventions d.n.a.
Outcomes McNaughton 2005b:
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, gender
Variables controlled by matching: age, gender
Heinen 2007:
Statistical methods: generalised linear models
Variables controlled in analysis: age, sex, intervention arm in RCT, energy intake, skin colour,
elastosis of the neck, smoking, use of dietary supplements, history of skin cancer
van der Pols 2009:
Statistical methods: generalised linear models
Variables controlled in analysis: age, sex, pack-years of smoking, alcohol intake, time spent
outdoors on weekdays, history of skin cancer before 1996
Risk estimates [95% CI] McNaughton 2005b:
Reference category: lowest quartile
Results:
Basal cell carcinoma (skin)
both genders: highest quartile: OR 0.86 (95% CI 0.38 to 1.96) biochemical selenium level
both genders: highest quartile: OR 1.13 (95% CI 0.47 to 2.74) selenium intake
Heinen 2007:
Reference category: lowest tertile
Results:
Basal cell carcinoma (skin)
both genders: highest tertile: RR 0.95 (95% CI 0.59 to 1.50)
Squamous cell carcinoma (skin)
both genders: highest tertile: RR 1.3 (95% CI 0.77 to 2.3)
van der Pols 2009:
Reference category: lowest exposure category
Results:
Basal cell carcinoma (skin)
both genders: highest exposure category: RR 0.58 (95% CI 0.32 to 1.07)
Squamous cell carcinoma (skin)
both genders: highest exposure category: RR 0.49 (95% CI 0.24 to 0.99)
Selenium levels in exposure categories McNaughton 2005b:
n.r.
Heinen 2007:
lowest tertile ≤ 76.20 µg/day
highest tertile ≥ 89.31 µg/day
van der Pols 2009:
lowest exposure category ≤ 1.0 µmol/l
highest exposure category ≥ 1.3 µmol/l
Notes Primary publication: McNaughton 2005b
Other publication: Heinen 2007, van der Pols 2009
tumour-based incidence: number of newly developed histologically confirmed BCC or SCC
divided by the person-years of follow-up accumulated over follow-up period
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McNaughton 2005 (Continued)
person-based incidence: number of persons newly affected by BCC or SCC during the same
person-years of follow-up time as calculated for the tumour-based analysis
Menkes 1986
Methods Matched, nested case-control study
Country: US
Participants Participants: 25,804 men and women
Inclusion criteria: female and male inhabitants of Washington county/Maryland; history of
cancer at baseline excluded
Name of parent cohort: CLUE I Cohort
Recruitment: September to November 1974
Menkes 1986b:
Outcome assessment: 1983
Number of cases:
Lung cancer: 99 (69% male/31% female)
Helzlsour 1996:
Inclusion criteria: women only; women who used hormones at baseline excluded
Outcome assessment: 1989
Number of cases:
Ovarian cancer: 35 (male/female: 0/35)
Breslow 1995:
Outcome assessment: 1994
Number of cases:
Melanoma: 23 (male/female: n.r.)
Basal cell carcinoma (skin): 17 (male/female: n.r.)
Squamous cell cancer: 37 (male/female: n.r.)
Zheng 1993:
Outcome assessment: 1990
Number of cases:
Oral and pharyngeal: 28 (male/female: n.r.)
Batieha 1993:
Inclusion criteria: 15,161 women
Outcome assessment: 31 May 1990
Number of cases:
Cervical cancer: 50 (male/female: 0/50)
Helzlsour 1989:
Inclusion criteria: 20,305 men and women
Outcome assessment: 1986
Number of cases:
Bladder cancer: 35 (male/female: n.r.)
Burney 1989:
Outcome assessment: 1986
Number of cases:
Pancreatic cancer: 22 (male/female: 9/13)
Ko 1994:
Outcome assessment: 25 September 1991
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Menkes 1986 (Continued)
Number of cases:
Colon cancer: 121 (male/female: 50/71)
Case definition: incidence
Years of follow-up: 8.0 to 16.8 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Menkes 1986b:
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year and month
of sample collection
Helzlsour 1986:
Statistical methods: conditional logistic regression
Variables controlled by matching: Age, race/ethnicity, day time of blood sample collec-
tion, hours since last meal, time since last menstrual period (post-menopausal: years, pre-
menopausal: days)
Breslow 1995:
Statistical methods: conditional logistic regression
Analysed cases: 17 of 98 basal cell carcinoma cases, and 23 of 30 melanoma cases (and all
squamous cell carcinoma cases) included in analysis
Variables controlled by matching: age, gender, race/ethnicity
Zheng 1993:
Statistical methods: n.r.
Variables controlled in analysis: smoking
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, hours between previous meal and blood collection
Batieha 1993:
Statistical methods: conditional logistic regression
Analysed cases: 50 of 60 cases (CIS and invasive cervical cancer) analysed (reason for non-
inclusion: no matched control available)
Variables controlled by matching: age, race/ethnicity, year and month of blood collection,
hours since last meal, time since last menstrual period
Helzlsour 1989:
Statistical methods: n.r.
Variables controlled in analysis: cigarette smoking, use of vitamin supplements
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal (all samples
collected in same year)
Burney 1989:
Statistical methods: n.r.
Variables controlled by matching: age, gender, race/ethnicity, hours since last meal
Ko 1994:
Analysed cases: 121of 154 cases analysed (reason for non-inclusion: no serum sample available,
tumour pathology or localisation unclear)
Statistical methods: conditional logistic regression
Variables controlled by matching: age, gender, race/ethnicity, year and month of sample col-
lection, hours since last meal, women: time since last menstrual period, women: use of hor-
mones/hormonal contraceptives
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Menkes 1986 (Continued)
Risk estimates [95% CI] Menkes 1986b:
Reference category: highest quintile
Results:
Lung cancer
both genders: lowest quintile: OR 0.68 (CI not reported)
Helzlsouer 1986:
Reference category: lowest tertile
Results:
Ovarian cancer
highest tertiles: OR 0.58 (95% CI 0.20 to 1.70)
Breslow 1995:
Reference category: lowest tertile
Results:
Melanoma
both genders: highest tertile: OR 0.9 (95% CI 0.3 to 2.5)
Basal cell carcinoma (skin)
both genders: highest tertile: OR 0.8 (95% CI 0.1 to 4.5)
Squamous cell cancer
both genders: highest tertile: OR 0.6 (95% CI 0.2 to 1.5)
Zheng 1993:
Reference category: lowest tertile
Results:
Oral and pharyngeal cancer
both genders: highest tertile: OR 5.43 (CI not reported)
Batieha 1993:
Reference category: highest tertile
Results:
Cervical cancer
lowest tertile: OR 1.12 (95% CI 0.50 to 2.53)
Helzlsour 1989:
Reference category: highest tertile
Results:
Bladder cancer
both genders: lowest tertile: OR 2.06 (95% CI 0.67 to 6.35)
Burney 1989:
Reference category: highest tertile
Results:
Pancreatic cancer
both genders: lowest tertile: OR 4.5 (CI not reported) (unmatched analysis)
both genders: lowest tertile vs. higher two tertiles: OR 3.90 (95% CI 1.13 to 13.2) (matched
analysis)
male: 12.5 (95% CI 1.8 to 84.0) (unmatched analysis)
female: 1.2 (95% CI 0.6 to 2.5) (unmatched analysis)
Ko 1994:
Reference category: highest quartile
Results:
Colon cancer
both genders: lowest quartile: OR 0.82 (95% CI 0.35 to 1.92)
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Menkes 1986 (Continued)
Selenium levels in exposure categories Menkes 1986b:
quintiles: n.r.
Helzlsouer 1986:
women:
lowest tertile: ≤ 10.50 µg/dl
highest tertile: ≥ 11.61 µg/dl
Breslow 1995:
tertiles: n.r.
Zheng 1993:
tertiles: n.r.
Batieha 1993:
women:
lowest tertile: ≤ 0.109 ppm
highest tertile: ≥ 0.124 ppm
Helzlsour 1989:
both genders:
lowest tertile: ≤ 10.90 µg/dl
highest tertile: ≥ 11.91 µg/dl
Burney 1989:
lowest: 0.99 to 1.26 µmol/l; highest: 1.44 to 1.81 µmol/l
Ko 1994:
lowest quartile: ≤ 9.90 µg/dl
highest quartile: ≥ 11.81 µg/dl
Notes Primary publication: Menkes 1986b
Other publications: Helzlsour 1996, Breslow 1995, Zheng 1993, Batieha 1993, Helzlsour
1989, Burney 1989, Ko 1994, Schober 1987 (cases included in Ko 1994), Menkes 1986a
(cases included in Menkes 1986b)
Michaud 2002
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 29,133 men
Inclusion criteria: 50 to 69 years of age; smokers; no history of cancer (other than non-
melanoma skin cancer) at baseline; no severe physical or psychiatric illness; intake of vitamin
E/A/beta-carotene supplements in excess of defined amounts
Name of parent cohort: Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Recruitment: 1985 to 1988
Outcome assessment: 30 April 1993
Number of cases:
Bladder cancer: 133 (male/female: 133/0)
Case definition: incidence
Years of follow-up: 5.0 to 8.0 years
Type of selenium marker: toenail
Interventions d.n.a.
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Michaud 2002 (Continued)
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: smoking dose and duration
Variables controlled by matching: age, year/month of sample collection, intervention group
status in RCT (only male smokers included in cohort)
Risk estimates [95% CI] Reference category: lowest tertile/quartile
Results:
Bladder cancer
male: highest tertile: OR 0.90 (95% CI 0.45 to 1.78)
male: highest quartile: OR 0.87 (95% CI 0.30 to 2.52)
Selenium levels in exposure categories n.r.
Notes
Michaud 2005
Methods Matched, nested case-control study
Country: US
Participants Participants: 101,950: 33,737 men, 68,213 women
Inclusion criteria: cohort of HPFS (men) and NHS (women); no history of cancer at baseline
Name of parent cohort: Health Professional Follow-Up Study (HPFS) and Nurses’ Health
Study (NHS)
Recruitment: 1987 (HPFS), 1983 (NHS)
Outcome assessment: 2000
Number of cases:
Bladder cancer: 337 (male/female: 221/116)
Case definition: incidence
Years of follow-up: 13.0 to 17.0 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: pack-years of smoking, heavy smoking at baseline
Variables controlled by matching: age, gender, smoking status, month of sample collection
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Bladder cancer
male: highest quartile: OR 1.17 (95% CI 0.66 to 2.07)
female: highest quartile: OR 0.36 (95% CI 0.14 to 0.91)
Selenium levels in exposure categories men:
lowest quartile: ≤ 0.722 µg/g
highest quartile: ≥ 0.912 µg/g
women:
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Michaud 2005 (Continued)
lowest quartile: ≤ 0.686 µg/g
highest quartile: ≥ 0.840 µg/g
Notes
Nomura 1987
Methods Unmatched, nested case-control study
Country: US
Participants Participants: 6860 men
Inclusion criteria: born 1900 to 1919; Japanese ancestry; inhabitants of Oahu/Hawaii; par-
ticipants in the Honolulu Heart Program (1965 to 68)
Name of parent cohort: Honolulu Heart Program
Recruitment: 1971 to 1975
Outcome assessment: n.r.
Number of cases:
Any cancer: 280 (male/female: 280/0)
Stomach cancer: 66 (male/female: 66/0)
Rectal cancer: 32 (male/female: 32/0)
Lung cancer: 71 (male/female: 71/0)
Colon cancer: 82 (male/female: 82/0)
Bladder cancer: 29 (male/female: 29/0)
Case definition: incidence
Years of follow-up: 11.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: proportional hazards regression/Cox regression
Variables controlled in analysis:
age at examination, cigarettes/day (any cancer, lung cancer, bladder cancer)
age at examination (stomach, rectum, colon)
Risk estimates [95% CI] Reference category: highest quintile
Results:
Stomach cancer:
male: lowest quintile: OR 0.9 (CI not reported)
Rectal cancer
male: lowest quintile: OR 1.6 (CI not reported)
Lung cancer
male: lowest quintile: OR 1.1 (CI not reported)
Colon cancer
male: lowest quintile: OR 1.8 (CI not reported)
Bladder cancer
male: lowest quintile: OR 3.1 (CI not reported)
All five types of cancer
male: lowest quintile: OR 1.3 (CI not reported)
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Selenium levels in exposure categories lowest quintile: ≤ 10.30 µg/dl
highest quintile: ≥ 13.31 µg/dl
Notes N.B.: “Any cancer” in this study comprises all cancer cases for stomach, rectal, lung, colon
and bladder cancer
Nomura 2000
Methods Matched, nested case-control study
Country: US
Participants Participants: 9345 men
Inclusion criteria: no cancer diagnosis at baseline, blood sample available for analysis, men
from two cohorts: sub-cohort one: participants of Nomura 1987; sub-cohort 2: brothers of
participants in Nomura 1987
Recruitment: 1971 to 1977
Outcome assessment: 1995
Number of cases:
Prostate cancer: 249 (male/female: 249/0)
Case definition: incidence
Years of follow-up: 19.0 to 25.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: random sample of 249 (out of 360) cases analysed because of limited resources
Statistical methods: generalised linear model
Variables controlled in analysis: cigarette smoking history, age
Variables controlled by matching: age, year/month of sample collection, recruitment in sub-
cohort 1 or 2
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
highest quartile: OR 0.5 (95% CI 0.3 to 0.9)
Selenium levels in exposure categories lowest quartile: ≤ 119.29 ng/ml
highest quartile: ≥ 147.20 ng/ml
Notes
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NPCT 2002
Methods Randomised controlled trial
Nutritional Prevention of Cancer Trial (NPCT)
Allocation: random, block/stratified by clinic
Sequence generation: computer generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist unclear, review/
coding of medical records blinded
Dropouts/withdrawals: “9 patients (5 in the selenium group and 4 in the placebo group)
declined to provide additional illness information” (Clark 1996, p. 1959) - 0 participants
lost to vital follow-up
Intention-to-treat-analysis: yes
Recruitment period: 1983 to 1991
End of predefined study period: 31 December 1993
Blinded intervention continued until the end of the blinded period: 31 January 1996
Intervention duration:
31 December 1993 (end of study period): mean = 4.5 years
31 January 1996 (end of blinded period): mean = 7.9 years
Observation period/dermatologic follow-up:
31 December 1993 (end of study period): mean = 6.4 years
31 January 1996 (end of blinded period): mean = 7.4 years
Detection of cases: dermatologic examination and interview every 6 months during follow-up;
incident BCC and SCCwere diagnosed by biopsy and confirmed by another dermatopathol-
ogist
Informed consent: written informed consent forms, approval by institutional review board of
participating institutions
Participants Country: US
Number of participants: 1312 (randomised to selenium group: 653, to placebo group: 659)
Condition: male and female participants with history of 2 or more squamous cell or basal
cell skin cancers
Demographics:mean age 63.4 years (selenium)/63.0 years (placebo); 73.8% men (selenium)
. 75.6% men (placebo)
Recruitment and setting: seven dermatological clinics (three academic units, four private
practices) in the US
Interventions Intervention: 200 µg selenium supplied as 500 mg selenium yeast tablets p.o./daily
Control: placebo
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin:
all analyses were based on 1250 participants with initial blood collection within four days
after randomisation (621 in the selenium group and 629 in the placebo group)
Other reported outcomes and secondary outcome measures:
Reported in Clark 1996: Incidence of lung cancer, prostate cancer, colorectal cancer, any
cancer, head and neck cancer, bladder cancer, oesophageal cancer, breast cancer, melanoma,
haematologic cancer,
Reported in Duffield-Lillico 2002: Overall cancer mortality
Risk estimates [95% CI] Primary outcomes:
1) at the end of study period (31 December 1993) (Clark 1996):
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NPCT 2002 (Continued)
BCC: RR 1.10 (95% CI 0.95 to 1.28); cases: selenium group: 377, placebo group: 350;
incidence per person-year under follow-up: selenium group 0.16, placebo group 0.15
SCC: RR 1.14 (95% CI 0.93 to 1.39); cases: selenium group 218, placebo group: 190;
incidence per person-year under follow-up: selenium group 0.07, placebo group 0.06
2) at the end of blinded period (31 January 1996) (Duffield-Lillico 2003):
BCC: RR 1.17 (95% CI 1.02 to 1.35), HR 1.09 (95%CI 0.94 to 1.26); number of cases not
reported; incidence per person-year under follow-up: selenium group: 0.16, placebo group
0.13
SCC: RR 1.32 (95% CI 1.09 to 1.60), HR 1.25 (95% CI 1.03 to 1.51); number of cases not
reported; incidence per person-year under follow-up: selenium group: 0.05, placebo group
0.07
NMSC: RR 1.27 (95% CI 1.11 to 1.45) HR 1.17 (95% CI 1.02 to 1.34); number of cases
not reported; incidence per person-year under follow-up: selenium group: 0.20, placebo
group 0.16
Other reported outcomes and secondary outcomes:
1) at the end of study period (31 December 1993) (Clark 1996):
lung cancer RR 0.54 (95% CI 0.30 to 0.98), adjusted HR 0.56 (95% CI 0.31 to 1.01) cases
selenium: 17, placebo: 31
prostate cancer RR 0.37 (95% CI 0.18 to 0.71), adjusted HR 0.35 (95% CI 0.18 to 0.65)
cases selenium: 13, placebo: 35
colorectal cancer RR 0.42 (95% CI 0.18 to 0.95), adjusted HR 0.39 (95% CI 0.17 to 0.90)
cases selenium: 8, placebo: 19
any cancer RR 0.63 (95% CI 0.47 to 0.85), adjusted HR 0.61 (95% CI 0.46 to 0.82) cases
selenium: 77, placebo: 119
head and neck cancer RR 0.74 (95% CI 0.21 to 2.43), adjusted HR 0.77 (95% CI 0.27 to
2.24) cases selenium: 6, placebo: 8
bladder cancer RR 1.32 (95% CI 0.40 to 4.61), adjusted HR 1.27 (95% CI 0.44 to 3.67)
cases selenium: 8, placebo: 6
oesophageal cancer RR 0.33 (95% CI 0.03 to 1.84), adjusted HR 0.30 (95% CI 0.06 to 1.
49) cases selenium: 2, placebo: 6
breast cancer RR 2.88 (95% CI 0.72 to 16.5), adjusted HR 2.95 (95% CI 0.80 to 10.9)
cases selenium: 9, placebo:3
melanoma RR 0.97 (95% CI 0.32 to 2.96), adjusted HR 0.92 (95% CI 0.34 to 2.45) cases
selenium: 8, placebo: 8
haematological cancer RR 1.58 (95% CI 0.46 to 6.14), adjusted HR 1.50 (95% CI 0.49 to
4.60) cases selenium: 8, placebo: 5
other specific carcinomas RR 0.55 (95% CI 0.14 to 1.82), adjusted HR 0.54 (95% CI 0.18
to 1.62), cases selenium: 5, placebo: 9
total carcinoma RR 0.55 (95% CI 0.40 to 0.77), adjusted HR 0.54 (95% CI 0.39 to 0.75)
, cases selenium: 59; placebo: 104
leukaemia /lymphomas RR 1.58 (95% CI 0.46 to 6.14), adjusted HR 1.50 (95% CI 0.49
to 4.60), cases selenium: 8, placebo 5
other specific non-carcinomas RR 0.99 (95% CI 0.13 to 7.37), HR 0.99 (95% CI 0.20 to
4.94), cases selenium: 3, placebo: 3
total non-carcinomas RR 1.17 (95% CI 0.57 to 2.44), adjusted HR 1.16 (95% CI 0.60 to
2.27), cases selenium: 19; placebo: 16
2) at the end of the blinded period (31 January 1996) (Duffield-Lillico 2002):
lung cancer RR 0.70 (95% CI 0.40 to 1.21), adjusted HR 0.74 (95% CI 0.44 to 1.24), cases
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selenium: 25, placebo: 35
prostate cancer RR 0.51 (95% CI 0.29 to 0.87), adjusted HR 0.48 (95% CI 0.28 to 0.80),
cases selenium: 22, placebo: 42
colorectal cancer RR 0.46 (95% CI 0.19 to 1.08), adjusted HR 0.46 (95% CI 0.21 to 1.02)
, cases selenium: 9, placebo: 19
any cancer RR 0.75 (95% CI 0.58 to 0.98), adjusted HR 0.75 (95% CI 0.58 to 0.97), cases
selenium: 105, placebo: 137
head and neck cancer RR 1.27 (95% CI 0.42 to 4.01), adjusted HR 1.27 (95% CI 0.47 to
3.42), cases selenium: 9, placebo: 7
bladder cancer RR 1.24 (95% CI 0.44 to 3.61), adjusted HR 1.28 (95% CI 0.50 to 3.25),
cases selenium: 10, placebo: 8
oesophageal cancer RR 0.39 (95% CI 0.04 to 2.41), adjusted HR 0.40 (95% CI 0.08 to 2.
07), cases selenium: 2, placebo: 5
breast cancer RR 1.82 (95% CI 0.62 to 6.01), adjusted HR 1.89 (95% CI 0.69 to 5.14),
cases selenium: 11, placebo: 6
melanoma RR 1.21 (95% CI 0.46 to 3.30), adjusted HR 1.18 (95% CI 0.49 to 2.85), cases
selenium: 11, placebo: 9
haematological cancer (lymphoma and leukaemia) RR 1.32 (95% CI 0.40 to 4.61), adjusted
HR 1.25 (95% CI 0.43 to 3.61), cases selenium: 8, placebo: 6
cancer mortality, all sites RR 0.59 (95% CI 0.39 to 0.89), adjusted HR 0.59 (95% CI 0.39
to 0.87), cases selenium: 40, placebo: 66
other carcinomas RR 0.66 (95% CI 0.19 to 2.07), adjusted HR 0.67 (95% CI 0.24 to 1.
88), cases selenium: 6, placebo:9
other non-carcinomas RR 0.59 (95% CI 0.09 to 3.04), adjusted HR 0.59 (95% CI 0.14 to
2.47), cases selenium: 3, placebo: 5
Selenium levels in exposure categories d.n.a.
Notes Adverse effects: Clark 1996: 35 participants (21 in selenium and 14 in control group) com-
plained of adverse effects, mostly involving gastrointestinal upset, and withdrew treatment
Post-hoc introduced secondary outcomes were: all-cause mortality, total cancer mortality,
total cancer incidence and incidence of lung / prostate / colorectal cancers
HR: adjusted for sex, age, smoking status, clinic site, plasma selenium concentration, clinical
sun damage, sunscreen use at baseline and number of BCCs/SCCs/NMSCs in the 12months
before randomisation
Overvad 1991
Methods Cohort/sub-cohort-controlled cohort study
Country: Channel Islands
Participants Participants: 5162 women
Inclusion criteria: ≥ 35 years of age; ostensibly healthy inhabitants of Guernsey
Name of parent cohort: Channel Island Cohort
Recruitment: 1967 to 1976
Outcome assessment: end of 1985
Number of cases:
Breast cancer: 46 (male/female: 0/46)
Case definition: incidence
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Years of follow-up: mean: 11 years for cases
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 46 of 88 cases analysed (reason for non-inclusion: no plasma available)
Statistical methods: logistic regression
Variables controlled in analysis: age, age at menarche, age at first baby, parity, BMI
Risk estimates [95% CI] Reference category: highest quartile
Results:
Breast cancer
lowest quartile: RR 0.80 (95% CI 0.29 to 2.19)
Selenium levels in exposure categories lowest quartile: ≤ 84.90 µg/l
highest quartile: ≥ 116.00 µg/l
Notes
Peleg 1985
Methods Matched, nested case-control study
Country: US
Participants Participants: 2530 men and women
Inclusion criteria: 15 years of age and older; residents of Evans county; cases within first two
years of follow-up excluded
Name of parent cohort: Evans County Study
Recruitment: 1967 to 1969
Outcome assessment: January 1981
Number of cases:
Any cancer: 130 (male/female: 78/52)
Case definition: incidence
Years of follow-up: 11.0 to 14.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: n.r.
Variables controlled by matching: age, gender, race/ethnicity, year/month of sample collection
Risk estimates [95% CI] Reference category: highest quartile
Results:
Any cancer
both genders: lowest quartile: OR 1.0 (CI not reported)
Selenium levels in exposure categories lowest quartile: ≤ 0.103 µg/ml
highest quartile: ≥ 0.127 µg/ml
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Peleg 1985 (Continued)
Notes
Persson 2000
Methods Matched, nested case-control study
Country: Sweden
Participants Participants: approximately 9500 men (exact figure not reported)
Inclusion criteria: 46 to 48 years; residents of Malmo/Sweden
Name of parent cohort: Malmö Preventive Programme
Recruitment: 1974 to 1982
Outcome assessment: end of 1988
Number of cases:
Any cancer: 302 (male/female: 302/0)
Gastrointestinal cancer: 115 (male/female: 115/0)
Respiratory tract cancer: 69 (male/female: 69/0)
Other: 61 (male/female: 61/0)
Urinary tract cancer: 57 (male/female: 57/0)
Case definition: incidence
Years of follow-up: 6.0 to 15.0 years
Type of selenium marker: plasma selenium P
Interventions d.n.a.
Outcomes Analysed cases: 302 of 400 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: logistic regression, Mantel-Haenszel
Variables controlled in analysis: smoking
Variables controlled by matching: age, year/month/date of sample collection
Risk estimates [95% CI] Reference category: highest tertile/quintile
Results:
Any cancer
male: lowest quintile: OR 5.2 (95% CI 1.2 to 23.4)
Gastrointestinal cancer
male: lowest tertile: OR 3.4 (95% CI 1.1 to 10.2)
Respiratory tract cancer
male: lowest tertile: OR 6.0 (95% CI 1.5 to 24.2)
Other cancers:
male: lowest tertile: OR 0.6 (95% CI 0.2 to 2.1)
Urinary tract cancer
male: lowest tertile: OR 0.2 (95% CI 0.0 to 1.4)
Selenium levels in exposure categories
Notes Arbitrary unit: Concentration of selenoprotein was expressed in arbitrary units (AU) relative
to a standard of pooled plasma. 0.3 AU equal one standard deviation
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Peters 2007
Methods Matched, nested case-control study
Country: US
Participants Participants: 26,975 white non-Hispanic men
Inclusion criteria: 55 to 74 years of age; excluded: no baseline questionnaire/informed con-
sent/blood sample, no further contact after screening
Name of parent cohort: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Recruitment: September 1993 to June 2001
Outcome assessment: 1 October 2001
Number of cases:
Prostate cancer: 724 (male/female: 724/0)
Case definition: incidence
Years of follow-up: 0.3 to 8.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 724 of 803 cases included in analysis (reason for non-inclusion: no selenium
measurement available)
Statistical methods: n.r.
Variables controlled in analysis: age, time since initial screening, year of blood collection, study
centre
Variables controlled by matching: age, month of sample collection, time since initial screening
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Prostate cancer
highest quartile: OR 0.84 (95% CI 0.62 to 1.14)
Selenium levels in exposure categories lowest quartile: 50.5 to 126.7 ng/ml
highest quartile: 158.0 to 253.0 ng/ml
Notes
Peters 2008
Methods Cohort study
Country: US
Participants Inclusion criteria: aged 50 to 76 years, participants recruited from subscribers of commercial
mailing list, residents of western Washington state, non-whites excluded, no malignant dis-
ease at baseline
Name of parent cohort: Vitamins and lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Type of selenium marker: supplemental intake (questionnaire: use of supplements over the
last 10 years, mean supplemental intake / day calculated)
Case definition: incidence
Peters 2008:
Participants: 35,242 men
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Peters 2008 (Continued)
Outcome assessment: 31 December 2004
Number of cases:
Prostate cancer: 818 (male/female: 818/0)
Years of follow-up: 2 to 4 years
Asgari 2009:
Participants: 69,671 men and women
Outcome assessment: 31 December 2006
Number of cases:
Melanoma: 461 (male/female: n.r.)
Years of follow-up: 4 to 5 years
Interventions d.n.a.
Outcomes Peters 2008:
Analysed cases: 818 of 830 cases analysed (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression analysis
Variables controlled in analysis: age, family history of prostate cancer, BPH, income, multivi-
tamin use
Asgari 2009:
Analysed cases: one case not analysed (reason for non-inclusion: not reported)
Statistical methods: Cox proportional hazard regression
Variables controlled in analysis: age, sex, education, family history of melanoma, personal
history of non-melanoma skin cancer, mole removal, freckles, sunburns, hair colour, reaction
to sunlight exposure
Risk estimates [95% CI] Reference category: no supplemental selenium intake (lowest exposure category)
Peters 2008:
Results:
Prostate cancer
highest exposure category: RR 0.90 (95% CI 0.62 to 1.30)
Asgari 2009:
Results:
Melanoma
highest exposure category HR 0.98 (95% CI 0.69 to 1.41)
Selenium levels in exposure categories stratification according to supplemental selenium intake
Peters 2008:
lowest category: no supplemental intake
highest category ≥ 51 µg/day
Asgari 2009:
lowest exposure category: no supplemental intake
highest exposure category ≥ 50 µg/day
Notes
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Ratnasinghe 2000
Methods Matched, nested case-control study
Country: China
Participants Participants: 9143 men
Inclusion criteria: 35 years or older; tin miners employed by the Yunnan Tin Corporation;
10 or more years of underground mining / smelting; no history of cancer at baseline
Recruitment: 1992 to 1997
Outcome assessment: 1997
Number of cases:
Lung cancer: 108 (male/female: 108/0)
Case definition: incidence
Years of follow-up: 3 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: plasma was available for 108 of a total of 339 identified cases
Statistical methods: logistic regression, conditional logistic regression, Wilcoxon rank sum
test
Variables controlled in analysis: radon exposure, smoking
Variables controlled by matching: age, year and month of sample collection
Risk estimates [95% CI] Reference category: lowest tertile
Results:
Lung cancer
highest tertile: OR 1.2 (95% CI 0.6 to 2.4)
Selenium levels in exposure categories lowest tertile: 20 to 39 ng/ml
highest tertile: 55 to 121 ng/ml
Notes
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Reid 2008
Methods Randomised controlled trial
Sub-study of the Nutritional Prevention of Cancer Trial (NPCT 2002)
Allocation: random
Sequence generation: computer generated random numbers
Concealment: central assignment (sealed pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist unclear, review/
coding of medical records blinded
Dropouts/withdrawals: two participants declined to provide additional illness information,
no participant lost to vital follow -up
Intention-to-treat-analysis: yes
Recruitment period: 1989-1992
Treatment duration:
Blinded intervention continued until the end of the blinded period; 1 February 1996
Observation period/dermatologic follow-up:
1 February 1996
Detection of cases: dermatological examination and interview every 6 months during fol-
low-up; incident BCC and SCC were diagnosed by biopsy and confirmed by another der-
matopathologist
Informed consent: written informed consent forms, approval by institutional review board of
participating institutions
Participants 423 male and female participants with prior non-melanoma skin cancer
Country: US
Number of patients: 423 (randomised to selenium group: 210, to placebo group: 213)
Condition: male and female patients with history of 2 or more squamous cell or basal cell
skin cancers
Demographics:mean age 63.8 years (selenium)/63.8 years (placebo); 66.2% men (selenium)
. 68.2% men (placebo)
Recruitment and setting: dermatologic clinic in Macon, Georgia
Interventions Intervention: 400 µg selenium supplied as selenium yeast tablets p.o./daily. Control: placebo
400 µg/day of selenium yeast or identical-appearing low selenium yeast placebo
Recruitment: 12 September 1989 to 3 April 1992
End of the blinded treatment period: 2 February 1996
Outcomes Primary outcome measure: incidence of basal and squamous cell carcinoma of the skin:
all analyses were based on n = 423 participants with initial blood collection within 4 days
after randomizations
Other reported outcomes:
total internal cancer incidence
Risk estimates [95% CI] Primary outcomes:
BCC:RR0.90 (95%CI 0.65 to 1.24); cases: selenium group: 76, placebo group: 83; adjusted
HR: 0.95 (95% CI 0.69 to 1.29)
SCC: RR 1.05 (95%CI 0.71 to 1.56); cases: selenium group: 56, placebo group: 53; adjusted
HR: 1.05 (95% CI 0.72 to 1.53)
NMSC: RR 0.88 (95% CI 0.66 to 1.16); cases: selenium group: 98, placebo group: 108;
adjusted HR: 0.91 (95% CI 0.69 to 1.20)
NMSC in women: RR 0.40 (95% CI 0.20 to 0.80)
Other reported outcomes:
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total internal cancer incidence:
RR 1.10 (95% CI 0.57 to 2.17); cases: selenium group: 21, placebo group: 19
Selenium levels in exposure categories d.n.a.
Notes Information on study design, which was not reported in Reid 2008, was taken from the
information available on the Nutritional Prevention of Cancer Trial
Adverse effects: not reported
HR: adjusted for: age (continuous), smoking status (never, former, current), gender
Ringstad 1988
Methods Matched, nested case-control study
Country: Norway
Participants Participants: 9364 men and women
Inclusion criteria: 20 to 54 years of age (men), 20 to 49 years of age (women); inhabitants of
Tromso; blood sample provided in 1979; no history of cancer at baseline
Name of parent cohort: Tromso Heart Study II
Recruitment: 1979 to 1980
Outcome assessment: 1985
Number of cases:
Any cancer: 60 (male/female: 26/34)
Case definition: incidence
Years of follow-up: 5.0 to 7.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 60 of 72 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: n.r.
Variables controlled by matching: age, gender, smoking status, month of sample collection,
place of residence (district of Tromso)
Risk estimates [95% CI] Reference category: highest three quartiles
Results:
Any cancer
both genders: lowest quartile: OR 1.4 (95% CI 0.6 to 3.5)
Selenium levels in exposure categories lowest quartile: ≤ 114.49 µg/l
highest three quartiles: 114.50 to 114.51 µg/l
Notes
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Sakoda 2005
Methods Matched, nested case-control study
Country: China
Participants Participants: 41,563 men and women
Inclusion criteria: inhabitants of Haiman city of Chinese origin; written consent; toenail
clipping available
Recruitment: January 1993 to December 1993
Outcome assessment: 30 September 2000
Number of cases:
Primary liver cancer: 166 (male/female: 154/12)
Case definition:mortality
Years of follow-up: 6.8 to 7.8 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 166 of 455 observed cases included in analysis (only cases with questionnaire,
blood sample and toenail specimen analysed after 2000 due to different methods of selenium
analysis)
Statistical methods: not specified
Variables controlled in analysis:
both genders: age, gender, HBsAg-status, alcohol intake, history of acute hepatitis, occupa-
tion
men: age, HBsAg-status, alcohol intake, history of acute hepatitis, family history of HCC,
occupation
women: HBsAg-status, age, history of acute hepatitis
Variables controlled by matching: age, gender, township of residence
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Primary liver cancer
both genders: highest quartile: OR 0.50 (95% CI 0.28 to 0.90)
male: highest quartile: OR 0.57 (95% CI 0.31 to 1.05)
female: highest three quartiles: OR 0.18 (95% CI 0.03 to 1.13)
Selenium levels in exposure categories both genders and men:
lowest quartile: 0 to 1.70 ppm
highest quartile: ≥ 4.43 ppm
women:
lowest quartile: 0.00 to 1.70 ppm
highest three quartiles ≥ 1.71 ppm
Notes
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Salonen 1984
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 8113 men and women
Inclusion criteria: 31 to 59 years of age; random sample of inhabitants of two Finnish
provinces; initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: February to April 1972
Outcome assessment: 31 December 1978
Number of cases:
Any cancer: 128 (male/female: n.r.)
Case definition: incidence
Years of follow-up: 8.5 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistic regression / paired-sample OR
Variables controlled in analysis: tobacco consumption, serum cholesterol, beer consumption,
dietary saturated fats, years of education, study area
Variables controlled by matching: age, gender, smoking (tobacco use/day), total serum choles-
terol
Risk estimates [95% CI] Reference category: above 30th percentile
Results:
Any cancer
both genders: ≤ 30th percentile: OR 3.1 (95% CI 1.5 to 7.7)
both genders: ≤ 0th percentile: OR 3.0 (95% CI 1.2 to 21.9)
Selenium levels in exposure categories 1 to 10th percentile ≤ 34.00 µg/l
above 30th percentile ≥ 45.00 µg/l
Notes
Salonen 1985
Methods Matched, nested case-control study
Country: Finland
Participants Participants: 12,155 men and women
Inclusion criteria: 30 to 64 years of age; random sample of residents of two Finnish provinces;
initially free of cancer
Name of parent cohort: North Karelia Project
Recruitment: January to March 1977
Outcome assessment: 31 December 1980
Number of cases:
Any cancer: 51 (male/female: 30/21)
Case definition:mortality
Years of follow-up: 3.7 years
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Type of selenium marker: serum
Interventions d.n.a.
Outcomes Analysed cases: 51 out of 56 cases (reason for non-inclusion: no serum sample available)
Statistical methods: logistic regression
Variables controlled by matching: age, gender, smoking (tobacco use/day)
Risk estimates [95% CI] Reference category: highest two tertiles
Results:
Any cancer
both genders: lowest tertile: OR 5.8 (95% CI 1.2 to 29.0)
Selenium levels in exposure categories lowest tertile: ≤ 47.00 µg/l
highest two tertiles ≥ 47.10 µg/l
Notes
SELECT 2009
Methods Randomised controlled trial
SELECT (Selenium and Vitamin E Cancer Prevention Trial)
Allocation: random, block/stratified by clinic
Sequence generation: computer-generated random numbers
Concealment: central assignment (pill bottles)
Blinding: participant blinded, doctor blinded, outcome assessor/pathologist blinded, review/
coding of medical records blinded
Dropouts/withdrawals: of 35,533 randomised participants, 645 were excluded from analysis
because they had prior prostate cancer, did not give informed consent or participated at two
study sites, which were excluded due to management and regulatory issues
Intention-to-treat-analysis: yes
Recruitment period: 22 August 2001 to 24 June 2004
End of study period: 1 August 2009
Blinded intervention was discontinued on 23 October 2008 following the recommendation
of the data safety and monitoring committee after the second formal interim analysis in
September 2008
Detection of cases: Participants had clinic visits once every 6 months and reported prostate
cancers to the study staff. Study staff obtained medical records to verify the diagnosis. Tissue
and the corresponding pathology report were sent to the central pathology laboratory for
confirmation
Informed consent: yes
Participants Countries: US, Canada, Puerto Rico
Number of participants: 34,888 men, randomised to four groups: placebo (8696), vitamin E
(8737), selenium (8752), selenium + vitamin E (8703)
Condition: healthy men, aged 50 years or older (African American) or 55 years or older (all
other), no prior diagnosis of prostate cancer, 4 ng/ml or less of PSA in serum, a digital rectal
examination not suspicious for cancer, no current use of anticoagulant therapy other than
175 mg/day or less of acetylsalicylic acid or 81 mg/day or less of acetylsalicylic acid with
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SELECT 2009 (Continued)
clopidogrel bisulphate, no history of haemorrhagic stroke, normal blood pressure
Demographics:median age: 62.3-62.6 years in all four intervention groups, 79% white in all
four intervention groups
Recruitment and setting: 427 participating sites
Interventions Group 1: placebo + placebo
Group 2: 400 IU/day all rac-alpha-tocopheryl acetate + placebo
Group 3: 200 µg/day L-selenomethionine + placebo
Group 4: 400 IU/day all rac-alpha-tocopheryl acetate + 200 µg/day L-selenomethionine
Outcomes Primary outcome: incidence of prostate cancer as determined by routine clinical management
Secondary outcomes: incidence of any cancer / lung cancer / colorectal cancer, diabetesmellitus,
cardiovascular events, death from any cause
Risk estimates [95% CI] Results are presented for the comparison of selenium alone (group 3) versus placebo (group
1)
Primary outcome:
prostate cancer HR 1.04, (95% CI 0.90 to 1.18), (99% CI 0.87 to 1.24), cases: selenium
432 (5-year rate: 4.56%), placebo 416 (5-year rate 4.43%)
Secondary outcomes:
any cancer HR 1.01, (95% CI 0.89 to 1.15)
lung cancer HR 1.12, (99% CI 0.73 to 1.72)
colorectal cancer 1.05, (99% CI 0.66 to 1.67)
other primary cancer (excluding prostate cancer, basal cell and squamous cell skin cancer) 0.
95, (99% CI 0.77 to 1.17)
diabetes mellitus 1.07, (99% CI 0.94 to 1.22)
cardiovascular events 1.02, (99% CI 0.92 to 1.13)
deaths 0.99, (99% CI 0.82 to 1.19)
deaths from cancer 1.02, (99% CI 0.74 to 1.41)
Selenium levels in exposure categories d.n.a.
Notes Adverse effects:
alopecia RR 1.28, (99% CI 1.01 to 1.62)
dermatitis grade 1-2 RR 1.17, (99% CI 1.00 to 1.35)
dermatitis grade 3-4 RR 1.74, (99% CI 0.56 to 5.44)
halitosis RR 1.17, (99% CI 0.99 to 1.38)
nail changes RR 1.04, (99% CI 0.94 to 1.16)
fatigue grade 1-2 RR 1.09, (99% CI 0.95 to 1.26)
fatigue grade 3-4 RR 0.87, (99% CI 0.40 to 1.88)
nausea grade 1-2 RR 1.19, (99% CI 0.94 to 1.52)
nausea grade 3 RR 0.99, (99% CI 0.30 to 3.34)
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Steevens 2010
Methods Cohort/sub-cohort-controlled cohort study
Country: the Netherlands
Participants Name of parent cohort: Netherlands Cohort Study (NLCS)
Recruitment: 1986
van den Brandt 1993b:
Participants: 120,852: 58,279men and 62,573women; aged 55 to 69 years; returned baseline
questionnaire; no history of cancer at baseline
Outcome assessment: 31/12/2002
Number of cases:
esophageal squamous cell carcinoma (ESCC): 64 (male/female: 40/24)
esophageal adenocarcinoma (EAC): 112 (male/female: 93/19)
gastric cardia adenocarcinoma (GCA): 114 (male/female: 97/17)
Case definition: incidence
Years of follow-up:
16.3 years,
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases:
esophageal squamous cell carcinoma (ESCC): 64 of 71
esophageal adenocarcinoma (EAC): 112 of 129
gastric cardia adenocarcinoma (GCA): 114 of 127
Statistical methods: Cox proportional hazards models
Variables controlled in analysis: age, sex, cigarette smoking (current yes/no, number of
cigarettes smoked daily, and number of smoking years), alcohol consumption (g/day),
andBMI (kg/m2)
Risk estimates [95% CI] Reference category: lowest quartile
Results:
esophageal squamous cell carcinoma (ESCC):
both genders: highest quartile: RR 0.37 (95% CI 0.16 to 0.86)
men: highest quartile: RR 0.81 (95% CI 0.64 to 1.4)
women: highest quartile: RR 0.79 (95% CI 0.63 to 0.99)
esophageal adenocarcinoma (EAC):
both genders: highest quartile: RR 0.76 (95% CI 0.41 to 1.40)
men: highest quartile: RR 1.07 (95% CI 0.99 to 1.15)
women: highest quartile: RR 0.72 (95% CI 0.61 to 0.84)
gastric cardia adenocarcinoma (GCA):
both genders: highest quartile: RR 0.52 (95% CI 0.27 to 1.02)
men: highest quartile: RR 0.94 (95% CI 0.84 to 1.06)
women: highest quartile: RR 0.73 (95% CI 0.56 to 0.95)
Selenium levels in exposure categories lowest quartile: ≤ 0.498 µg/g
highest quartile: ≥ 0.613 µg/g
Notes
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Steinbrecher 2010
Methods Nested case-control study
Country: Germany
Participants Participants: 11928 men (from the total cohort of 25540 men and women)
Name of parent cohort: EPIC-Heidelberg cohort
Recruitment: 1994-1998.
Outcome assessment: 2/2007
Number of cases: prostate cancer: 248
Case definition: incidence
Years of follow-up: mean: 3 years
Type of selenium marker: serum selenium concentration
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: family history of prostate cancer, participation in PSA testing,
smoking status, and vigorous physical activity
variables controlled in matching: age group and time of recruitment
Risk estimates [95% CI] Prostate cancer
Reference category: lowest quartile
highest quartile OR 1.10 (95% CI, 0.58-2.09)
Selenium levels in exposure categories lowest quartile: ≤ 78.9 µg/L
highest quartile: ≥ 95 µg/L
Notes
Suadicani 2012
Methods Cohort Study
Country: Denmark
Participants Participants: 3,333males,male participantswere derived from14workplaces inCopenhagen:
the air force, army, navy, emergency management agency, postal service, customs service, a
railroad company, national bank, a telephone company, three municipal service centres (for
electricity and engineering and a fire brigade), a pharmaceutical company, and a building
contractor company
Name of parent cohort: Copenhagen male study
Recruitment: from 1970-1971/1985-1986
Outcome assessment: 1985-1986/2001
Number of cases: deaths for lung cancer: 167
Case definition: death for lung cancer
Years of follow-up: 16 years
Type of selenium marker: serum selenium concentration
Interventions d.n.a.
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Suadicani 2012 (Continued)
Outcomes Statistical methods: Cox logistic regression
Variables controlled in analysis: age, pack-years of smoking, spirits intake and dietary markers
Risk estimates [95% CI] Reference category: lowest exposure category: 0.4-1.0 µmol.Lˆ-1
Results:
Deaths for lung cancer
highest exposure category: HR 1.43 (95% CI 0.96 to 2.14)
Selenium levels in exposure categories lowest category: 0.4-1.0 µmol.Lˆ-1
highest category: 1.3-3.0 µmol.Lˆ-1
Notes
Thomson 2008
Methods Cohort Study
Country: US
Participants Participants: 133,614 women
Inclusion criteria: post-menopausal participants (aged 50 to 79 years) of the WHI clinical
trial and observational study
Name of parent cohort: Women’s Health Initiative (WHI)
Recruitment: n.r.
Outcome assessment: December 2004
Number of cases: ovarian cancer: 451 (0/451)
Case definition: incidence
Years of follow-up: mean: 7 years
Type of selenium marker: supplemental selenium intake (food frequency questionnaire)
Interventions d.n.a.
Outcomes Statistical methods: Cox logistic regression
Variables controlled in analysis: participation in observational or intervention study, age, log
calories, number of relatives with breast/ovarian cancer, dietary modification randomisation
arm, hysterectomy, minority race, pack-years of smoking, physical activity, NSAID use,
parity, infertility, duration of oral contraceptive use, number of lifetime ovulatory cycles,
partial oophorectomy, age at menopause, hormone therapy at study entry
Risk estimates [95% CI] Reference category: no intake of supplemental selenium (lowest exposure category)
Results:
Ovarian Cancer
highest exposure category: HR 1.00 (95% CI 0.73 to 1.37)
Selenium levels in exposure categories lowest exposure category: no supplemental selenium intake
highest exposure category: > 20 µg/day supplemental selenium intake
Notes
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van den Brandt 1993a
Methods Cohort/sub-cohort-controlled cohort study
Country: the Netherlands
Participants Name of parent cohort: Netherlands Cohort Study (NLCS)
Recruitment: 1986
van den Brandt 1993b:
Participants: 120,852: 58,279men and 62,573women; aged 55 to 69 years; returned baseline
questionnaire; no history of cancer at baseline
Outcome assessment: n.r.
Number of cases:
Stomach cancer: 104 (male/female: 84/20)
Colon cancer: 234 (male/female: 121/113)
Rectal cancer: 113 (male/female: 77/36)
van den Brandt 1993a:
Participants: 120,852: 58,279 men and 62,573 women; age 55 to 69 years; returned baseline
questionnaire; no history of cancer at baseline
Outcome assessment: n.r.
Number of cases:
Lung cancer: 370 (male/female: 335/35)
van den Brandt 1994:
Participants: 62,573 post-menopausal women
Outcome assessment: 1989
Number of cases:
Breast cancer (post-menopausal): 355 (male/female: 0/355)
Breast cancer (post-menopausal), multivariate analysis: 270 (male/female: 0/270)
Zeegers 2002:
Participants: 120,852: 58,279 men and 62,573 women
Outcome assessment: December 1992
Number of cases:
Bladder cancer: 431 (male/female: 372/59)
van den Brandt 2003:
Participants: 58,279 men
Outcome assessment: n.r. (probably December 1992)
Number of cases:
Prostate cancer: 540 (male/female: 540/0)
Case definition: incidence
Years of follow-up:
3.3 years (Brandt 1993a; Brandt 1993b; Brandt 1994),
6.3 years (Zeegers 2002; Brandt 2003)
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes van den Brandt 1993b:
Analysed cases: 234 of 351 colon cancer cases / 104 of 176 stomach cancer cases / 113 of
185 rectal cancer cases analysed (reasons for non-inclusion: history of cancer at baseline not
available, no pathological confirmation or CIS, no toenail clipping available)
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1993a:
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van den Brandt 1993a (Continued)
Analysed cases: 370 of 617 cases analysed (reasons for non-inclusion: history of cancer at
baseline not available, no toenail clipping, no pathological confirmation, problems with
selenium measurement)
Statistical methods:
Statistical methods:Mantel-Haenszel
Variables controlled in analysis: age, gender
van den Brandt 1994:
Analysed cases: 355 of 553 cases analysed (reasons for non-inclusion: history of cancer at
baseline not available, CIS, no toenail sample or problems with selenium detection)
Statistical methods:multivariate case-cohort analysis
Variables controlled in analysis: age, history of benign breast disease, maternal breast cancer,
breast cancer in sister(s), age at menarche, age at menopause, oral contraceptive use, parity,
age at first birth, body mass index, education, current cigarette smoking, alcohol intake,
energy intake
Zeegers 2002:
Analysed cases: 431 of 619 cases analysed (reason for non-inclusion: no toenails available)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, gender, number of cigarettes/day, years of cigarette smok-
ing
van den Brandt 2003:
Analysed cases: 540 of 704 cases analysed (reason for non-inclusion: no toenail samples or
selenium detection not possible)
Statistical methods: exponentially distributed failure time regression models
Variables controlled in analysis: age, family history of prostate cancer, number of cigarettes/
day, years of cigarette smoking, level of education
Risk estimates [95% CI] Reference category: lowest quartile/quintile
Results:
van den Brandt 1993b:
Stomach cancer
both genders: highest quintile: RR 0.61 (95% CI 0.33 to 1.11); highest quintile: RR 0.64
(95% CI 0.33 to 1.27) (max. adj.)
men: highest quintile: RR 0.40 (95% CI 0.17 to 0.96) (max. adj.)
women: highest quartile: RR 1.68 (95% CI 0.43 to 6.54) (max. adj.)
Colon cancer
both genders: highest quintile: RR 0.77 (95% CI 0.49 to 1.19); highest quintile: RR 0.80
(95% CI 0.50 to 1.29) (max. adj.)
men: highest quintile: RR 0.82 (95% CI 0.43 to 1.58) (max. adj.)
women: highest quintile: RR 0.77 (95% CI 0.41 to 1.45) (max. adj.)
Rectal cancer
both genders: highest quintile: RR 1.01 (95% CI 0.55 to 1.84); highest quintile: RR 1.05
(95% CI 0.54 to 2.03) (max. adj.)
men: highest quintile: RR 0.91 (95% CI 0.41 to 2.00) (max. adj.)
women: highest quartile: RR 1.58 (95% CI 0.59 to 4.22) (max. adj.)
van den Brandt 1993a:
Lung cancer
both genders: highest quintile: RR 0.40 (95% CI 0.27 to 0.59)
men: highest quintile: RR 0.50 (95% CI 0.30 to 0.82)
women: highest quartile: RR 0.40 (95% CI 0.13 to 1.24)
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van den Brandt 1993a (Continued)
van den Brandt 1994:
Breast cancer
multivariate analysis: highest quintile: RR 0.84 (95% CI 0.55 to 1.27)
age-stratified analysis: highest quintile: RR 0.93 (95% CI 0.65 to 1.33)
Zeegers 2002:
Bladder cancer
both genders: highest quintile: RR 0.67 (95% CI 0.46 to 0.97)
van den Brandt 2003:
Prostate cancer
highest quintile: RR 0.69 (95% CI 0.48 to 0.99)
Selenium levels in exposure categories van den Brandt 1993b:
lowest quintile: ≤ 0.483 µg/g
highest quintile: ≥ 0.631 µg/g
lowest quartile: ≤ 0.497 µg/g
highest quartile: ≥ 0.613 µg/g
van den Brandt 1993a:
both genders and men:
lowest quintile: ≤ 0.483 µg/g
highest quintile: ≥ 0.631 µg/g
women:
lowest quartile ≤ 0.497 µg/g
highest quartile ≥ 0.613 µg/g
van den Brandt 1994:
women:
lowest quintile: ≤ 0.499 µg/g
highest quintile: ≥ 0.646 µg/g
Zeegers 2002 :
lowest quintile: ≤ 0.483 µg/g
highest quintile: ≥ 0.631 µg/g
van den Brandt 2003:
men:
lowest quintile: ≤ 0.467 µg/g
highest quintile: ≥ 0.617 µg/g
Notes Primary publication: van den Brandt 1993b
Other publications: Zeegers 2002, van den Brandt 1993a, van den Brandt 1994, van den
Brandt 2003
van Noord 1987
Methods Matched, nested case-control study
Country: the Netherlands
Participants Participants: 8760 women
Inclusion criteria: 42 to 52 years of age; pre-menopausal; inhabitants of Utrecht
Name of parent cohort: DOM (Diagnostic onderzoek mammacarcinoom) Study
Recruitment: n.r.
Outcome assessment: 1 February 1986
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van Noord 1987 (Continued)
Number of cases:
Breast cancer (pre-menopausal): 27 (male/female: 0/27)
Case definition: incidence
Years of follow-up: 0.6 to 3.5 years, mean: 2.1 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Analysed cases: 7 cases were detected in the initial mammography screening in this study and
not included in the analysis of incident cases
Statistical methods: n.r.
Variables controlled by matching: age, date of birth, pre-menopausal status
Risk estimates [95% CI] Reference category: lowest quartile
Results:
Breast cancer (pre-menopausal)
highest quartile: OR 1.1 (95% CI 0.5 to 2.9)
Selenium levels in exposure categories n.r.
Notes
Virtamo 1987
Methods Cohort/sub-cohort-controlled cohort study
Country: Finland
Participants Participants: 1110 men
Inclusion criteria: 55 to 74 years of age; inhabitants of Finnish rural areas; participants of
prior study on CHD; serum sample available: cases within first year of follow-up excluded
Name of parent cohort: Men in rural East and West Finland
Recruitment: 1974
Outcome assessment: 31 December 1983
Number of cases:
Any cancer: 109 (male/female: 109/0)
Case definition: incidence
Years of follow-up: 10.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: conditional logistic regression
Variables controlled in analysis: age, area of residence, smoking, serum cholesterol, alcohol
intake
Risk estimates [95% CI] Reference category: highest tertile
Results:
Any cancer
lowest tertile OR 1.14 (95% CI 0.66 to 1.98)
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Virtamo 1987 (Continued)
Selenium levels in exposure categories lowest tertile: 15 to 46µg/l
highest tertile: 60 to 136µg/l
Notes
Walter 2011
Methods Cohort study
Country: US
Participants Inclusion criteria: aged 50 to 76 years, participants recruited from subscribers of commercial
mailing list, residents of western Washington state, non-whites excluded, no malignant dis-
ease at baseline
Name of parent cohort: Vitamins and lifestyle (VITAL) study
Recruitment: 1 October 2000 to 31 December 2002
Outcome assessment: 31/12/2008
Type of selenium marker: supplemental intake (questionnaire: use of supplements over the
last 10 years, mean supplemental intake / day calculated)
Case definition: incidence
Number of cases:
hematologic malignancies: 588
Interventions d.n.a.
Outcomes Statistical methods: cox proportional hazards regression,
Variables controlled in analysis: sex, race/ethnicity (white, Hispanic, other), education (high
school graduate or less, some college, college or advanced degree), smoking (pack-years), self-
rated health (excellent, very good, good, fair, poor), vegetable servings per day (excluding
potato servings); fruit servings per day; history of coronary artery disease (defined as history
of heart attack, coronary bypass surgery, angioplasty, and/or angina; yes, no), history of
rheumatoid arthritis (yes, no), history of fatigue or lack of energy over the year prior to baseline
(yes, no), and number of first-degree relatives with a history of leukemia or lymphoma (none,
1, 2)
Risk estimates [95% CI] Reference category: none
Results:
highest level: RR 0.95 (95% CI 0.75 to 1.20)
Selenium levels in exposure categories lowest level: none
highest level: 20.1-400.0 mg/d
Notes
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Wei 2004
Methods Frequency-matched cohort controlled study
Country: China
Participants Participants:Mark 2000: 29,584 men and women; Wei 2004: 1103 people who were origi-
nally selected as disease-free controls in Mark 2000
Inclusion criteria: 40 to 69 years of age; healthy inhabitants of 4 Linxian communities;
participants of a randomised controlled trial
Name of parent cohort: General Population Trial Linxian
Recruitment: 1985
Outcome assessment:May 1991 (Mark 2000); n.r. (Wei 2004)
Number of cases:
Wei 2004:
oesophageal cancer: 75 (male/female: 49/26) mortality
stomach, cardia cancer: 36 (male/female: 22/14) mortality
stomach, non-cardia cancer: 24 (male/female: 20/4) mortality
other: 32 (male/female: 22/10) mortality
Mark 2000:
oesophageal cancer: 590 (male/female: 286/304) incidence
oesophageal cancer: 332 (male/female: n.r.) mortality
stomach, cardia cancer: 402 (male/female: 239/163) incidence
stomach, cardia cancer: 232 (male/female: n.r.) mortality
stomach, non-cardia cancer: 87 (male/female: 66/21) incidence
stomach, non-cardia cancer: 68 (male/female: n.r.) mortality
Case definition:mortality, incidence
Years of follow-up: unclear/approximately 9 years (Wei 2004), 6 years (Mark 2000)
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: cox-proportional hazard model
Variables controlled in analysis: Wei 2004: age, cholesterol, smoking, alcohol intake, BMI;
Mark 2000: age
Variables controlled by matching: age category, gender
Risk estimates [95% CI] Wei 2004:
Reference category: lowest quartile
Results:
Oesophageal cancer
both genders: highest quartile: RR 0.35 (95% CI 0.16 to 0.81)
Stomach, cardia cancer
both genders: highest quartile: RR 0.31 (95% CI 0.11 to 0.87)
Stomach, non-cardia cancer
both genders: highest quartile: RR 1.64 (95% CI 0.49 to 5.48)
Other cancers
both genders: highest quartile: RR 1.95 (95% CI 0.66 to 5.81)
Mark 2000:
Reference category: lowest quartile
Results:
Oesophageal cancer
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Wei 2004 (Continued)
both genders / incidence: highest quartile: RR 0.56 (95% CI 0.44 to 0.71)
both genders / mortality: highest quartile: RR 0.62 (95% CI 0.44 to 0.89)
Stomach, cardia cancer
both genders / incidence: highest quartile: RR 0.47 (95% CI 0.33 to 0.65)
both genders / mortality: highest quartile: RR 0.59 (95% CI 0.39 to 0.90)
Stomach, non-cardia cancer
both genders / incidence: highest quartile: OR 1.07 (95% CI 0.55 to 2.08)
both genders / mortality: highest quartile: OR 1.03 (95% CI 0.85 to 2.02)
Selenium levels in exposure categories Wei 2004:
lowest quartile: 0.00 to 0.76 µmol/l
highest quartile ≥ 1.07 µmol/l
Mark 2000:
lowest quartile: 0.00 to 59.70 µg/l
highest quartile ≥ 82.20 µg/l
Notes Primary publication: Wei 2004
Other publication: Mark 2000
Remark:
Wei 2004 measured serum selenium in a sub-cohort derived from 29,584 male and female
participants of the Linxian Population Trial. The earlier publication of this study, Mark 2000
reported 332 fatal cases and 590 incident cases. The later publication, Wei 2004 reported
deaths from oesophageal cancer in the disease-free controls of Mark 2000 and analysed 75
fatal cases
Willett 1983
Methods Matched, nested case-control study
Country: US
Participants Participants: 10,940 men and women
Inclusion criteria: 30 to 69 years of age; serum sample available (only 4480 samples of cohort
were available because of freezer breakdown); participants of an RCT on hypertension;
institutionalised and bedfast people were excluded
Name of parent cohort: Hypertension Detection Follow-Up Programme (HDFP)
Recruitment: 1973 to 1974
Outcome assessment: n.r.
Number of cases:
Any cancer: 111 (male/female: 60/51)
Case definition: incidence
Years of follow-up: 5.0 years
Type of selenium marker: serum
Interventions d.n.a.
Outcomes Statistical methods: logistic regression of unmatched data
Variables controlled by matching: age, gender, race/ethnicity, smoking status, year/month of
sample collection, initial blood pressure, use of antihypertensive medication, randomisation
group
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Willett 1983 (Continued)
in women: parity, menopausal status
Risk estimates [95% CI] Reference category: highest quintile, highest three quintiles
Results:
Any cancer
both genders: lowest quintile versus highest quintile: OR 2.0 (CI not reported)
both genders: lowest quintile versus highest three quintiles: OR 1.9 (95% CI 1.1 to 3.3)
Selenium levels in exposure categories lowest quintile: ≤ 0.114 µg/ml
highest quintile: ≥ 0.154 µg/ml
Notes
Yoshizawa 1998
Methods Matched, nested case-control study
Country: US
Participants Participants: 33,737 men
Inclusion criteria: 40 to 75 years of age; physicians from all 50U.S. states; provision of toenails
in 1987 and completed baseline questionnaire in 1986; exclusion of histologically confirmed
prostate cancer at baseline and cases within first 2 years of follow-up
Name of parent cohort: Health Professionals Follow-Up Study (HPFS)
Recruitment: 1986 to 1987
Outcome assessment: 1994
Number of cases:
Prostate cancer: 181 (male/female: 181/0)
Case definition: incidence
Years of follow-up: 8.0 to 9.0 years
Type of selenium marker: toenail
Interventions d.n.a.
Outcomes Statistical methods: logistic regression, conditional logistic regression
Variables controlled in analysis: quintiles of lycopene, saturated fat, calcium, family history of
prostate cancer, BMI, vasectomy
Variables controlled by matching: age, smoking status, year/month of sample collection
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Prostate cancer (advanced)
highest quintile: OR 0.39 (95% CI 0.18 to 0.84)
Selenium levels in exposure categories lowest quintile: 0.530 to 0.730 µg/g
highest quintile: 0.941 to 7.090 µg/g
Notes
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Yu 1991
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: described as double-blind; blinding of participants: adequate, placebo tablets; blind-
ing of investigators and doctors: unclear
Dropouts/withdrawals: unclear, not described
Intention-to-treat-analysis: unclear, not described
Recruitment period: unclear, not described
Observation period: 2 years
Study period: 2 years
Detection of cases: unclear, use of “national standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 2,474
Condition: first-degree relatives within three generations of families with 2 or more cases of
liver cancer during the period 1972 to 1985
Demographics: gender distribution not reported; age: 15 to 75 years
Recruitment and setting: participants were residents in Qidong province
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily, intervention period unclear
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer within 2 years after start of
intervention
Results:
13 cases in 1030 placebo subjects
10 cases in 1444 selenium subjects
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes Data were extracted from Yu 1991.
We identified two later publications (Li 2002, Yu 1993), which we assumed to report on
the same trial as Yu 1991. However, total number of participants differed from the initial
report (N = 3849 in the later publications with 1485 receiving placebo and 2364 receiving
selenium). The total number of cases was not reported in either Li 1992 or Yu 1993
The reported results were:
Li 1992:
person-year incidence rate in intervention and control group:
within one year of follow-up: selenium group 175.36/100,000; placebo group: 414.65/100,
000
within two years of follow-up: selenium group 219.37/100,000; placebo group: 553.15/
100,000
Yu 1993:
cumulated incidence:
after one year: selenium group 1.75/1000; placebo group: 4.15/1000
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Yu 1991 (Continued)
after two years: selenium group 2.19/1000; placebo group: 5.53/1000
We could not make contact with the study investigators to clarify these discrepancies. As we
could not clarify the actual number of liver cancer cases in the later publications, we decided
to use the data of Yu 1991 for this review
Adverse effects were not mentioned in Yu 1991 or Li 1992. Yu 1993 stated that no cases of
selenosis were observed in the trial
Yu 1997
Methods Randomised controlled trial
Allocation: random
Sequence generation: unclear, not described
Concealment: unclear, not described
Blinding: of participants: adequate (placebo), of investigators and doctors: unclear, not described
Dropouts/withdrawals: unclear, not described
Recruitment period: unclear, not described
Intention-to-treat-analysis: unclear, not described
Observation period: 1987 to 1994
Intervention period: 1987 to 1990
Detection of cases: unclear, monthly blood sample during follow-up for liver enzymes (SGPT,
ZnTT), use of “national standards” for the diagnosis of liver cancer
Informed consent: unclear, not described
Participants Country: China
Number of participants: 226 (selenium group: 113; placebo group 113)
Condition: HBs-antigen carriers with normal liver function
Demographics: 95 men, 131 women; age: 21 to 63 years
Recruitment and setting: recruitment “through screening in a village in the city Qidong” (Li
1992)
Interventions Intervention: 200 µg selenium as selenised yeast p.o. daily for 4 years
Control: placebo
Outcomes Primary outcome measure: incidence of primary liver cancer (defined as increase of SGPT and
ZnTT)
Results: at the end of the intervention period: 0 cases in the selenium group; 7 cases in the
placebo group in a total of 445 person years of observation (person-time incidence rate: 1,
573.03/100,000)
Risk estimates [95% CI] n.r.
Selenium levels in exposure categories d.n.a.
Notes Adverse effects: “No side effects have been found in these trials.” (Yu 1997, p124)
further data reported in: Li 1992 (Chinese, translated); Yu 1991
In Yu 1991 a different incidence in the selenium group was reported (5 cases). We could not
clarify this discrepancy to the later papers Li 1992 and Yu 1997
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Yu 1999
Methods Matched, nested case-control study
Country: China (Taiwan)
Participants Participants: 4841 men
Inclusion criteria: 30 to 65 years of age; HBsAg-positive or/and HCV-positive; recruited at
two centres: Government EmployeeCentral Clinics or Liver Unit of Chang-GungMemorial
Hospital
Recruitment: August 1988 to June 1992
Outcome assessment: 31 December 1996
Number of cases:
Primary liver cancer: 69 (male/female: 69/0)
Case definition: incidence
Years of follow-up: 4.5 to 8.3 years
Type of selenium marker: plasma
Interventions d.n.a.
Outcomes Analysed cases: 69 of 73 cases analysed (reason for non-inclusion: no sample available)
Statistical methods: conditional logistic regression
Variables controlled in analysis: age, cigarette smoking, alcohol intake, plasma levels of retinol/
alpha-tocopherol/alpha-carotene/beta-carotene/lycopene
Variables controlled by matching: age, year and season of sample collection, recruitment clinic
Risk estimates [95% CI] Reference category: lowest quintile
Results:
Primary liver cancer
highest quintile: OR 0.62 (95% CI 0.21 to 1.86)
Selenium levels in exposure categories lowest quintile ≤ 124.90 µg/l
highest quintile ≥ 162.40 µg/l
Notes
(lower border; upper border) lower and upper border of the 95% CI (if not otherwise specified)
µ micro
AFP alpha-fetoprotein
ALT alanine aminotransferase
ATBC Alpha-tocopherol, beta-carotene cancer prevention study
AU arbitrary unit
BCC basal cell carcinoma
BMI body-mass-index
BPH benign prostate hyperplasia
CARET Carotene and Retinol Efficacy Trial
CHD coronary heart disease
CI confidence interval
CIS carcinoma in situ
CVD cardiovascular disease
dl deciliter
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d.n.a. does not apply
DOM Diagnostic onderzoek mammacarcinoom
EVA Etude du Vieillissement Antériel
EPOZ Epidemiologisch onderzoek naar risico-indicatoren voor hart- en vaatziekten
FFQ food-frequency questionnaire
g gram
HBsAg Hepatitis B surface antigen
HCC hepatocellular carcinoma
HCV hepatitis C virus
HPFP Hypertension Detection Follow-up Programme
HPFS Health Professionals Follow-up Study
HR hazard ratio
IU international unit
l litre
m milli
max. adj. maximally adjusted
MHC Mobile Health Clinic
n nano
NHS Nurses‘ Health Study
NLCS Netherlands Cohort Study
NMSC non-melanoma skin cancer
NPCT Nutritional Prevention of Cancer Trial
n.r. not reported
NSAID non-steroidal antiinflammatory drugs
OR Odds ratio
p. page
p.o. per os
ppm parts per million
PSA prostate-specific antigen
RCT randomised controlled trial
RR relative risk
SCC squamous cell carcinoma
SGPT alanine aminotransferase
TIA transient ischemic attack
UK United Kingdom
US United States of America
VITAL Vitamins and Lifestyle Study
ZnTT zinc turbidity test
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bostick 1993 Cohort study: Iowa Women’s Health Study cohort
Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no in ques-
tionnaire assessed
Brock 1991 Case-control study with precancerous condition (carcinoma in situ of the cervix)
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(Continued)
Chen 1988 Case-control study
Chen 2003 Case-control study
Connelly-Frost 2009 Case-control study
Costello 2001 APPOSE (Australian Prostate Cancer Prevention Trial Using Selenium): publication describes study design,
trial was not started
Criqui 1991 Population-based prospective case-control study: Lipid Research Clinic Prevalence and Follow-Up study
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Cui 2007 Nested case-control study
Selenium exposure not assessed according to eligibility: selenium measurement conducted in tissue of benign
breast disease
Davies 2002 Nested case-control study: EPIC Norfolk study cohort
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Fleshner 2003 Randomised Study of Vitamin E, Selenium, and Soy Protein Isolate in Patients with High-Grade Prostatic
Intraepithelial Neoplasia:
Multicomponent Intervention
Hagmar 1992 Historical cohort study
Harris 2012 Cancer was not a study endpoint
Hartman 2002 Nested case-control study: ATBC cohort
Results not reported according to inclusion criteria: differences inmean selenium levels reported;OR reported
as graph and could not be calculated from reported data
Huzarski 2006 Interventional studywithout control groupwith 1489 female participants withBRCA1mutationwho received
a selenium-containing nutritional supplement
Joniau 2007 Intervention study without control group with male participants with high-grade intraepithelial neoplasia of
the prostate who received a selenium-containing nutritional supplement
Kellen 2008 Case-control study
Kilander 2001 Cohort study in Uppsala/Sweden
Results not reported according to inclusion criteria: RR estimate per unit increase in selenium level reported
Knekt 1988a Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Knekt 1988b Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
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(Continued)
Knekt 1991 Nested case-control study: Mobile Health Clinic cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kok 1987b Nested case-control study: Zoetermeer cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
Kune 2006 Case-control study
Kuroda 1988 Case-control study
Lawson 2007 Cohort study on multivitamin use and risk of prostate cancer
Le Marchand 2006 Case-control study
Li 2004b RCT for gastric cancer prevention with multicomponent intervention (200 mg synthetic allitridum and 100
µg selenium per day)
Limburg 2005 Randomised controlled trial: primary endpoint in this two-by-two factorial design trial with selenomethio-
nine 200 µg daily and/or celecoxib 200 mg twice daily was the per-participant change (regression, stable,
progression) of preexisting oesophageal dysplasia-cancer incidence and mortality were not endpoints in this
study
Linxian Pilot 2000 Randomised controlled trial with selenium supplements and celecoxib in participants with oesophageal
squamous dysplasia in Linxian, China
Endpoint was “regression of disease”, cancer was not an endpoint in this investigation
Neuhouser 2009 Cohort study (Women’s Health Initiative) on multivitamin use and risk of cancer and cardiovascular disease
No data for selenium and cancer risk reported
Ray 2006 Cohort study (Women’s Health and Aging Studies I and II) on selenium and carotenoid serum levels and
mortality
No data for selenium and cancer mortality reported
Rayman 2001 PRECISE trial (Prevention of Cancer by Intervention with Selenium): trial has been stopped
Rendon Randomised controlled trial: Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients with
High-Grade Prostate Neoplasia: Multicomponent Intervention
Steevens 2010b Cancer was not a study endpoint
Thompson 2009 Cohort study: Iowa Women’s Health Study cohort
Selenium exposure not assessed according to eligibility: only intake of selenium supplements yes/no in ques-
tionnaire assessed
Tsugane 1996 Case-control and cross-sectional studies
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(Continued)
Ujiie 2002 A part of this study is a prospective cohort study in Miyagi/Japan
Results not reported according to inclusion criteria: differences in mean selenium levels reported
van Noord 1992 Nested case-control study: DOM cohort
Results not reported according to inclusion criteria: differences in mean selenium levels reported
van Noord 1993 Nested case-control study: DOM II cohort
Results not reported according to inclusion criteria: RR estimate per unit increase of selenium level reported
van’t Veer 1996 Case-control study
Wallace 2009 Case-control study
Watters 2009 Cohort study on smoking and prostate cancer risk. Selenium not reported as independent variable
Wright 2004 Cohort study: ATBC cohort
Exposure to antioxidants was assessed using a self-developed index
You 2005 Randomised controlled trial to test retardation of the progression of precancerous gastric lesions among 3400
adults in Shandong, China. Intervention: vitamin C, vitamin E, selenium, garlic preparation
Multicomponent intervention
Yuan 2006 Nested case-control study: Shanghai cohort study
No data on selenium and cancer risk reported
Zeegers 2009 Cohort study on factors influencing recurrence or progression of bladder cancer: West Midlands Bladder
Cancer Prognosis Programme
µ = micro
APPOSE = Australian Prostate Cancer Prevention Trial Using Selenium
ATBC = alpha-tocopherol, beta-carotene cancer prevention study
BRCA = breast cancer
DOM = Diagnostic Onderzoek Mammacarcinoom
EPIC = European Prospective Investigation of Cancer
m = milli
g = gram
OR = odds ratio
PRECISE = Prevention of Cancer by Intervention with Selenium
RCT = randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
Epi˙Nomura 2002
Trial name or title Cancer Sero Epidemiology Among the Japanese in Hawaii
Methods This is a sero-epidemiological prospective study to identify biochemical markers related to common cancers
Among the aims are (a) to see whether low serum selenium levels increase prostate cancer risk, and (b) to
determine whether low serum selenium levels increase urinary bladder cancer risk in men
Participants 9345 male American Japanese subjects, examined in Hawaii
Interventions d.n.a.
Outcomes Risk of prostate and urinary bladder cancer
Starting date Project start: 15 September 1983, Project end planned for 30 June 2004
Contact information Abraham M. Nomura
Kuakini Medical Center
347 N Kuakini St
Honolulu, HI 96817
Notes
RCT˙Cheng 2003
Trial name or title Selenium Supplementation for the Prevention ofHepatocellular Carcinomas inHBsAg Positive Patients (pilot
study)
Methods Randomised controlled trial
Participants Men 45 to 64 years of age with positive HBsAg test, negative AFP test and normal ALT values
Interventions Placebo or 200 mg (sic!)/d selenium as selenised yeast
Outcomes Primary liver cancer
Starting date 2003
Contact information Prof Kar Keung Cheng, University of Birmingham, UK
Notes Study author contacted for further information, but no reply received
Should probably say 200 µg/d selenium yeast as intervention in the publication
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RCT˙Cheng 2006
Trial name or title Bladder Cancer Prognosis Programme (incorporating SELENIB trial)
Methods Double-blinded, placebo-controlled, two-by-two factorial, randomised controlled trial (SELENIB), nested
within a prospective observational cohort study (Bladder Cancer Prognosis Programme BCPP)
Participants 1200 participants in the Bladder Cancer Prognosis Programme in the United Kingdom
Inclusion criteria:
Histopathologically confirmed non-muscle invasive transitional cell carcinoma. Solitary grade 1 pTa larger
than 3 cm and all other stage pTa, pT1 or pTcis
Exclusion criteria:
1. Disease characteristics-solitary grade 1 pTa < 3 cm or stage pT2 and above
2. Patients who are pregnant or breastfeeding
3. Patients diagnosed with human immunodeficiency virus (HIV) infection
4. Patients who are on immunosuppressive therapy following organ transplantation
5. Patients taking cyclosporin
6. Any condition that, in the opinion of the local investigator, might interfere with the safety of the participant
or with evaluation of trial objectives
Interventions Four study arms:
1. Selenium
2. Alpha-tocopherol
3. Selenium and alpha-tocopherol
4. Placebo
Outcomes Primary outcomes: recurrence-free survival, progression-free survival
SELENIB trial-secondary outcomes
1. All-cause mortality
2. Incidence of transitional cell carcinoma (TCC) outside the bladder
3. Incidence of all other malignancies clinically diagnosed
4. Incidence of cardiovascular events: myocardial infarction, stroke, death from cardiovascular causes
5. Quality of life-as assessed by quality of life instruments: EuropeanOrganisation for Research and Treatment
of Cancer (EORTC) QLQ-C30, QLQ-BLS24 and QLQ-BLM30
Starting date
Contact information
Notes Ongoing trial
Contact details:
Prof K. K. Cheng
The Public Health Building
University of Birmingham
Edgbaston
Birmingham
United Kingdom
B15 2TT
http://www.bcpp.bham.ac.uk
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RCT˙ECOG 2002
Trial name or title Randomised Chemoprevention Study of Selenium in Participants With Previously Resected Stage I Non-
Small Cell Lung Cancer
Methods Randomised controlled trial
Participants Disease characteristics:
Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small-cell lung cancer
(except carcinoid)
Completion of treatment for stage I lung cancer within the past six to 36 months and currently disease free
At least one mediastinal lymph node sampled at resection
Age: 18 years and older
Performance status: ECOG zero to one
A total of 1960 participants (980 per arm) will be accrued for this study within four years
Interventions Arm I: Participants receive oral selenium yeast daily for six months. Treatment repeats every six months for
eight courses for a total of four years in the absence of unacceptable toxicity
Arm II: Participants receive an oral yeast placebo as in arm I
Participants are followed annually
Outcomes Second incidence/recurrence of primary lung tumours
Toxicity
Incidence of specific cancers, mortality from cancer and overall survival
Starting date October 2000
Contact information Eastern Cooperative Oncology Group
Daniel Karp, MD, Protocol chair Phone: 713-745-7398; 800-392-1611
Southwest Oncology Group
Omer Kucuk, MD, Protocol chair Phone: 313-576-8739; 800-527-6266
Email: kucuko@karmanos.org
Notes Recruiting
RCT˙NBT˙Stratton 2003
Trial name or title Negative Biopsy Trial (NBT)
Methods This study is a phase III cancer chemoprevention study among men at high risk of prostate cancer because of
a persistent elevation in PSA above 4 ng/mL and a negative initial biopsy
Participants The trial will randomly assign at least 700 participants with persistently elevated PSA levels (> 4 ng/mL) and
at least one negative biopsy for prostate cancer. The principal purpose of this trial is to assess the potential for
treatment with the essential trace element of selenium to prevent prostate cancer (PCa)
Interventions The trial will randomly assign participants to placebo or to one of two selenium dosages-200 µg/d or 400 µg/
d
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RCT˙NBT˙Stratton 2003 (Continued)
Outcomes The primary endpoints for the trial are the incidence of PCa and the velocity of the primary serum marker
of prostate cancer progression, prostate-specific antigen (PSA). Safety endpoints for the trial include onset of
mild symptoms of selenium toxicity and significant changes in liver and kidney enzyme levels
Starting date 30 September 1999
Contact information M. Suzanne Stratton, Ph.D.
Research Assistant Professor
Arizona Cancer Center
Prostate Cancer Prevention Program
2504 E Elm Street.
Tucson, AZ 85716
http://www.selenium.arizona.edu
Notes
µ = micro
AARP = American Association of Retired Persons
AFP = alpha-fetoprotein
ALT = alanine aminotransferase
BCC = basal cell carcinoma
BCPP = Bladder Cancer Prognosis Programme
BRCA = breast cancer
cm = centimeter
d.n.a. = does not apply
ECG = electrocardiogram
ECOG = Eastern Cooperative Oncology Group
EORTC = European Organisation for Research and Treatment of Cancer
EPIC = European Prospective Investigation of Cancer
g = gram
HBs-Ag = hepatitis B surface antigen
HGPIN = high-grade prostatic intraepithelial neoplasia
HIV = human immunodeficiency virus
iU = international unit
l = liter
m = milli
n = nano
n.r. = not reported
NHANES = National Health and Nutrition Examination Survey
NIH = National Institutes of Health
p = page
PSA = prostate-specific antigen
pT = tumour after pathological assessment, according to the tumour/nodules/metastases TNM staging system
QLQ = Quality of Life Questionnaire
RCT = randomised controlled trial
SCC = squamous cell carcinoma
SELECT = Selenium and Vitamin E Cancer Prevention Trial
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SELENIB = randomised controlled trial of selenium and vitamin E in the recurrence and progression of non-muscle invasive bladder
cancer
TCC = transitional cell carcinoma
UK = United Kingdom
US = United States of America
WHAS = Women’s Health and Aging Study
WHI = Women’s Health Initiative
WHO = World Health Organization
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D A T A A N D A N A L Y S E S
Comparison 1. Observational studies: highest versus lowest selenium exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cancer incidence and
mortality
14 Odds Ratio (Random, 95% CI) Subtotals only
1.1 Incidence 8 Odds Ratio (Random, 95% CI) 0.69 [0.53, 0.91]
1.2 Mortality 6 Odds Ratio (Random, 95% CI) 0.60 [0.39, 0.93]
2 Total cancer incidence and
mortality (men)
8 Odds Ratio (Random, 95% CI) Subtotals only
2.1 Incidence 5 Odds Ratio (Random, 95% CI) 0.66 [0.42, 1.05]
2.2 Mortality 3 Odds Ratio (Random, 95% CI) 0.56 [0.38, 0.81]
3 Total cancer incidence and
mortality (women)
5 Odds Ratio (Random, 95% CI) Subtotals only
3.1 Incidence 2 Odds Ratio (Random, 95% CI) 0.90 [0.45, 1.77]
3.2 Mortality 3 Odds Ratio (Random, 95% CI) 0.92 [0.79, 1.07]
4 Total cancer incidence and
mortality (ascending order of
selenium levels)
12 Odds Ratio (Random, 95% CI) Subtotals only
4.1 Incidence 6 1297 Odds Ratio (Random, 95% CI) 0.69 [0.52, 0.91]
4.2 Mortality 6 1041 Odds Ratio (Random, 95% CI) 0.60 [0.39, 0.93]
5 Breast cancer risk (women) 7 Odds Ratio (Random, 95% CI) 1.00 [0.77, 1.29]
5.1 Breast cancer (all) 6 Odds Ratio (Random, 95% CI) 1.01 [0.74, 1.36]
5.2 Breast cancer
(premenopausal)
1 Odds Ratio (Random, 95% CI) 1.10 [0.46, 2.65]
6 Bladder cancer risk 5 Odds Ratio (Random, 95% CI) 0.67 [0.46, 0.97]
6.1 All (male + female) 2 Odds Ratio (Random, 95% CI) 0.65 [0.46, 0.92]
6.2 Male 3 Odds Ratio (Random, 95% CI) 0.82 [0.41, 1.62]
6.3 Female 1 Odds Ratio (Random, 95% CI) 0.36 [0.14, 0.92]
7 Lung cancer risk
(gender-aggregated data)
12 Odds Ratio (Random, 95% CI) 0.83 [0.61, 1.13]
7.1 Incidence 10 Odds Ratio (Random, 95% CI) 0.75 [0.54, 1.03]
7.2 Mortality 2 Odds Ratio (Random, 95% CI) 1.34 [0.93, 1.93]
8 Lung cancer risk
(gender-disaggregated data)
12 Odds Ratio (Random, 95% CI) 0.84 [0.65, 1.09]
8.1 All (female + male) 4 Odds Ratio (Random, 95% CI) 0.58 [0.39, 0.86]
8.2 Female 4 Odds Ratio (Random, 95% CI) 0.83 [0.43, 1.61]
8.3 Male 7 Odds Ratio (Random, 95% CI) 0.98 [0.68, 1.39]
9 Lung cancer risk 12 Odds Ratio (Random, 95% CI) 0.83 [0.61, 1.13]
9.1 Intake 1 Odds Ratio (Random, 95% CI) 0.98 [0.41, 2.35]
9.2 Serum or plasma 9 Odds Ratio (Random, 95% CI) 0.91 [0.70, 1.18]
9.3 Toenail 2 Odds Ratio (Random, 95% CI) 1.05 [0.11, 10.36]
10 Lung cancer risk (ascending
order of selenium levels)
8 1867 Odds Ratio (Random, 95% CI) 0.97 [0.74, 1.27]
11 Prostate cancer risk 17 Odds Ratio (Random, 95% CI) 0.79 [0.69, 0.90]
12 Prostate cancer risk (by
selenium measurement)
17 Odds Ratio (Random, 95% CI) 0.79 [0.69, 0.90]
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12.1 Biochemical selenium
level
15 Odds Ratio (Random, 95% CI) 0.76 [0.67, 0.88]
12.2 Estimated selenium
intake
2 Odds Ratio (Random, 95% CI) 1.00 [0.73, 1.36]
13 Prostate cancer risk (by
exposure assessment)
17 Odds Ratio (Random, 95% CI) 0.79 [0.69, 0.90]
13.1 Intake 2 Odds Ratio (Random, 95% CI) 1.00 [0.73, 1.36]
13.2 Serum or plasma 12 Odds Ratio (Random, 95% CI) 0.82 [0.72, 0.93]
13.3 Toenail 3 Odds Ratio (Random, 95% CI) 0.53 [0.35, 0.81]
14 Prostate cancer risk (by
continent)
17 Odds Ratio (Random, 95% CI) 0.79 [0.69, 0.90]
14.1 Europe 6 Odds Ratio (Random, 95% CI) 0.86 [0.73, 1.02]
14.2 North America 11 Odds Ratio (Random, 95% CI) 0.73 [0.60, 0.88]
15 Prostate cancer risk (by
country)
17 Odds Ratio (Random, 95% CI) 0.79 [0.69, 0.90]
15.1 Several European
countries
3 Odds Ratio (Random, 95% CI) 0.87 [0.71, 1.07]
15.2 Finland 2 Odds Ratio (Random, 95% CI) 1.24 [0.75, 2.05]
15.3 The Netherlands 1 Odds Ratio (Random, 95% CI) 0.69 [0.48, 0.99]
15.4 US 11 Odds Ratio (Random, 95% CI) 0.73 [0.60, 0.88]
16 Prostate cancer risk (ascending
order of selenium levels)
12 2982 Odds Ratio (Random, 95% CI) 0.82 [0.72, 0.93]
17 Stomach cancer risk 5 Odds Ratio (Random, 95% CI) 0.66 [0.43, 1.01]
17.1 Stomach 4 Odds Ratio (Random, 95% CI) 0.65 [0.35, 1.19]
17.2 Stomach: cardia cancer 1 Odds Ratio (Random, 95% CI) 0.47 [0.33, 0.66]
17.3 Stomach: non-cardia
cancer
1 Odds Ratio (Random, 95% CI) 1.07 [0.55, 2.08]
18 Stomach cancer risk (by gender) 5 Odds Ratio (Random, 95% CI) 0.66 [0.42, 1.04]
18.1 All (female + male) 2 Odds Ratio (Random, 95% CI) 0.75 [0.41, 1.36]
18.2 Female 2 Odds Ratio (Random, 95% CI) 0.73 [0.12, 4.35]
18.3 Male 3 Odds Ratio (Random, 95% CI) 0.43 [0.14, 1.32]
19 Colorectal cancer risk 5 Odds Ratio (Random, 95% CI) 0.89 [0.65, 1.23]
19.1 Colon and rectal cancer 2 Odds Ratio (Random, 95% CI) 1.11 [0.50, 2.46]
19.2 Colon cancer 3 Odds Ratio (Random, 95% CI) 0.80 [0.56, 1.15]
20 Colorectal cancer risk (by
gender)
5 Odds Ratio (Random, 95% CI) 0.89 [0.65, 1.23]
20.1 All (female + male) 1 Odds Ratio (Random, 95% CI) 1.22 [0.52, 2.86]
20.2 Female 3 Odds Ratio (Random, 95% CI) 1.06 [0.57, 2.00]
20.3 Male 3 Odds Ratio (Random, 95% CI) 0.69 [0.42, 1.12]
Comparison 2. Randomised controlled trials: highest versus lowest selenium exposure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any cancer risk 2 18698 Risk Ratio (IV, Random, 95% CI) 0.90 [0.70, 1.17]
2 Cancer mortality 2 18698 Risk Ratio (IV, Random, 95% CI) 0.81 [0.49, 1.32]
3 Liver cancer risk 3 4765 Risk Ratio (IV, Random, 95% CI) 0.50 [0.35, 0.71]
4 Non-melanoma skin cancer risk 3 Risk Ratio (Random, 95% CI) 1.44 [0.95, 2.17]
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5 Prostate cancer risk 4 19110 Risk Ratio (IV, Random, 95% CI) 0.90 [0.71, 1.14]
6 Prostate cancer risk for studies
with low RoB
3 18183 Risk Ratio (IV, Random, 95% CI) 1.02 [0.90, 1.14]
7 Lung cancer risk 2 18698 Risk Ratio (IV, Random, 95% CI) 0.94 [0.62, 1.42]
8 Bladder cancer risk 2 18698 Risk Ratio (IV, Random, 95% CI) 1.14 [0.81, 1.61]
9 Colorectal cancer risk 2 18698 Risk Ratio (IV, Random, 95% CI) 0.77 [0.37, 1.62]
Analysis 1.1. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 1
Total cancer incidence and mortality.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 1 Total cancer incidence and mortality
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Coates 1988 0 (0.32676883) 10.3 % 1.00 [ 0.53, 1.90 ]
Knekt 1990 -0.15082287 (0.17949557) 17.4 % 0.86 [ 0.60, 1.22 ]
Knekt 1990 -0.89159813 (0.19836824) 16.4 % 0.41 [ 0.28, 0.60 ]
Nomura 1987 -0.26236423 (0.29924162) 11.4 % 0.77 [ 0.43, 1.38 ]
Peleg 1985 0 (0.32691842) 10.3 % 1.00 [ 0.53, 1.90 ]
Persson 2000 -1.6486586 (0.75775878) 2.9 % 0.19 [ 0.04, 0.85 ]
Ringstad 1988 -0.33647222 (0.44989504) 6.8 % 0.71 [ 0.30, 1.73 ]
Virtamo 1987 -0.13102825 (0.28025823) 12.2 % 0.88 [ 0.51, 1.52 ]
Willett 1983 -0.64185387 (0.28025823) 12.2 % 0.53 [ 0.30, 0.91 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.53, 0.91 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 15.61, df = 8 (P = 0.05); I2 =49%
Test for overall effect: Z = 2.67 (P = 0.0076)
2 Mortality
Akbaraly 2005 -1.401183 (0.5047159) 11.6 % 0.25 [ 0.09, 0.66 ]
Bleys 2008 -0.37106368 (0.13508107) 25.3 % 0.69 [ 0.53, 0.90 ]
Fujishima 2011 1.0919 (0.801) 6.1 % 2.98 [ 0.62, 14.32 ]
Kok 1987a -0.64185387 (0.33397056) 17.2 % 0.53 [ 0.27, 1.01 ]
Kornitzer 2004 0.35667496 (0.4270348) 13.9 % 1.43 [ 0.62, 3.30 ]
Kornitzer 2004 -0.78845738 (0.26682873) 20.0 % 0.45 [ 0.27, 0.77 ]
Salonen 1985 -1.757858 (0.81249343) 6.0 % 0.17 [ 0.04, 0.85 ]
0.01 0.1 1 10 100
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 100.0 % 0.60 [ 0.39, 0.93 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 15.69, df = 6 (P = 0.02); I2 =62%
Test for overall effect: Z = 2.28 (P = 0.022)
0.01 0.1 1 10 100
Analysis 1.2. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 2
Total cancer incidence and mortality (men).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 2 Total cancer incidence and mortality (men)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Knekt 1990 -0.89159813 (0.19836824) 27.5 % 0.41 [ 0.28, 0.60 ]
Nomura 1987 -0.26236423 (0.29924162) 22.1 % 0.77 [ 0.43, 1.38 ]
Peleg 1985 0.51082558 (0.85634884) 6.2 % 1.67 [ 0.31, 8.93 ]
Peleg 1985 0.10536054 (0.49602147) 13.6 % 1.11 [ 0.42, 2.94 ]
Persson 2000 -1.6486586 (0.75775878) 7.5 % 0.19 [ 0.04, 0.85 ]
Virtamo 1987 -0.13102825 (0.28025823) 23.1 % 0.88 [ 0.51, 1.52 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.42, 1.05 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 11.43, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.75 (P = 0.081)
2 Mortality
Bleys 2008 -0.35667496 (0.12845059) 54.1 % 0.70 [ 0.54, 0.90 ]
Kok 1987a -0.99325179 (0.43360709) 15.6 % 0.37 [ 0.16, 0.87 ]
Kornitzer 2004 -0.78845738 (0.26682873) 30.3 % 0.45 [ 0.27, 0.77 ]
Subtotal (95% CI) 100.0 % 0.56 [ 0.38, 0.81 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.66, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 3.02 (P = 0.0025)
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 3
Total cancer incidence and mortality (women).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 3 Total cancer incidence and mortality (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Knekt 1990 -0.15082287 (0.17949557) 68.7 % 0.86 [ 0.60, 1.22 ]
Peleg 1985 -1.757858 (1.2286268) 7.3 % 0.17 [ 0.02, 1.92 ]
Peleg 1985 0.51082558 (0.6016002) 23.9 % 1.67 [ 0.51, 5.42 ]
Subtotal (95% CI) 100.0 % 0.90 [ 0.45, 1.77 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 2.90, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Mortality
Bleys 2008 -0.07257069 (0.08211736) 90.6 % 0.93 [ 0.79, 1.09 ]
Bleys 2008 -0.4942963 (0.39748588) 3.9 % 0.61 [ 0.28, 1.33 ]
Kok 1987a -0.40546511 (0.52696443) 2.2 % 0.67 [ 0.24, 1.87 ]
Kornitzer 2004 0.35667496 (0.4270348) 3.3 % 1.43 [ 0.62, 3.30 ]
Subtotal (95% CI) 100.0 % 0.92 [ 0.79, 1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
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Analysis 1.4. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 4
Total cancer incidence and mortality (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 4 Total cancer incidence and mortality (ascending order of selenium levels)
Study or subgroup
Upper bor-
der/lowest
level
Lower bor-
der/highest
leve log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Knekt 1990 49 -0.89159813 (0.19836824) 78 19.3 % 0.41 [ 0.28, 0.60 ]
Knekt 1990 49 -0.15082287 (0.17949557) 78 20.8 % 0.86 [ 0.60, 1.22 ]
Nomura 1987 103 -0.26236423 (0.29924162) 133 12.9 % 0.77 [ 0.43, 1.38 ]
Peleg 1985 103 127 0 (0.32691842) 11.6 % 1.00 [ 0.53, 1.90 ]
Ringstad 1988 114 -0.33647222 (0.44989504) 115 7.4 % 0.71 [ 0.30, 1.73 ]
Virtamo 1987 (1) 46 -0.13102825 (0.28025823) 60 14.0 % 0.88 [ 0.51, 1.52 ]
Willett 1983 114 -0.64185387 (0.28025823) 128 14.0 % 0.53 [ 0.30, 0.91 ]
Subtotal (95% CI) 100.0 % 0.69 [ 0.52, 0.91 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 11.45, df = 6 (P = 0.08); I2 =48%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Mortality
Akbaraly 2005 75 -1.401183 (0.5047159) 96 11.6 % 0.25 [ 0.09, 0.66 ]
Bleys 2008 117 -0.37106368 (0.13508107) 130 25.3 % 0.69 [ 0.53, 0.90 ]
Fujishima 2011 4 5 1.0919 (0.801) 6.1 % 2.98 [ 0.62, 14.32 ]
Kok 1987a 103 -0.64185387 (0.33397056) 103 17.2 % 0.53 [ 0.27, 1.01 ]
Kornitzer 2004 72 -0.78845738 (0.26682873) 85 20.0 % 0.45 [ 0.27, 0.77 ]
Kornitzer 2004 72 0.35667496 (0.4270348) 85 13.9 % 1.43 [ 0.62, 3.30 ]
Salonen 1985 47 -1.757858 (0.81249343) 47 6.0 % 0.17 [ 0.04, 0.85 ]
Subtotal (95% CI) 100.0 % 0.60 [ 0.39, 0.93 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 15.69, df = 6 (P = 0.02); I2 =62%
Test for overall effect: Z = 2.28 (P = 0.022)
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Analysis 1.5. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 5
Breast cancer risk (women).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 5 Breast cancer risk (women)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Breast cancer (all)
Coates 1988 1.2237755 (0.59689179) 4.7 % 3.40 [ 1.06, 10.95 ]
Dorgan 1998 -0.10536054 (0.3836932) 11.1 % 0.90 [ 0.42, 1.91 ]
Garland 1995 0.0953102 (0.22933655) 28.8 % 1.10 [ 0.70, 1.72 ]
Knekt 1990 -0.44628712 (0.44815248) 8.2 % 0.64 [ 0.27, 1.54 ]
Overvad 1991 0.22314354 (0.51575917) 6.3 % 1.25 [ 0.45, 3.43 ]
van den Brandt 1993a -0.17435342 (0.21348313) 32.6 % 0.84 [ 0.55, 1.28 ]
Subtotal (95% CI) 91.8 % 1.01 [ 0.74, 1.36 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.29, df = 5 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Breast cancer (premenopausal)
van Noord 1987 0.0953102 (0.44843315) 8.2 % 1.10 [ 0.46, 2.65 ]
Subtotal (95% CI) 8.2 % 1.10 [ 0.46, 2.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 100.0 % 1.00 [ 0.77, 1.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.34, df = 6 (P = 0.39); I2 =5%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 1.6. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 6
Bladder cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 6 Bladder cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (male + female)
Menkes 1986 -0.72270596 (0.57370723) 9.1 % 0.49 [ 0.16, 1.49 ]
van den Brandt 1993a -0.40047754 (0.19032388) 36.7 % 0.67 [ 0.46, 0.97 ]
Subtotal (95% CI) 45.8 % 0.65 [ 0.46, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Male
Michaud 2002 -0.13926206 (0.54291624) 10.0 % 0.87 [ 0.30, 2.52 ]
Michaud 2005 0.15700371 (0.29159795) 24.4 % 1.17 [ 0.66, 2.07 ]
Nomura 1987 -1.1314021 (0.64600567) 7.4 % 0.32 [ 0.09, 1.14 ]
Subtotal (95% CI) 41.9 % 0.82 [ 0.41, 1.62 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.57 (P = 0.57)
3 Female
Michaud 2005 -1.0216512 (0.47750056) 12.3 % 0.36 [ 0.14, 0.92 ]
Subtotal (95% CI) 12.3 % 0.36 [ 0.14, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
Total (95% CI) 100.0 % 0.67 [ 0.46, 0.97 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.10, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 1.96, df = 2 (P = 0.38), I2 =0.0%
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Analysis 1.7. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 7
Lung cancer risk (gender-aggregated data).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 7 Lung cancer risk (gender-aggregated data)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Incidence
Coates 1988 -0.22314354 (0.948341) 2.3 % 0.80 [ 0.12, 5.13 ]
Comstock 1997 -0.43078295 (0.26193982) 10.3 % 0.65 [ 0.39, 1.09 ]
Epplein 2009 -0.02020269 (0.43266643) 6.9 % 0.98 [ 0.42, 2.29 ]
Epplein 2009 -0.35667496 (0.32638552) 8.9 % 0.70 [ 0.37, 1.33 ]
Garland 1995 1.4655675 (1.0612346) 1.9 % 4.33 [ 0.54, 34.66 ]
Goodman 2001 0.1823216 (0.22771341) 11.1 % 1.20 [ 0.77, 1.88 ]
Kabuto 1994 -0.58778664 (0.50155941) 5.9 % 0.56 [ 0.21, 1.48 ]
Knekt 1998 -0.89159813 (0.43624526) 6.9 % 0.41 [ 0.17, 0.96 ]
Nomura 1987 -0.0953102 (0.42360895) 7.1 % 0.91 [ 0.40, 2.09 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 8.4 % 1.20 [ 0.60, 2.40 ]
van den Brandt 1993a -0.91629072 (0.19941339) 11.7 % 0.40 [ 0.27, 0.59 ]
Subtotal (95% CI) 81.6 % 0.75 [ 0.54, 1.03 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 21.54, df = 10 (P = 0.02); I2 =54%
Test for overall effect: Z = 1.75 (P = 0.080)
2 Mortality
Kromhout 1987 -0.02020269 (0.44649482) 6.7 % 0.98 [ 0.41, 2.35 ]
Suadicani 2012 0.3577 (0.2033) 11.7 % 1.43 [ 0.96, 2.13 ]
Subtotal (95% CI) 18.4 % 1.34 [ 0.93, 1.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 100.0 % 0.83 [ 0.61, 1.13 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 31.39, df = 12 (P = 0.002); I2 =62%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 5.50, df = 1 (P = 0.02), I2 =82%
0.01 0.1 1 10 100
133Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 8
Lung cancer risk (gender-disaggregated data).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 8 Lung cancer risk (gender-disaggregated data)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (female + male)
Coates 1988 -0.22314354 (0.948341) 1.8 % 0.80 [ 0.12, 5.13 ]
Comstock 1997 -0.43078295 (0.26193982) 10.4 % 0.65 [ 0.39, 1.09 ]
Kabuto 1994 -0.58778664 (0.50155941) 5.0 % 0.56 [ 0.21, 1.48 ]
Knekt 1998 -0.89159813 (0.43624526) 6.0 % 0.41 [ 0.17, 0.96 ]
Subtotal (95% CI) 23.2 % 0.58 [ 0.39, 0.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0066)
2 Female
Epplein 2009 -0.02020269 (0.43266643) 6.1 % 0.98 [ 0.42, 2.29 ]
Garland 1995 1.4655675 (1.0612346) 1.4 % 4.33 [ 0.54, 34.66 ]
Goodman 2001 -0.27443686 (0.49387987) 5.1 % 0.76 [ 0.29, 2.00 ]
van den Brandt 1993a -0.91629072 (0.57533986) 4.1 % 0.40 [ 0.13, 1.24 ]
Subtotal (95% CI) 16.7 % 0.83 [ 0.43, 1.61 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 4.21, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.54 (P = 0.59)
3 Male
Epplein 2009 -0.35667496 (0.32638552) 8.5 % 0.70 [ 0.37, 1.33 ]
Goodman 2001 0.42526772 (0.31200675) 8.9 % 1.53 [ 0.83, 2.82 ]
Kromhout 1987 -0.02020269 (0.44649482) 5.9 % 0.98 [ 0.41, 2.35 ]
Nomura 1987 -0.0953102 (0.42360895) 6.3 % 0.91 [ 0.40, 2.09 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 7.8 % 1.20 [ 0.60, 2.40 ]
Suadicani 2012 0.3577 (0.2033) 12.3 % 1.43 [ 0.96, 2.13 ]
van den Brandt 1993a -0.69314718 (0.25651067) 10.5 % 0.50 [ 0.30, 0.83 ]
Subtotal (95% CI) 60.1 % 0.98 [ 0.68, 1.39 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 13.77, df = 6 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 100.0 % 0.84 [ 0.65, 1.09 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 24.55, df = 14 (P = 0.04); I2 =43%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 3.74, df = 2 (P = 0.15), I2 =47%
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Analysis 1.9. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 9
Lung cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 9 Lung cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Intake
Kromhout 1987 -0.02020269 (0.44649482) 6.7 % 0.98 [ 0.41, 2.35 ]
Subtotal (95% CI) 6.7 % 0.98 [ 0.41, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 Serum or plasma
Coates 1988 -0.22314354 (0.948341) 2.3 % 0.80 [ 0.12, 5.13 ]
Comstock 1997 -0.43078295 (0.26193982) 10.3 % 0.65 [ 0.39, 1.09 ]
Epplein 2009 -0.35667496 (0.32638552) 8.9 % 0.70 [ 0.37, 1.33 ]
Epplein 2009 -0.02020269 (0.43266643) 6.9 % 0.98 [ 0.42, 2.29 ]
Goodman 2001 0.1823216 (0.22771341) 11.1 % 1.20 [ 0.77, 1.88 ]
Kabuto 1994 -0.58778664 (0.50155941) 5.9 % 0.56 [ 0.21, 1.48 ]
Knekt 1998 -0.89159813 (0.43624526) 6.9 % 0.41 [ 0.17, 0.96 ]
Nomura 1987 -0.0953102 (0.42360895) 7.1 % 0.91 [ 0.40, 2.09 ]
Ratnasinghe 2000 0.1823216 (0.35364652) 8.4 % 1.20 [ 0.60, 2.40 ]
Suadicani 2012 0.3577 (0.2033) 11.7 % 1.43 [ 0.96, 2.13 ]
Subtotal (95% CI) 79.6 % 0.91 [ 0.70, 1.18 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 13.40, df = 9 (P = 0.15); I2 =33%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Toenail
Garland 1995 1.4655675 (1.0612346) 1.9 % 4.33 [ 0.54, 34.66 ]
van den Brandt 1993a -0.91629072 (0.19941339) 11.7 % 0.40 [ 0.27, 0.59 ]
Subtotal (95% CI) 13.7 % 1.05 [ 0.11, 10.36 ]
Heterogeneity: Tau2 = 2.25; Chi2 = 4.87, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 100.0 % 0.83 [ 0.61, 1.13 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 31.39, df = 12 (P = 0.002); I2 =62%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
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Analysis 1.10. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 10
Lung cancer risk (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 10 Lung cancer risk (ascending order of selenium levels)
Study or subgroup Lowest level Highest level log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Coates 1988 148 -0.22314354 (0.948341) 171 2.0 % 0.80 [ 0.12, 5.13 ]
Epplein 2009 128 -0.02020269 (0.43266643) 139 8.2 % 0.98 [ 0.42, 2.29 ]
Epplein 2009 128 -0.35667496 (0.32638552) 144 12.7 % 0.70 [ 0.37, 1.33 ]
Goodman 2001 106 0.1823216 (0.22771341) 129 20.1 % 1.20 [ 0.77, 1.88 ]
Kabuto 1994 99 -0.58778664 (0.50155941) 128 6.4 % 0.56 [ 0.21, 1.48 ]
Knekt 1998 45 -0.89159813 (0.43624526) 61 8.1 % 0.41 [ 0.17, 0.96 ]
Nomura 1987 103 -0.0953102 (0.42360895) 133 8.5 % 0.91 [ 0.40, 2.09 ]
Ratnasinghe 2000 (1) 39 0.1823216 (0.35364652) 55 11.3 % 1.20 [ 0.60, 2.40 ]
Suadicani 2012 48 63 0.3577 (0.2033) 22.7 % 1.43 [ 0.96, 2.13 ]
Total (95% CI) 100.0 % 0.97 [ 0.74, 1.27 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 10.79, df = 8 (P = 0.21); I2 =26%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 11
Prostate cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 11 Prostate cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Agalliu 2011 -0.2744 (0.2906) 4.3 % 0.76 [ 0.43, 1.34 ]
Allen 2008 -0.04082202 (0.15987297) 10.5 % 0.96 [ 0.70, 1.31 ]
Brooks 2001 -1.4271164 (0.61170797) 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 -0.19845095 (0.16802577) 9.8 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 0.01980261 (0.2297925) 6.3 % 1.02 [ 0.65, 1.60 ]
Grundmark 2011 -0.1863 (0.1656) 10.0 % 0.83 [ 0.60, 1.15 ]
Hartman 1998 0.23901689 (0.2921256) 4.3 % 1.27 [ 0.72, 2.25 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 2.3 % 0.38 [ 0.17, 0.85 ]
Knekt 1990 0.13976192 (0.5352475) 1.4 % 1.15 [ 0.40, 3.28 ]
Li 2004a -0.2484614 (0.1883683) 8.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 4.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 -0.17435342 (0.15537348) 10.9 % 0.84 [ 0.62, 1.14 ]
Peters 2008 -0.10536054 (0.18887756) 8.4 % 0.90 [ 0.62, 1.30 ]
Steinbrecher 2010 -0.2485 (0.2372) 6.0 % 0.78 [ 0.49, 1.24 ]
van den Brandt 1993a -0.37106368 (0.18467318) 8.7 % 0.69 [ 0.48, 0.99 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.5 % 0.39 [ 0.18, 0.84 ]
Total (95% CI) 100.0 % 0.79 [ 0.69, 0.90 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 20.73, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 12
Prostate cancer risk (by selenium measurement).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 12 Prostate cancer risk (by selenium measurement)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Biochemical selenium level
Agalliu 2011 -0.2744 (0.2906) 4.3 % 0.76 [ 0.43, 1.34 ]
Allen 2008 -0.04082202 (0.15987297) 10.5 % 0.96 [ 0.70, 1.31 ]
Brooks 2001 -1.4271164 (0.61170797) 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 -0.19845095 (0.16802577) 9.8 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 0.01980261 (0.2297925) 6.3 % 1.02 [ 0.65, 1.60 ]
Grundmark 2011 -0.1863 (0.1656) 10.0 % 0.83 [ 0.60, 1.15 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 2.3 % 0.38 [ 0.17, 0.85 ]
Knekt 1990 0.13976192 (0.5352475) 1.4 % 1.15 [ 0.40, 3.28 ]
Li 2004a -0.2484614 (0.1883683) 8.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 4.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 -0.17435342 (0.15537348) 10.9 % 0.84 [ 0.62, 1.14 ]
Steinbrecher 2010 -0.2485 (0.2372) 6.0 % 0.78 [ 0.49, 1.24 ]
van den Brandt 1993a -0.37106368 (0.18467318) 8.7 % 0.69 [ 0.48, 0.99 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.5 % 0.39 [ 0.18, 0.84 ]
Subtotal (95% CI) 87.3 % 0.76 [ 0.67, 0.88 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.62, df = 14 (P = 0.22); I2 =21%
Test for overall effect: Z = 3.89 (P = 0.00010)
2 Estimated selenium intake
Hartman 1998 0.23901689 (0.2921256) 4.3 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 8.4 % 0.90 [ 0.62, 1.30 ]
Subtotal (95% CI) 12.7 % 1.00 [ 0.73, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 100.0 % 0.79 [ 0.69, 0.90 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 20.73, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Chi2 = 2.35, df = 1 (P = 0.13), I2 =57%
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Analysis 1.13. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 13
Prostate cancer risk (by exposure assessment).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 13 Prostate cancer risk (by exposure assessment)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Intake
Hartman 1998 0.23901689 (0.2921256) 4.3 % 1.27 [ 0.72, 2.25 ]
Peters 2008 -0.10536054 (0.18887756) 8.4 % 0.90 [ 0.62, 1.30 ]
Subtotal (95% CI) 12.7 % 1.00 [ 0.73, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Serum or plasma
Agalliu 2011 -0.2744 (0.2906) 4.3 % 0.76 [ 0.43, 1.34 ]
Allen 2008 -0.04082202 (0.15987297) 10.5 % 0.96 [ 0.70, 1.31 ]
Brooks 2001 -1.4271164 (0.61170797) 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 -0.19845095 (0.16802577) 9.8 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 0.01980261 (0.2297925) 6.3 % 1.02 [ 0.65, 1.60 ]
Grundmark 2011 -0.1863 (0.1656) 10.0 % 0.83 [ 0.60, 1.15 ]
Knekt 1990 0.13976192 (0.5352475) 1.4 % 1.15 [ 0.40, 3.28 ]
Li 2004a -0.2484614 (0.1883683) 8.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 4.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 -0.17435342 (0.15537348) 10.9 % 0.84 [ 0.62, 1.14 ]
Steinbrecher 2010 -0.2485 (0.2372) 6.0 % 0.78 [ 0.49, 1.24 ]
Subtotal (95% CI) 73.7 % 0.82 [ 0.72, 0.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.44, df = 11 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
3 Toenail
Helzlsouer 2000 -0.96758404 (0.4105709) 2.3 % 0.38 [ 0.17, 0.85 ]
van den Brandt 1993a -0.37106368 (0.18467318) 8.7 % 0.69 [ 0.48, 0.99 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.5 % 0.39 [ 0.18, 0.84 ]
Subtotal (95% CI) 13.6 % 0.53 [ 0.35, 0.81 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.05; Chi2 = 2.97, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 2.91 (P = 0.0036)
Total (95% CI) 100.0 % 0.79 [ 0.69, 0.90 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 20.73, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Chi2 = 5.46, df = 2 (P = 0.07), I2 =63%
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Analysis 1.14. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 14
Prostate cancer risk (by continent).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 14 Prostate cancer risk (by continent)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Europe
Allen 2008 -0.04082202 (0.15987297) 10.5 % 0.96 [ 0.70, 1.31 ]
Grundmark 2011 -0.1863 (0.1656) 10.0 % 0.83 [ 0.60, 1.15 ]
Hartman 1998 0.23901689 (0.2921256) 4.3 % 1.27 [ 0.72, 2.25 ]
Knekt 1990 0.13976192 (0.5352475) 1.4 % 1.15 [ 0.40, 3.28 ]
Steinbrecher 2010 -0.2485 (0.2372) 6.0 % 0.78 [ 0.49, 1.24 ]
van den Brandt 1993a -0.37106368 (0.18467318) 8.7 % 0.69 [ 0.48, 0.99 ]
Subtotal (95% CI) 40.9 % 0.86 [ 0.73, 1.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.19, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.082)
2 North America
Agalliu 2011 -0.2744 (0.2906) 4.3 % 0.76 [ 0.43, 1.34 ]
Brooks 2001 -1.4271164 (0.61170797) 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Epplein 2009 -0.19845095 (0.16802577) 9.8 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 0.01980261 (0.2297925) 6.3 % 1.02 [ 0.65, 1.60 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 2.3 % 0.38 [ 0.17, 0.85 ]
Li 2004a -0.2484614 (0.1883683) 8.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 4.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 -0.17435342 (0.15537348) 10.9 % 0.84 [ 0.62, 1.14 ]
Peters 2008 -0.10536054 (0.18887756) 8.4 % 0.90 [ 0.62, 1.30 ]
Yoshizawa 1998 -0.94160858 (0.39297066) 2.5 % 0.39 [ 0.18, 0.84 ]
Subtotal (95% CI) 59.1 % 0.73 [ 0.60, 0.88 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 15.29, df = 10 (P = 0.12); I2 =35%
Test for overall effect: Z = 3.32 (P = 0.00090)
Total (95% CI) 100.0 % 0.79 [ 0.69, 0.90 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 20.73, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Chi2 = 1.81, df = 1 (P = 0.18), I2 =45%
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Analysis 1.15. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 15
Prostate cancer risk (by country).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 15 Prostate cancer risk (by country)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Several European countries
Allen 2008 -0.04082202 (0.15987297) 10.5 % 0.96 [ 0.70, 1.31 ]
Grundmark 2011 -0.1863 (0.1656) 10.0 % 0.83 [ 0.60, 1.15 ]
Steinbrecher 2010 -0.2485 (0.2372) 6.0 % 0.78 [ 0.49, 1.24 ]
Subtotal (95% CI) 26.5 % 0.87 [ 0.71, 1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.19)
2 Finland
Hartman 1998 0.23901689 (0.2921256) 4.3 % 1.27 [ 0.72, 2.25 ]
Knekt 1990 0.13976192 (0.5352475) 1.4 % 1.15 [ 0.40, 3.28 ]
Subtotal (95% CI) 5.7 % 1.24 [ 0.75, 2.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
3 The Netherlands
van den Brandt 1993a -0.37106368 (0.18467318) 8.7 % 0.69 [ 0.48, 0.99 ]
Subtotal (95% CI) 8.7 % 0.69 [ 0.48, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
4 US
Agalliu 2011 -0.2744 (0.2906) 4.3 % 0.76 [ 0.43, 1.34 ]
Brooks 2001 -1.4271164 (0.61170797) 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 -0.19845095 (0.16802577) 9.8 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 0.01980261 (0.2297925) 6.3 % 1.02 [ 0.65, 1.60 ]
Helzlsouer 2000 -0.96758404 (0.4105709) 2.3 % 0.38 [ 0.17, 0.85 ]
Li 2004a -0.2484614 (0.1883683) 8.4 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 -0.69314718 (0.28025822) 4.6 % 0.50 [ 0.29, 0.87 ]
Peters 2007 -0.17435342 (0.15537348) 10.9 % 0.84 [ 0.62, 1.14 ]
Peters 2008 -0.10536054 (0.18887756) 8.4 % 0.90 [ 0.62, 1.30 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Yoshizawa 1998 -0.94160858 (0.39297066) 2.5 % 0.39 [ 0.18, 0.84 ]
Subtotal (95% CI) 59.1 % 0.73 [ 0.60, 0.88 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 15.29, df = 10 (P = 0.12); I2 =35%
Test for overall effect: Z = 3.32 (P = 0.00090)
Total (95% CI) 100.0 % 0.79 [ 0.69, 0.90 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 20.73, df = 16 (P = 0.19); I2 =23%
Test for overall effect: Z = 3.58 (P = 0.00035)
Test for subgroup differences: Chi2 = 5.29, df = 3 (P = 0.15), I2 =43%
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Analysis 1.16. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 16
Prostate cancer risk (ascending order of selenium levels).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 16 Prostate cancer risk (ascending order of selenium levels)
Study or subgroup
Upper bor-
der/lowest
level
Lower bor-
der/highest
leve log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Agalliu 2011 467 17 -0.2744 (0.2906) 4.8 % 0.76 [ 0.43, 1.34 ]
Allen 2008 62 -0.04082202 (0.15987297) 84 15.7 % 0.96 [ 0.70, 1.31 ]
Brooks 2001 107 -1.4271164 (0.61170797) 133 1.1 % 0.24 [ 0.07, 0.80 ]
Coates 1988 148 171 -1.2039728 (1.118034) 0.3 % 0.30 [ 0.03, 2.68 ]
Epplein 2009 127 -0.19845095 (0.16802577) 159 14.2 % 0.82 [ 0.59, 1.14 ]
Goodman 2001 101 0.01980261 (0.2297925) 126 7.6 % 1.02 [ 0.65, 1.60 ]
Grundmark 2011 84 59 -0.1863 (0.1656) 14.7 % 0.83 [ 0.60, 1.15 ]
Knekt 1990 (1) 49 0.13976192 (0.5352475) 78 1.4 % 1.15 [ 0.40, 3.28 ]
Li 2004a 92 -0.2484614 (0.1883683) 124 11.3 % 0.78 [ 0.54, 1.13 ]
Nomura 2000 119 -0.69314718 (0.28025822) 147 5.1 % 0.50 [ 0.29, 0.87 ]
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Study or subgroup
Upper bor-
der/lowest
level
Lower bor-
der/highest
leve log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Peters 2007 127 -0.17435342 (0.15537348) 158 16.6 % 0.84 [ 0.62, 1.14 ]
Steinbrecher 2010 116 127 -0.2485 (0.2372) 7.1 % 0.78 [ 0.49, 1.24 ]
Total (95% CI) 100.0 % 0.82 [ 0.72, 0.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.44, df = 11 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
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(1) Study results in ascending order of serum/plasma selenium exposure (in g/l), when reported
Analysis 1.17. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 17
Stomach cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 17 Stomach cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Stomach
Kabuto 1994 0 (0.3405615) 18.2 % 1.00 [ 0.51, 1.95 ]
Knekt 1990 -2.4079456 (1.0652725) 3.7 % 0.09 [ 0.01, 0.73 ]
Knekt 1990 -1.3093333 (0.88197684) 5.1 % 0.27 [ 0.05, 1.52 ]
Nomura 1987 0.10536052 (0.60607205) 9.3 % 1.11 [ 0.34, 3.64 ]
van den Brandt 1993a -0.4462871 (0.3437958) 18.1 % 0.64 [ 0.33, 1.26 ]
Subtotal (95% CI) 54.4 % 0.65 [ 0.35, 1.19 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 6.61, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Stomach: cardia cancer
Wei 2004 -0.75502258 (0.1729285) 27.3 % 0.47 [ 0.33, 0.66 ]
Subtotal (95% CI) 27.3 % 0.47 [ 0.33, 0.66 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000013)
3 Stomach: non-cardia cancer
Wei 2004 0.06765865 (0.33933798) 18.3 % 1.07 [ 0.55, 2.08 ]
Subtotal (95% CI) 18.3 % 1.07 [ 0.55, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 100.0 % 0.66 [ 0.43, 1.01 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 12.20, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Chi2 = 4.86, df = 2 (P = 0.09), I2 =59%
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Analysis 1.18. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 18
Stomach cancer risk (by gender).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 18 Stomach cancer risk (by gender)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (female + male)
Kabuto 1994 0 (0.3405615) 17.4 % 1.00 [ 0.51, 1.95 ]
Wei 2004 -0.75502258 (0.1729285) 24.0 % 0.47 [ 0.33, 0.66 ]
Wei 2004 0.06765865 (0.33933798) 17.4 % 1.07 [ 0.55, 2.08 ]
Subtotal (95% CI) 58.9 % 0.75 [ 0.41, 1.36 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 7.12, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Female
Knekt 1990 -1.3093333 (0.88197684) 5.6 % 0.27 [ 0.05, 1.52 ]
van den Brandt 1993a 0.51879379 (0.69436409) 8.0 % 1.68 [ 0.43, 6.55 ]
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Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 13.6 % 0.73 [ 0.12, 4.35 ]
Heterogeneity: Tau2 = 1.04; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Male
Knekt 1990 -2.4079456 (1.0652725) 4.1 % 0.09 [ 0.01, 0.73 ]
Nomura 1987 0.10536052 (0.60607205) 9.6 % 1.11 [ 0.34, 3.64 ]
van den Brandt 1993a -0.91629073 (0.44161603) 13.9 % 0.40 [ 0.17, 0.95 ]
Subtotal (95% CI) 27.6 % 0.43 [ 0.14, 1.32 ]
Heterogeneity: Tau2 = 0.53; Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 100.0 % 0.66 [ 0.42, 1.04 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 15.22, df = 7 (P = 0.03); I2 =54%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.19. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 19
Colorectal cancer risk.
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 19 Colorectal cancer risk
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Colon and rectal cancer
Garland 1995 0.71294979 (0.43009643) 13.6 % 2.04 [ 0.88, 4.74 ]
Knekt 1990 -0.63487833 (0.7845604) 4.2 % 0.53 [ 0.11, 2.47 ]
Knekt 1990 -0.22314354 (0.52904067) 9.1 % 0.80 [ 0.28, 2.26 ]
Subtotal (95% CI) 26.8 % 1.11 [ 0.50, 2.46 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 3.19, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Colon cancer
Menkes 1986 0.19845095 (0.43422125) 13.3 % 1.22 [ 0.52, 2.86 ]
Nomura 1987 -0.58778664 (0.42140211) 14.1 % 0.56 [ 0.24, 1.27 ]
van den Brandt 1993a -0.19845095 (0.3319885) 22.2 % 0.82 [ 0.43, 1.57 ]
van den Brandt 1993a -0.26136479 (0.32223513) 23.5 % 0.77 [ 0.41, 1.45 ]
Subtotal (95% CI) 73.2 % 0.80 [ 0.56, 1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Total (95% CI) 100.0 % 0.89 [ 0.65, 1.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
147Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.20. Comparison 1 Observational studies: highest versus lowest selenium exposure, Outcome 20
Colorectal cancer risk (by gender).
Review: Selenium for preventing cancer
Comparison: 1 Observational studies: highest versus lowest selenium exposure
Outcome: 20 Colorectal cancer risk (by gender)
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 All (female + male)
Menkes 1986 0.19845095 (0.43422125) 13.3 % 1.22 [ 0.52, 2.86 ]
Subtotal (95% CI) 13.3 % 1.22 [ 0.52, 2.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 Female
Garland 1995 0.71294979 (0.43009643) 13.6 % 2.04 [ 0.88, 4.74 ]
Knekt 1990 -0.22314354 (0.52904067) 9.1 % 0.80 [ 0.28, 2.26 ]
van den Brandt 1993a -0.26136479 (0.32223513) 23.5 % 0.77 [ 0.41, 1.45 ]
Subtotal (95% CI) 46.2 % 1.06 [ 0.57, 2.00 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 3.57, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.19 (P = 0.85)
3 Male
Knekt 1990 -0.63487833 (0.7845604) 4.2 % 0.53 [ 0.11, 2.47 ]
Nomura 1987 -0.58778664 (0.42140211) 14.1 % 0.56 [ 0.24, 1.27 ]
van den Brandt 1993a -0.19845095 (0.3319885) 22.2 % 0.82 [ 0.43, 1.57 ]
Subtotal (95% CI) 40.5 % 0.69 [ 0.42, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 100.0 % 0.89 [ 0.65, 1.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.24, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 1.91, df = 2 (P = 0.39), I2 =0.0%
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Analysis 2.1. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 1 Any cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 1 Any cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
NPCT 2002 (1) 105/621 137/629 41.7 % 0.78 [ 0.62, 0.98 ]
SELECT 2009 (2) 837/8752 824/8696 58.3 % 1.01 [ 0.92, 1.11 ]
Total (95% CI) 9373 9325 100.0 % 0.90 [ 0.70, 1.17 ]
Total events: 942 (Experimental), 961 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.36, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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(1) We used the data from Duffield 2002
(2) We used the data from Lippman 2009
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Analysis 2.2. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 2 Cancer mortality.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 2 Cancer mortality
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
NPCT 2002 (1) 40/621 66/629 45.8 % 0.61 [ 0.42, 0.89 ]
SELECT 2009 (2) 128/8752 125/8696 54.2 % 1.02 [ 0.80, 1.30 ]
Total (95% CI) 9373 9325 100.0 % 0.81 [ 0.49, 1.32 ]
Total events: 168 (Experimental), 191 (Control)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.86, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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(1) We used the data from Duffield 2002
(2) We used the data from Lippman 2009
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Analysis 2.3. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 3 Liver cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 3 Liver cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Li 2000 34/1112 57/953 71.6 % 0.51 [ 0.34, 0.77 ]
Yu 1991 10/1444 13/1030 18.4 % 0.55 [ 0.24, 1.25 ]
Yu 1997 4/113 11/113 10.0 % 0.36 [ 0.12, 1.11 ]
Total (95% CI) 2669 2096 100.0 % 0.50 [ 0.35, 0.71 ]
Total events: 48 (Experimental), 81 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.85 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 4 Non-melanoma skin cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 4 Non-melanoma skin cancer risk
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Algotar 2013 0.9722 (0.6706) 9.0 % 2.64 [ 0.71, 9.84 ]
Dreno 2007 1.1204 (0.8031) 6.4 % 3.07 [ 0.64, 14.80 ]
NPCT 2002 0.239 (0.0687) 84.6 % 1.27 [ 1.11, 1.45 ]
Total (95% CI) 100.0 % 1.44 [ 0.95, 2.17 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.36, df = 2 (P = 0.31); I2 =15%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 2.5. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 5 Prostate cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 5 Prostate cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Algotar 2013 24/234 26/232 14.4 % 0.92 [ 0.54, 1.55 ]
Marshall 2011 48/135 49/134 26.3 % 0.97 [ 0.71, 1.34 ]
NPCT 2002 (1) 22/457 42/470 15.4 % 0.54 [ 0.33, 0.89 ]
SELECT 2009 (2) 432/8752 416/8696 43.9 % 1.03 [ 0.90, 1.18 ]
Total (95% CI) 9578 9532 100.0 % 0.90 [ 0.71, 1.14 ]
Total events: 526 (Experimental), 533 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 6.17, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) We used the data from Duffield 2002
(2) We used the data from Lippman 2009
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Analysis 2.6. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 6 Prostate cancer risk for studies with low RoB.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 6 Prostate cancer risk for studies with low RoB
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Algotar 2013 24/234 26/232 5.1 % 0.92 [ 0.54, 1.55 ]
Marshall 2011 48/135 49/134 13.8 % 0.97 [ 0.71, 1.34 ]
SELECT 2009 (1) 432/8752 416/8696 81.1 % 1.03 [ 0.90, 1.18 ]
Total (95% CI) 9121 9062 100.0 % 1.02 [ 0.90, 1.14 ]
Total events: 504 (Experimental), 491 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) We used the data from Lippman 2009
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Analysis 2.7. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 7 Lung cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 7 Lung cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
NPCT 2002 (1) 25/621 35/629 39.9 % 0.72 [ 0.44, 1.19 ]
SELECT 2009 (2) 75/8752 67/8696 60.1 % 1.11 [ 0.80, 1.54 ]
Total (95% CI) 9373 9325 100.0 % 0.94 [ 0.62, 1.42 ]
Total events: 100 (Experimental), 102 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.98, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) We used the data from Duffield 2002
(2) We used the data from Lippman 2009
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Analysis 2.8. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 8 Bladder cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 8 Bladder cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
NPCT 2002 (1) 10/621 8/629 13.7 % 1.27 [ 0.50, 3.19 ]
SELECT 2009 (2) 60/8752 53/8696 86.3 % 1.12 [ 0.78, 1.63 ]
Total (95% CI) 9373 9325 100.0 % 1.14 [ 0.81, 1.61 ]
Total events: 70 (Experimental), 61 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) We used the data from Duffield 2002
(2) We used the data from Lotan 2012
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Analysis 2.9. Comparison 2 Randomised controlled trials: highest versus lowest selenium exposure,
Outcome 9 Colorectal cancer risk.
Review: Selenium for preventing cancer
Comparison: 2 Randomised controlled trials: highest versus lowest selenium exposure
Outcome: 9 Colorectal cancer risk
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
NPCT 2002 (1) 9/621 19/629 39.4 % 0.48 [ 0.22, 1.05 ]
SELECT 2009 (2) 63/8752 60/8696 60.6 % 1.04 [ 0.73, 1.48 ]
Total (95% CI) 9373 9325 100.0 % 0.77 [ 0.37, 1.62 ]
Total events: 72 (Experimental), 79 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
(1) We used the data from Duffield 2002
(2) We used the data from Lippman 2009
A D D I T I O N A L T A B L E S
Table 1. Included observational studies by outcome
Organ sys-
tem
Outcome Num-
ber of stud-
ies/case def-
initions
Meta-
analysis
Countries Num-
ber of par-
ticipants
Number of
cases
Selenium
assessment
Reporting
study
Any cancer Any cancer total: 16
incidence: 8
mortality: 6
incidence
and mortal-
ity
combined: 1
√
yes US
Finland
Netherlands
Sweden
Norway
Belgium
France
Japan
total: ~ 152,
000
total: 3010
male: 1700
female: 736
serum: 12
plasma: 2
serum +
plasma: 1
plasma sele-
nium P: 1
Knekt 1990
Coates 1988
Kok 1987a
Salonen
1984
Nomura
1987
Virtamo
1987
Willett
1983
Fex 1987
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Table 1. Included observational studies by outcome (Continued)
Ringstad
1988
Persson
2000
Salonen
1985
Peleg 1985
Kornitzer
2004
Akbaraly
2005
Bleys 2008
Fujishima
2011
Gynaeco-
logical can-
cer
Fe-
male breast
cancer
total: 7
incidence: 7
incidence
and mortal-
ity
combined: 0
√
yes US
Finland
Netherlands
Channel Is-
lands
total/fe-
male: > 155,
000
(one study
did not re-
port cohort
size)
total/fe-
male: 1078
serum: 2
plasma: 1
serum +
plasma: 1
toenail: 3
Dorgan
1998
van
den Brandt
1993a
Coates 1988
Overvad
1991
Knekt 1990
Garland
1995
van Noord
1987
Cervical
cancer
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US to-
tal/female: >
15,161
(one study
did not re-
port cohort
size)
total/
female: 62
serum: 2 Menkes
1986
Coates 1988
Uterine can-
cer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US total/
female: 62,
641
total/
female: 91
toenail: 1 Garland
1995
Ovarian
cancer
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
× no US
Finland
total/fe-
male: ~ 214,
000
total/
female: 568
serum: 2
toenail: 1
supplemen-
tal intake: 1
Knekt 1990
Garland
1995
Menkes
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Table 1. Included observational studies by outcome (Continued)
ity
combined: 0
1986
Thomson
2008
Gynaeco-
logical can-
cer (without
breast can-
cer)
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Finland to-
tal/female: ~
18,000
total/
female: 86
serum: 1 Knekt 1990
Urological
cancers
Uri-
nary bladder
cancer
total: 6
incidence: 6
mortality: 0
incidence &
mortality
combined: 0
√
yes US/Hawaii
Finland
Netherlands
total: 356,
150
female: 130,
786
male: 128,
009
total: 1295
female: 175
male 755
serum: 3
toenail: 3
Menkes
1986
Nomura
1987
Michaud
2002
van
den Brandt
1993a
Michaud
2005
Hotaling
2011
Urinary
tract cancer
total: 2
incidence: 2
mortality: 0
incidence &
mortality
combined: 0
× no Netherlands
Finland
total: 48,
000
total: 104
male: 91
female: 13
serum: 1
plasma: 1
Knekt 1990
Persson
2000
Respi-
ratory tract
cancers
Lung cancer total: 14
incidence:
12
mortality: 2
incidence
and mortal-
ity
combined: 0
√
yes China
Japan
US
Finland
Netherlands
Denmark
total: ~ 336,
000
male: 125,
341
female: 181,
895
total: 2002
male: 1256
female: 333
serum: 9
serum +
plasma: 2
toenail: 2
dietary
intake: 1
(one study
re-
ported both
serum levels
and food in-
take)
Knekt 1990
Knekt 1998
Garland
1995
Coates 1988
Nomura
1987
van
den Brandt
1993a
Kabuto
1994
Menkes
1986
Goodman
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Table 1. Included observational studies by outcome (Continued)
2001
Comstock
1997
Kromhout
1987
Ratnasinghe
2000
Epplein
2009
Suadicani
2012
Oral/pha-
ryngeal can-
cer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US total: 25,
804
total: 28 serum: 1 Menkes
1986
Any cancer
of the respi-
ratory tract
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Sweden total/male: ~
9500
total/male:
69
plasma sele-
nium P: 1
Persson
2000
Andrologi-
cal cancers
Prostate
cancer
total: 17
incidence:
17
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes US
Europe
total/male: >
421,000
(one study
did not re-
port cohort
size)
total/male:
6366
serum: 8
plasma: 3
toenail: 3
dietary
intake: 3
Hartman
1998
Helzlsouer
2000
Coates 1988
Brooks
2001
van
den Brandt
1993a
Nomura
2000
Goodman
2001
Yoshizawa
1998
Li 2004a
Peters 2007
Peters 2008
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Table 1. Included observational studies by outcome (Continued)
Allen 2008
Epplein
2009
Gastroin-
testinal
cancers
Oe-
sophageal
cancer
total: 2
incidence: 2
mortality: 1
incidence
and mortal-
ity
combined: 0
× no China
US
total: 29,
923
total: > 959 serum: 1
supplemen-
tal intake: 1
Wei 2004
Dong 2008
Oe-
sophageal
squamous
cell
carcinoma
total:1
incidence: 1
mortality:0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 120,
852
total: 64 toenail: 1 Steinbrecher
2010
Oe-
sophageal
adenocarci-
noma
total:1
incidence:1
mortality:0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 120,
852
total: 112 toenail: 1 Steinbrecher
2010
Oe-
sophageal/
stomach
cancer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 36,
265
total: 86
male: 51
female: 35
serum: 1 Knekt 1998
Gastric car-
dia adeno-
carcinoma
total:1
incidence:1
mortality:0
incidence
and mortal-
ity
combined: 0
× no Netherlands total: 120,
852
total:114 toenail: 1 Steinbrecher
2010
Stomach
cancer
total: 5
incidence: 5
mortality: 1
incidence
and mortal-
ity
√
yes China
Japan
US/Hawaii
Finland
Netherlands
total: ~ 197,
000
male: 86,
311
female: 80,
669
total: 955
male: 626
female: 329
serum: 4
toenail: 1
Knekt 1990
van
den Brandt
1993a
Nomura
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Table 1. Included observational studies by outcome (Continued)
combined: 0 1987
Kabuto
1994
Wei 2004
Primary
liver cancer
total: 2
incidence: 1
mortality: 1
incidence
and mortal-
ity
combined: 0
× no Taiwan total: 46,
404
total: 235
male: 223
female: 12
plasma: 1
toenail: 1
Yu 1999
Sakoda
2005
Pancreatic
cancer
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US
Finland
total: 65,
072
total: 67
male: 31
female: 36
serum: 2 Menkes
1986
Knekt
1990).
Colon/col-
orectal can-
cer
total:
colon 2, col-
orectum 3
incidence: 5
mortality: 0
incidence
and mortal-
ity
combined: 0
√
yes US
Netherlands
Finland
total: 255,
425
male: 86,
311
female: 143,
310
total: 617
male: 285
female: 332
serum: 3
toenail: 2
van
den Brandt
1993a
Nomura
1987
Menkes
1986
Garland
1995
Knekt 1990
Rectal can-
cer
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US/Hawaii
Netherlands
total: 127,
712
total: 145
male: 109
female: 36
serum: 1
toenail: 1
van
den Brandt
1993a
Nomura
1987
All gastroin-
testinal can-
cers
total: 2
incidence: 2
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US
Sweden
total: > 9500
(one study
did not re-
port cohort
size)
total: 143 plasma +
serum: 1
plasma sele-
nium P: 1
Coates 1988
Persson
2000
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Table 1. Included observational studies by outcome (Continued)
Skin cancer Melanoma total: 3
incidence: 3
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US total: ~ 158,
000
total: 547 serum: 1
toenail: 1
supplemen-
tal intake: 1
Garland
1995
Menkes
1986 Peters
2008
Basal cell
carcinoma
total: 3
incidence: 3
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Australia
US
Finland
total: > 66,
000
total: 292 serum: 3
dietary
intake: 1
Knekt 1990
Menkes
1986
Mc-
Naughton
2005
Squamous
cell
carcinoma
total: 4
incidence: 4
mortality: 0
incidence
and mortal-
ity
combined: 0
× no Australia
US
total: ~ 30,
000
total: 488 serum: 2
plasma: 1
dietary
intake: 1
Combs
1993
Karagas
1997
Menkes
1986
Mc-
Naughton
2005
Total non-
melanoma
skin cancer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US total: 117 total: 19 plasma: 1 Clark 1985
Rare and
other can-
cers
Haemato-
logical can-
cers
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
combined: 0
× no US total: ~ 6200 total: 12 serum +
plasma: 12
Coates 1988
Thyroid
cancer
total: 1
incidence: 1
mortality: 0
incidence
and mortal-
ity
× no Norway total: 100,
000
total: 43
male: 12
female: 31
serum: 1 Glattre
1989
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Table 1. Included observational studies by outcome (Continued)
combined: 0
Other can-
cers
total: 5
incidence:4
mortality:1
incidence
and mortal-
ity
combined: 0
× no China
US
Finland
Sweden
total: 573
male: 230
female: 285
Garland
1995
Coates 1988
Knekt 1990
Wei 2004
Persson
2000
Some studies did not report the gender of participants or cancer cases; consequently, figures for women and men do not always sum
up to the total number of participants or cancer cases.
Table 2. Risk of bias: observational studies
Study Publica-
tion
Newcastle Ottawa Scale (cohort) Newcastle Ottawa Scale (case-control)
Selection Compara-
bility
Outcome Total Selection Compara-
bility
Exposure Total
Kabuto
1994
Kabuto
1994
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Ratnas-
inghe
2000
Ratnas-
inghe
2000
1-1-1-1 2 1-0-0 7 0-0-1-1 2 1-1-1 7
Sakoda
2005
Sakoda
2005
0-1-1-0 1 1-1-0 5 1-1-1-1 1 1-1-1 8
Wei 2004 Wei 2004 1-1-1-1 1 1-1-1 8 .-.-.-. . .-.-. .
Mark 2000 1-1-1-1 1 1-1-1 8 .-.-.-. . .-.-. .
Yu 1999 Yu 1999 0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Mc-
Naughton
2005
Mc-
Naughton
2005
1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Heinen
2007
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van der
Pols 2009
1-1-1-1 2 1-1-0 8 .-.-.-. . .-.-. .
Akbaraly
2005
Akbaraly
2005
0-1-1-1 2 0-1-0 6 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Allen 2008 Allen 2008 1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
Fex 1987 Fex 1987 1-1-1-0 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Glattre
1989
Glattre
1989
0-1-1-0 1 1-1-1 6 1-1-1-1 1 1-1-1 8
Hartman
1998
Hartman
1998
1-1-0-1 2 1-1-0 7 .-.-.-. . .-.-. .
Knekt
1990
Knekt
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Hakama
1990
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1988
1-1-1-1 2 1-1-1 9 0-0-1-1 2 1-1-1 7
Knekt
1996
1-1-1-1 1 1-1-1 8 0-1-1-1 1 1-1-1 7
Knekt
1991
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Knekt
1998
Knekt
1998
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Kok 1987a Kok1987b 1-1-1-1 2 1-1-1 9 1-0-1-1 2 1-1-1 8
Kok 1987a .-.-.-. . .-.-. . .-.-.-. . .-.-. .
Kornitzer
2004
Kornitzer
2004
1-1-1-0 1 1-1-1 7 1-1-1-1 1 1-1-1 8
Kromhout
1987
Kromhout
1987
1-1-1-0 2 1-1-1 8 .-.-.-. . .-.-. .
Michaud
2002
Michaud
2002
1-1-1-1 2 1-1-0 8 0-1-1-1 2 1-1-1 8
Overvad
1991
Overvad
1991
1-1-1-0 1 1-1-0 6 .-.-.-. . .-.-. .
Persson
2000
Persson-
Moschos
2000
1-1-1-0 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Ringstad
1988
Ringstad
1988
1-1-1-1 2 1-1-0 8 1-1-1-1 2 1-1-1 9
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Table 2. Risk of bias: observational studies (Continued)
Salonen
1984
Salonen
1984
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-1-1 8
Salonen
1985
Salonen
1985
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
van Noord
1987
van Noord
1987
1-1-1-0 1 1-0-1 6 1-1-1-0 1 1-1-1 7
van
den Brandt
1993a
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
1994
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
1993
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
van
den Brandt
2003
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Zeegers
2002
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Steevens
2010
1-1-1-1 2 1-1-1 9 0-1-1-1 2 1-0 6
Virtamo
1987
Virtamo
1987
0-1-1-1 2 1-1-1 8 .-.-.-. . .-.-. .
Bleys 2008 Bleys 2008 1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Brooks
2001
Brooks
2001
0-1-1-0 2 1-0-0 5 1-0-1-1 2 1-1-0 7
Clark
1985
Clark
1985
0-1-1-0 0 0-0-0 2 .-.-.-. . .-.-. .
Coates
1988
Coates
1988
0-1-1-0 1 1-1-0 5 1-0-1-0 1 1-1-1 6
Coates
1987
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Combs
1993
Combs Jr
1993
0-1-1-0 2 1-0-0 5 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Comstock
1997
Comstock
1997
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Dong
2008
Dong
2008
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Dorgan
1998
Dorgan
1998
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
Epplein
2009
Epplein
2009
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Gill 2009 0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Garland
1995
Garland
1995
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Hunter
1990
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Goodman
2001
Goodman
2001
0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
Helzlsouer
2000
Helzlsouer
2000
0-1-1-1 1 1-1-0 6 1-1-1-1 1 1-1-1 8
Karagas
1997
Karagas
1997
0-1-1-1 2 1-1-1 8 1-1-1-1 2 1-1-1 9
Li 2004a Li 2004 0-1-1-1 2 0-1-1 7 1-1-1-1 2 1-1-1 9
Menkes
1986
Menkes
1986
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Batieha
1993
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Breslow
1995
0-1-1-1 2 1-1-0 7 1-0-1-1 2 1-1-1 8
Burney
1989
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1996
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Helzlsouer
1989
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Ko 1994 0-1-1-0 2 1-1-0 6 1-1-1-1 2 1-1-1 9
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Table 2. Risk of bias: observational studies (Continued)
Menkes
1986
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Schober
1987
0-1-1-1 1 1-1-0 6 0-1-1-1 1 1-1-1 7
Schober
1986
.-.-.-. . .-.-. . .-.-.-. . .-.-. .
Zheng
1993
0-1-1-1 2 1-1-0 7 0-1-1-1 2 1-1-1 8
Michaud
2005
Michaud
2005
0-1-1-1 2 0-1-0 6 1-1-1-1 2 1-1-1 9
Nomura
1987
Nomura
1987
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Nomura
2000
Nomura
2000
1-1-1-1 2 1-1-1 9 1-1-1-1 2 1-1-1 9
Peleg 1985 Peleg 1985 1-1-1-1 1 1-1-0 7 1-1-1-1 1 1-1-1 8
Peters
2007
Peters
2007
0-1-1-1 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Peters
2008
Peters
2008
0-1-1-1 1 1-1-1 7 .-.-.-. . .-.-. .
Asgari
2009
0-1-1-1 1 1-1-0 6 .-.-.-. . .-.-. .
Hotaling
2011
0-1-0-1 0 1-1-1 5 .-.-.-. . .-.-. .
Walter
2011
0-1-0-1 2 1-1-1 7 .-.-.-. . .-.-. .
Thomson
2008
Thomson
2008
0-1-1-1 2 0-1-0 6 .-.-.-. . .-.-. .
Willett
1983
Willett
1983
1-1-1-0 2 1-1-0 7 1-1-1-1 2 1-1-1 9
Yoshizawa
1998
Yoshizawa
1998
0-1-1-1 2 1-1-1 8 1-0-1-1 2 1-1-1 8
Fujishima
2011
Fujishima
2011
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
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Table 2. Risk of bias: observational studies (Continued)
Grund-
mark
2011
Grund-
mark
2011
1-1-1-1 2 1-1-1 9 .-.-.-. . .-.-. .
Bates 2011 Bates 2011 1-1-1-1 1 1-1-1 8 .-.-.-. . .-.-. .
Suadicani
2012
Suadicani
2012
0-1-1-1 2 1-1-1 8 .-.-.-. . .-.-. .
Agalliu
2011
Agalliu
2011
0-1-0-1 1 1-1-0 5 0-1-0-1 1 1-1-0 5
Stein-
brecher
2010
Stein-
brecher
2010
1-1-1-1 2 0-1-0 7 1-1-1-1 2 0-1-1 8
Table 3. Risk of bias: randomised controlled trials
Study Sequence
generation
Allocation conceal-
ment
Blinding Completeness of
outcome data
Risk of bias
NPCT 2002 adequate adequate unclear adequate unclear
Li 2000 unclear unclear adequate adequate unclear
Yu 1997 unclear unclear adequate unclear unclear
Yu 1991 unclear unclear adequate unclear unclear
SELECT 2009 adequate adequate adequate adequate low
Algotar 2013 adequate adequate adequate adequate low
Marshall 2011 adequate adequate adequate adequate low
Dreno 2007 adequate adequate unclear adequate unclear
The final results of the NPCT study, encompassing the whole period of follow-up (blinded and with active selenium administration),
were reported in the three Duffield-Lillico et al. papers published in 2002, 2003 and 2003, and a preliminary report of that trial
based on a shorter period of follow-up was published by Clark et al. in 1996.
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Table 4. Results of observational studies not included in meta-analysis
Organ system Cancer Case
definition
Rel-
ative risk es-
timate (high-
est vs lowest
exposure cat-
egory)
95% CI Selenium
marker
Gender Study
Gynaecologi-
cal
Cervix incidence 0.89 0.40 to 2.00 serum women Menkes 1986
(Batieha 1993)
1.10 n.r. serum Coates 1988
Gynaeco-
logical (with-
out breast)
incidence 0.96 n.r. serum Knekt 1990
Ovary incidence 0.87 0.25 to 5.26 serum Knekt 1990 (Knekt
1996)
1.22 0.44 to 3.38 toenail Garland 1995
0.58 0.2 to 1.7 serum Menkes 1986 (Hel-
zlsour 1996)
1.00 (HR) 0.73 to 1.37 suppl. intake Thomson 2008
Uterus incidence 1.38 0.62 to 3.08 toenail Garland 1995
Gastroin-
testinal
Gastrointesti-
nal tract (all)
incidence 1.00 n.r. serum/plasma both Coates 1988
0.29 0.10 to 0.91 plasma men Persson 2000
Oesophageal
squamous cell
carcinoma
incidence 0.37 0.16 to 0.86 toenail both Steevens 2010
Oe-
sophageal ade-
nocarcinoma
incidence 0.76 0.41 to 1.40 toenail both Steevens 2010
Oesophagus incidence 0.56 0.44 to 0.71 serum both Wei 2004 (Mark
2000)
mortality 0.62 0.44 to 0.89 serum
mortality 0.35 0.16 to 0.81 serum both Wei 2004 (Wei
2004)
incidence 0.27 0.03 to 2.21 suppl. intake both Dong 2008
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Table 4. Results of observational studies not included in meta-analysis (Continued)
Gastric cardio
adenocarci-
noma
incidence 0.52 0.27 to 1.02 toenail both Steevens 2010
Oesophagus
and stomach
incidence 0.45 n.r. serum men Knekt 1990 (Knekt
1988)
incidence 0.67 n.r. serum women
Liver incidence 0.62 0.21 to 1.86 plasma men Yu 1999
incidence 0.50 0.28 to 0.90 toenail both Sakoda 2005
mortality 0.50 0.28 to 0.90 both
0.57 0.31 to 1.05 men
0.18 0.03 to 1.13 women
Pancreas incidence 0.08 0.01 to 0.56) serum men Menkes 1986 (Bur-
ney 1989)
0.83 0.4 to 1.67 women
0.58 n.r. serum men Knekt 1990
3.49 n.r. women
Rectum incidence 0.625 n.r. serum men Nomura 19871 05 0 54 to 2.03 toenail both van den Brandt
1993a
0.91 0.41 to 2.00 men
1.58 0.59 to 4.22 women
Urinary tract Urinary tract
(all)
incidence 0.97 0.72 to 1.31 serum both Hotaling 2011
5.0 0.71 to plasma men Persson 2000
0.81 n.r. serum men Knekt 1990
4.12 n.r. women
Respiratory
tract
Cavum oris/
pharynx
incidence 5.43 n.r. serum both Menkes 1986
(Zheng 1993)
Respiratory
tract (all)
incidence 6.0 1.5 to 24.2 plasma men Persson 2000
Skin Melanoma incidence 1.66 0.71 to 3.85 toenail women Garland 1995
0.90 0.30 to 2.50 serum both Menkes 1986 (Bres-
low 1995)
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Table 4. Results of observational studies not included in meta-analysis (Continued)
0.98 0.69 to 1.41 suppl. intake both Peters 2008 (Asgari
2009)
Any non-
melanoma
cancer
incidence 0.77 n.r. plasma both Clark 1985
Basal cell car-
cinoma
incidence 0.54 n.r. serum men Knekt 1990
1.55 n.r. women
0.80 0.10 to 4.5 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.38 to 1.96 serum both McNaughton 2005
0.95 0.59 to 1.50 nutritional in-
take
Squamous cell
carcinoma
incidence 0.69 0.51 to 0.92 plasma both Combs 1993
0.60 0.20 to 1.50 serum both Menkes 1986 (Bres-
low 1995)
0.86 0.47 to 1.58 plasma both Karagas 1997
1.30 0.77 to 2.3 nutritional in-
take
both McNaughton 2005
0.49 0.24 to 0.99 serum
Other Haematologi-
cal
incidence 0.60 n.r. serum/plasma both Coates 1988
incidence 0.95 0.75 to 1.20 suppl. intake both Walter 2011
Thyroid incidence 0.15 0.0 to 5.0 serum men Glattre 1989
0.12 0.01 to 1.11 women
0.13 0.02 to 0.77 both
Not defined mortality 0.72 (HR) 0.58 to 0.89 plasma both Bates 2011
n.r. = not reported
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Date of most recent literature
search
Search strategy Comment
www.cancer.gov 4 Feb 2011 medication: selenium
indication: prevention
Cancerlit Oct 2004 1 selen* OR organoselen*
OR natriumselen*
2 random* OR placebo* OR
clinical trial* OR controlled
trial* OR controlled clinical
trial* OR double blind* OR
single blind*
3 epidemiologic stud*ORco-
hort OR case-control stud* OR
nested case-control* OR case-
control design* OR prospectiv*
4 2 OR 3
5 1 AND 4
Now included in MEDLINE
database
Clinical Contents in Medicine
(CCMed)
4 Feb 2011 selen*ORorganoselen*ORna-
triumselen*
CENTRAL 2013, Issue 1 #1 MeSH descriptor: [Sele-
nium] this term only
#2 MeSH descriptor: [Sele-
nium Compounds] explode all
trees
#3 MeSH descrip-
tor: [Organoselenium Com-
pounds] explode all trees
#4 selen*
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Neo-
plasms] explode all trees
#7 (neoplasm* or cancer* or
tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
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(Continued)
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*)
#8 #6 or #7
#9 #5 and #8
metaRegister of Controlled Tri-
als (mRCT, www.controlled-
trials.com)
4 Feb 2011 selen AND cancer
EMBASE Ovid 2013 week 6 1 selenium/
2 selen*.mp.
3 selenium derivative/
4 methylseleninic acid/
5 methylselenium.mp.
6 exp organoselenium deriva-
tive/
7 1 or 2 or 3 or 4 or 5 or 6
8 exp neoplasm/
9 (neoplasm* or cancer*
or tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*).mp
10 8 or 9
11 7 and 10
12 exp clinical study/
13 crossover procedure/
14 double-blind procedure/
15 single-blind procedure/
16 cohort analysis/
17 observational study/
18 (random* or factorial* or
crossover* or cross-over* or
cross over* or placebo* or (dou-
ble adj blind*) or (singl* adj
blind*) or assign* or allocat*
or volunteer* or observ* or co-
hort* or prospectiv* or (case*
and control*)).mp
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(Continued)
19 12 or 13 or 14 or 15 or 16
or 17 or 18
20 11 and 19
21 (exp animal/ or nonhuman/
or exp animal experiment/) not
human/
22 20 not 21
key:
[mp=
title, abstract, subject headings,
headingword, drug trade name,
original title, device manufac-
turer, drug manufacturer, de-
vice trade name, keyword]
GermanCancer StudyRegister:
www.studien.de
4 Feb 2011 selen
MEDLINE (via Ovid) Feb 2013 week 1 1 Selenium/
2 exp Selenium Compounds/
3 exp Organoselenium Com-
pounds/
4 selen*.mp.
5 1 or 2 or 3 or 4
6 exp Neoplasms/
7 (neoplasm* or cancer*
or tumor* or tumour* or car-
cino* or malignan* or ade-
nocarcinoma* or sarcoma* or
adenoma* or chondrosarcoma*
or fibrosarcoma* or dermatofi-
brosarcoma* or neurofibrosar-
coma* or hemangiosarcoma*
or leiomyosarcoma* or liposar-
coma* ormyosarcoma* or rhab-
domyosarcoma* or myxosar-
coma* or osteosarcoma* or lym-
phoma*).mp
8 6 or 7
9 5 and 8
10 randomized controlled trial.
pt.
11 controlled clinical trial.pt.
12 randomized.ab.
13 placebo.ab.
14 drug therapy.fs.
15 randomly.ab.
16 trial.ab.
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(Continued)
17 groups.ab.
18 exp case-control studies/
19 exp Cohort Studies/
20 (cohort* or observ* or
prospectiv* or (case* and con-
trol*)).mp
21 10 or 11 or 12 or 13 or 14
or 15 or 16 or 17 or 18 or 19 or
20
22 9 and 21
23 exp animals/ not humans.sh.
24 22 not 23
key:
mp=title, abstract, original ti-
tle, name of substance word,
subject heading word, keyword
heading word, protocol supple-
mentary concept, rare disease
supplementary concept, unique
identifier
pt=publication type
ab=abstract
fs=floating subheading
SIGLE Oct 2004 ?selen? database discontinued in 2005
Appendix 2. Newcastle-Ottawa Scale for Cohort Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) Selection
1.1) representativeness of the exposed cohort
a) truly representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
b) somewhat representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙ (target population) in the community (*)
c) selected group of users, e.g. volunteers / nurses
d) no description of the derivation of the cohort
1.2) selection of the non-exposed cohort
a) drawn from the same community as the exposed cohort (*)
b) drawn from a different source
c) no description
1.3) ascertainment of selenium exposure
a) secure record (biochemical records) (*)
b) structured interview (*)
c) written self report or medical record only
d) no description
1.4) demonstration that outcome of interest was not present at start of study
a) no history of disease or exclusion of cases that occurred in the first 12 months (*)
b) not stated
2) Comparability
2.1.) comparability of cohorts on the basis of the design or analysis
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a) study controls for AGE (*)
b) study controls for SMOKING (*)
3) Outcome
3.1) assessment of outcome
a) independent blind validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/
hospital records) (*)
b) record linkage (e.g. ICD codes in databases) (*)
c) self report
d) no description
3.2) Was follow-up long enough for outcomes to occur?
a) yes (> 3 years)
b) no
3.3) adequacy of follow up of cohorts
a) complete follow-up of all subjects (*)
OR
b) subjects lost to follow-up unlikely to introduce bias (< 5% lost to follow-up or description provided of lost people) (*)
c) follow-up-rate < 95% and no description of those lost
d) no statement
Appendix 3. Additional Newcastle-Ottawa Scale for Nested Case-Control Studies
((*) means that a ’star’ was assigned to the study for the corresponding item)
1) Selection
1.1) case definition
a) independent validation (> 1 person/record/time/process to extract information or reference to primary source such as X-rays/hospital
records) (*)
b) record linkage (e.g. ICD codes in databases) or self-report with no reference to primary record
c) no description
1.2) representativeness of cases:
a) all eligible cases with outcome of interest over a defined period, cases in a defined catchment area/hospital etc. or an appropriate/
random sample of those cases (*)
b) not satisfying requirements in part (a) or not stated
1.3) selection of controls:
a) community controls (same community and would be cases if had outcome) (*)
b) hospital controls (within the same population e.g. city as cases)
c) no description
1.4) definition of controls
a) cases had no history of outcome controls had no history of outcome OR case had new (not necessarily first) occurrence of outcome
controls with previous occurrence of outcome should not be excluded (*)
b) no mention of history of outcome
2) Comparability
(validated in cohort assessment in question 2 - number of stars was copied)
3) Exposure
3.1) ascertainment of selenium exposure:
(validated in cohort assessment in question 1.3 - number of stars was copied)
3.2) Same method of ascertainment for cases and controls
a) yes (*)
b) no
3.3) non-response rate
a) same rate for both groups (*)
b) non-respondents described
c) rate different and no designation
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F E E D B A C K
Selenium for preventing cancer, 23 November 2011
Summary
Re: Dennert et al., Selenium for preventing cancer, The Cochrane Library, 2011, Issue 5. As selenium scientists with considerable
knowledge of the selenium-cancer field, we wish to draw to the attention of The Cochrane Collaboration the shortcomings of the
recent review cited above. We contend that the quality of this review is not up to the expected standard of Cochrane systematic reviews.
We are not criticising the way in which the analyses were performed, but rather the ways they were interpreted and summarised, which
we believe to be overly negative and rather biased. For these reasons, we find the resulting report to be misleading to the reader. Some
of the weaknesses are listed below.
Abstract and Plain Language Summary:
These sections do not fairly represent the findings of the review. Contrary to the impression given in these summaries, the review itself
demonstrates that there is in fact a considerable body of evidence, much of it from prospective observational studies, for a beneficial
effect of selenium on a number of cancers. The stated summary of RCT findings is more conclusive than it should be, given the very
small number of published clinical trials with selenium alone and the limited trial data that the review authors arbitrarily chose to
consider. Furthermore, the NPCT is treated very harshly, and its secondary findings (lung, colorectal and prostate cancers) are more or
less discounted.
Body of the Paper:
1. Lack of appreciation of the importance of baseline selenium status in influencing trial outcomes (i.e. the fact that only people with
a low selenium status profited from supplementation). For example, no acknowledgement was made of the fact that lack of benefit
of a 200 µg/d dose of selenium for cancer risk in SELECT occurred in participants with relatively high baseline serum selenium
concentrations-well above those found to confer benefit from selenium supplementation in the NPC trial (NPCT). This point was
raised by us previously (Rayman et al. JAMA 2010).
2. Lack of discrimination between trials in which supplementation with selenium had the capacity tomaximise selenoprotein expression/
concentration (e.g. NPCT) and those (e.g. SELECT) in which selenoprotein expression/concentration would already have been
maximised at baseline.
3. Lack of appreciation that, despite the high selenium status of SELECT men, the effects of selenium supplementation on type 2
diabetes risk were not significant.
4. Failure to understand that biomarkers of selenium status are considerably more reliable than dietary data, which we know to be
much more error-prone.
5. Frequent failure to distinguish between significant and non-significant findings.
6. Lack of familiarity with the relevant selenium literature.
7. No mention of oesophageal or gastric cardia cancer results (although RCT results for these are not based on selenium alone) and, in
relation to colorectal cancer, no mention of adenoma data.
8. In ’Implications for research’, no mention is made of the need to carry out randomised controlled trials in low-selenium populations,
nor to take into consideration selenoprotein genotype, which has been shown to affect selenium metabolism. The relevance of the
species of selenium administered in various trials is not mentioned.
Reply
The authorswish to thank the colleaguesDoctorsBrigelius-Flohé,Combs,Davis,Green,Hesketh,Köhrle, Kristal, Rayman, Schomburg,
Taylor, van den Brandt, Waters and Whanger for their detailed commentary on the selenium review.
Their comments captured some of the same concerns that we had regarding the methodological challenges associated with conducting
a systematic review in the field of selenium and cancer.
In response to the commentary, we will first address concerns related to the specific setting of this review as a Cochrane review and will
then respond to concerns regarding the content of the review.
178Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We strongly agree with the concerns that it is difficult to capture all differentiations elaborated on by the review in the abstract and
summary, which are limited to a certain length. Similarly, length limitations were applied to the background section. We also share
the opinion that some headings in the review do not adequately reflect the content of the text that follows. For readers who have
not authored Cochrane reviews themselves, we wish to explain that Cochrane reviews are submitted in an electronic format that does
not allow for all adaptations authors might wish to make. The headings, for example, cannot be changed. This electronic format is
optimised for reviews on intervention studies. Our review included both RCTs and epidemiological studies, and so we encountered
several structural challenges throughout the review process. We hope that both the commentary of our colleagues and our experiences
will contribute to the continuing work of advancing the structural processes of The Cochrane Collaboration, including the electronic
software Review Manager, and to developing a more inclusive format for reviews, which encompasses epidemiological studies.
Has the condensation of information in the abstract and the plain text summary led to a distortion in the presentation of the review
results?
The abstract and the plain text summary present to readers the body of evidence that was reviewed as the main results for both study
questions. Our aim was to report the answers to our research questions, and although space was a limitation for the abstract and
summary results sections, we have endeavoured to provide across the entire review all the best available evidence for the role of selenium
in preventing cancer.
We agree with our colleagues that no studies can be found on the association of selenium with cancer in children or on the preventive
efficacy of selenium supplements in children. Hence, as stated in the abstract, there is currently no convincing evidence that selenium
supplementation may prevent cancer in children. However, we are completely happy not to mention children in the abstract if this
may be considered misleading.
We agree with our colleagues that long-term supplementation is more likely than short-term supplementation to influence cancer risk,
if any effect exists. The minimum of four weeks has been chosen arbitrarily. However, no consistent current agreement has indicated
where to draw the line between short-term and long-term selenium supplementation, so any cutoff would be arbitrary to some extent.
In addition, we wished to avoid making assumptions about supplementation effects in our inclusion criteria and decided rather to
address the question of the effect of shorter supplementation periods in the review discussion, if any trial would have been identified.
To our knowledge, there is currently no universal recommended daily allowance for selenium intake or upper tolerable level; therefore
recommending a selenium dose or level of safe intake would not be appropriate in this instance. This is clearly an area for further
research, taking into account some of the potential influencing factors cited in our review (e.g. baseline levels, gender, population,
source). We would like to thank the commentators for the hint to the RNI (reference nutrient intake) values for selenium in the UK,
which we are happy to include in a future update of the review. Nevertheless, regarding the RNI, we would like to draw attention to the
latest draft of a position paper on selenium by the Scientific Advisory Committee on Nutrition (2011), which notes “that the selenium
dietary reference value was set on very limited data and could be set too high” (p74).
Dr Brigelius-Flohé and colleagues commented that “Quoted recommendations such as 30 and 40 µg/d for men and women (WHO
2004) are no longer credible to anyone with up-to-date knowledge of the endpoints and biomarkers (SePP, GPx activity) that we have
in 2011. There is no justification for quoting the Vinceti 2009a opinion that 20 µg/day organic selenium should be the maximum safe
level.”
The suggestion of an upper safe limit of organic selenium of 20 µg/d was made by Vinceti et al. on the basis of preliminary results of
the ORDET study (Vinceti 2009b), published in 2010 (Stranges 2010), and of other studies (please see for a review Vinceti 2009a).
The recent availability of new data on endocrine (Lippman 2009; Stranges 2007) and dermatological (Lippman 2009) toxicity of low
doses of organic selenium adds new findings supporting the recommendations by the WHO Group. We would like to draw attention
to other recent studies on selenium toxicity (reviewed by Vinceti 2009a and Nogueira/Rocha 2011) and the issue of risk assessment
of selenium (including the use of uncertainty factors (UF) or alternative approaches) (Aggett 2010; Douron 2010; Renwick 2006;
Renwick/Walker 2008).
The diverse recommendations and the controversial discussions clearly underline the need for a systematic review in this field.
To address our research question-What evidence exists on the efficacy of selenium supplementation for cancer prevention?-we restricted
our focus to RCTs with mono-selenium supplementation. Multicomponent interventions, such as those chosen in the SU.VI.MAX,
involve several nutritional/antioxidant supplements (e.g. 120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100
µg of selenium, and 20 mg of zinc in SU.VI.MAX), some of which are reportedly thought to have a potentially synergistic effect
with selenium (Willett 1983); others may act as antagonists (Schrauzer/White/Schneider 1977) or may have an unknown biological
interaction. Although all these factors are important considerations for the overall efficacy of selenium in the long term, we thought
that inclusion of these studies in attempts to elucidate an actual anticarcinogenic role for selenium in its own right could potentially
conceal the true effects (positive or negative) of selenium. By including the four studies that were mentioned in the commentary, which
used multicomponent interventions, we may have gained numbers but lost out in trying to elucidate the actual effects of selenium.
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Therefore, these RCTs, which use selenium in combination with other nutritional factors, were outside the scope of the current review
process but have been addressed in the background and discussions and could be the focus of future valuable investigations.
To avoid any potential preferential and non-systematic selection of studies and hence results, we established a set of a priori inclusion
criteria during the initial stages of the study design. These were outlined in the protocol of the review, which has been available on The
Cochrane Library website and for comment since 2005.
The details of all selenium supplementation have been reported for each RCT, including the form of selenium when available, and
we emphasised the importance of carefully evaluating the different biological activity and toxicity of each selenium compound. Please
refer to the plain language summary: “In general there are two types of selenium supplements: one type uses the salt of selenium as the
main ingredient, the other type uses organic selenium. These two types may act differently in the human body when ingested,” and
in the RCTs and preventive efficacy section: “Interpretation of the results of clinical trials using selenium supplements should consider
the different biological forms as well as their potential differential health effects when supplemented”; and please refer to the table
Characteristics of included studies, for details on each RCT.
References are made throughout the review text to the baseline selenium status of study participants and potential interactions with
study results. Please refer to Section 2.3. Adverse effects, “The RR for developing type II diabetes mellitus was higher in the participants
in the upper two tertiles of plasma selenium levels, indicating a possible interaction with baseline exposure status”, for instance, or
page 38 in our review: “SELECT participants had a higher selenium level at randomisation than men in the NPCT. While the mean
plasma selenium concentration was 113 to 114 µg/l in the NPCT, median serum concentration was 135 to 138 µg/l in the different
study arms in SELECT. Lower prostate cancer incidence in the NPCT trial was confined to men with baseline selenium levels in the
lower two thirds (below 121 µg/l). Subgroup analyses of the SELECT trial are underway to investigate a possible modification by pre-
intervention selenium levels“.
Regarding the findings of NPCT and SELECT for type 2 diabetes, we would like to refer our readers to Section 2.3. Adverse effects, “A
statistically non-significant increase in diabetes mellitus type II in the selenium-alone group (HR 1.07 (99% CI 0.94: 1.22)) was seen.
An increased risk for diabetes mellitus type II was also observed in the NPCT (Stranges 2007, in: NPCT 1996). A secondary analysis
of participants who did not have diabetes at start of the study revealed an excess risk in the selenium group (adjusted HR 1.55 (95% CI
1.03 to 2.33))”. We have previously outlined the section that referred to the fact that selenium baseline levels were higher in this group
and would like to cite the original paper by Stranges et al. (2007), which stated: “Despite the lack of statistically significant interactions
between treatment group and baseline co-variates, the risk for type 2 diabetes was consistently higher in the selenium group within all
subgroups of baseline age, sex, smoking
status, and BMI.” (p220). Regarding the issue of a potential diabetogenic effect of selenium supplements and gender, we would like
to draw attention to a recent observational cohort study by Stranges (2010), which documented an excess risk of diabetes among a
large cohort of women from Varese, Northern Italy. Such a diabetogenic effect of selenium is also supported by suggestive laboratory
evidence, recently reviewed by Steinbrenner al. (2011).
Lippman et al. (2009) stated in their publication about the SELECT trial: “The data and safety monitoring committee had some
concern over the statistically non-significant increase in prostate cancer in the vitamin E-alone group (P=.09 per interim data of August
1, 2008) and over a non-significant increase in diabetes mellitus associated with selenium (P=.08 per interim data of August 1, 2008)”
(p45).
The observation from SELECT (Klein 2011) that the effect diminished over time may suggest exactly the opposite to that hypothesised
by Dr Brigelius-Flohé and colleagues. A decrease in the diabetogenic effect of selenium administration over time after interruption
of such administration may well indicate a decreasing adverse effect over time, as expected, of a causal association. This was what
occurred in the SU.VI.MAX study, in which administration of selenium/vitamins C-E/beta-carotene/zinc led to an excess incidence of
skin cancer, including melanoma (Hercberg 2004), which entirely disappeared after interruption of the intervention (Ezzedine 2010).
The investigators interpreted such decreasing risk as an indication of the causal effect of the treatment of skin cancer and the origin of
melanoma (Ezzedine 2010).
Regarding the interaction of baseline PSA levels with selenium effects in the NPCT, we would like to quote the original publication:
“The protective effect of SS [selenium supplements; GD] appeared to be confined to those with a baseline PSA level of <= 4 ng/
mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant“ (p608, Duffield-Lillico
2003a). To summarise, no statistically significant interaction was noted between baseline PSA levels and prostate cancer incidence, as
reported by the study authors.
Dr Brigelius-Flohé highlighted a sentence on page 4 that might be misunderstood if taken out of its context (“risk ratios (RRs) with
confidence intervals (CIs) were not calculated because of low numbers”). Our colleagues rightly stated that Hercberg et al. (2004)
provided hazard ratios for cancer incidence by gender. However, the sentence our colleagues quoted from our review reads in the context
as follows: “In the more recent French SU.VI.M.AX trial (Hercberg 2004), a supplementation with beta-carotene, vitamin C, vitamin
E and 100 µg selenium-enriched yeast did not alter the incidence of cancer of the digestive tract after a median period of 7.5 years in
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women. In men, the incidence rate was lower in the intervention group than in the placebo group, but risk ratios (RRs) with confidence
intervals (CIs) were not calculated because of low numbers”. The part of the sentence our colleagues cited about the men’s incidence
rate refers to cancer of the digestive tract. Site-specific cancer rates were not calculated or reported by gender: “We were not able to
analyze differences in site-specific cancers between men and women because of low statistical power” (p2340, Hercberg 2004).
Our colleagues highlighted another sentence on page 39: “Results from two randomised controlled trials (NPCT and SELECT) have
failed to provide evidence that non-melanoma skin cancer or prostate cancer can be prevented by selenium supplementation in men”.
This statement refers to the primary study outcomes of both investigations, which were non-melanoma skin cancer in NPCT and
prostate cancer in SELECT, and is correct. Contrary to what was stated by Dr Brigelius-Flohé and colleagues, the outcome measures in
the NPCT were incident basal cell carcinomas and squamous cell carcinomas, and recurrent skin tumors were excluded from analysis,
as summarised in the report of the primary NPCT endpoint by Duffield-Lillico et al. (2003b). We clearly stated in our review that the
NPCT was carried out among non-melanoma skin cancer participants at baseline.
Our conclusions have been based on the available evidence, and we have highlighted the paucity of literature and data available
from RCTs. Please refer to the ’Implications for research’ section: “Potential differential effects of sex/gender and the use of selenium
supplements in populations with a high burden of specific types of cancer diseases and differing selenium exposure levels, e.g. known
low nutritional selenium intake, require further examination”.
Dr Brigelius-Flohé and colleagues have also expressed concerns regarding our inclusion criteria for epidemiological studies and the ways
results of epidemiological studies were included and presented in the systematic review.
In reply to their concern, we might have omitted three relevant studies for gastrointestinal cancers; we would like to refer them to the
detailed references to both studies, Mark 2000 andWei 2004, throughout the review. The Steevens (2010) study has not been included,
as it was not available at the time of our review process and submission to The Cochrane Collaboration Group (please refer to Methods
section, Search strategy). As reported in Section 1.1.6 of the review, the strength of association varied according to what was included
in analyses (e.g. cardia vs non-cardia cancers, gender), thus preventing any clear and concise conclusion to be drawn between selenium
levels and upper gastrointestinal cancers in the observational summary results.
As we understood the publications Wei 2004 and Mark 2000, Wei 2004 reports on a population that was part of the population at risk
in Mark 2000. Participants in Wei 2004 were the disease-free controls for the cases of Mark 2000. Because of this overlap, we decided
to report the papers jointly and put emphasis on the detailed description of both papers and their study populations (please refer to
the Characteristics of included studies).
Dr Brigelius-Flohé and colleagues criticised inclusion in the review of observational studies assessing selenium exposure as intake (e.g.
with food frequency questionnaires).
Regarding the problems associated with dietary assessment, please refer to the section ’Bias and confounding’: “Assessment of total
selenium intake from food-frequency questionnaires (FFQ) or interviews has proven difficult in other investigations because of the lack
of food composition data which adequately reflects regional and seasonal variations in selenium concentration”. Additionally, “The
FFQ overestimated the mean selenium intake in study participants when compared with laboratory analyses of duplicate meals” and
”Validity problems, possibly leading to misclassification, have also been reported when questionnaires are used to assess supplement
use”.
However, studies using dietary assessment add a valuable perspective to the discussion of the relationship between selenium exposure
and cancer risk. Furthermore, in addition to the literature cited by Dr Brigelius-Flohé, other studies (van den Brandt PA et al, 1993;
Longnecker et al., 1996; Haldimann et al., 1996) have reported a direct correlation between dietary and body selenium (please also see
for a review of this topic Vinceti et al. 2000b and Vinceti et al. in press).
We consider the issue of selenium exposure assessment to be more complex than has been implicated by our colleagues´ comments.
Assessment of selenium intake, despite the difficulties associated with its variability and possible individual variability in absorption, in
some cases might even yield better estimates of actual exposure compared with biomarkers. This adds an important perspective to the
discussion of why several observational studies have suggested a protective effect of higher selenium exposure towards cancer risk and
others have not.
With regard to toxicity, animal studies have demonstrated that the intake of equivalent amounts of selenium, when administered in
different species, might induce a stronger effect even when retained to a lesser extent (Panter et al., 1996), as shown for the inorganic
compounds. The wealth of toxicological data from laboratory studies is clearly and, for obvious ethical reasons, much greater than those
yielded by human studies. The same is true for studies investigating tissue distribution and biological activity of the different selenium
compounds (see: Hatfield/Berry/Gladyshev 2012). We consider references to laboratory and animal studies as a necessary and valuable
contribution to the understanding of selenium effects in humans.
Dr Brigelius-Flohé and colleagues asked why our summary of the findings of the review of Ashton (2009) on the use of biomarkers for
seleniummeasurement did not mention singular nucleotide polymorphisms (p34 in our review).We summarised the findings of Ashton
2009 that were relevant for the discussion of bias and confounding in our review. Genetic polymorphisms were not included in the
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analyses of heterogeneity between study results by Ashton (2009). Instead, Ashton et al. proposed singular nucleotide polymorphisms in
their discussion as an area for future research and stated: “Also, for all potential biomarkers, more information is needed to understand
the limitations of applicability for different population groups, the possible effects of genotype, supplementation doses, duration,
baseline status, etc” (p2037S).
The criticism that we failed to distinguish between significant and non-significant findings in epidemiological studies points to
a fundamental difference in the interpretation of epidemiological study results. Indeed, we consider ‘statistical’ significance as an
inappropriate approach to data analysis and interpretation with regard to observational studies, as has been long recognised (RothmanKJ
1978; Sterne/Davey Smith 2001; Greenland 2011), with no connection with ‘biological significance’. Pitfalls of statistical significance
testing encompass dismissing so called ‘non-significant values´ in small studies or putting undue emphasis on ‘statistically significant’
results without attempting to integrate potential biases for a study finding that would affect the estimates from that study (see: e.g.
Rothman, Greenland & Lash 2008; Stang/Poole/Kuss 2010). This may lead to confusion between the validity of an investigation and
its statistical stability.
Analysis and interpretation of results in biomedical research must be based on a number of considerations, comprising both study
design and data analysis. We made a conscious effort in our selenium review to avoid use of an approach that dichotomised study results
according to which were statistically significant and which were not. We consider this effort a major strength of our review.
We have attempted to be prudent with our conclusions by highlighting important considerations associated with the results of
epidemiological studies that we reported. Both the current literature and our review indicate that although some associations have been
noted between selenium levels and risk of cancer at certain body sites (e.g. prostate, bladder), more research and information are clearly
required before it can be concluded that these results are “convincing” for a protective effect of selenium. The World Cancer Research
Fund’s Second Expert Report (2007) also suggests the possibility of residual confounding between selenium levels and healthy lifestyles
(p109).
We admit that the sentence about themarketing situationof selenium in our discussion section expresses a valuation, andwe acknowledge
that other colleagues might assess the marketing situation differently and as such might disagree with this sentence.
In the last part of our reply, we will address the concerns by Dr Brigelius-Flohé and colleagues regarding the content of the background
section of the review.
The reference Rodriguez 1995, which is listed in the MEDLINE database, in contrast to what our colleagues stated (please refer to
PubMed ID 7605824), is an early study that investigated urinary selenium in healthymen and women and addressed the study question
of the relationship between factors such as gender/sex, etc., and urinary selenium. It found gender/sex differences in urinary selenium
excretion, as well as influences of health behaviours (physical activity), as stated in our background text.
We do not agree that studies investigating primarily the relationship between selenium status, thyroid volume and gland echostructure
(Derumeaux 2003) or the relationship between baseline plasma selenium concentration and occurrence of dysglycaemia (Akbaraly
2010) would have been more suitable references for the statement that we made regarding gender differences.
We also would like to recapitulate the Vinceti et al. (2000a) paper because we feel that Dr Brigelius-Flohé and colleagues misreported
the methods and findings of this study. The Vinceti et al. studies in an unusual Northern Italy setting evaluated the health effects
of selenium in its inorganic hexavalent form-the one usually found in underground and drinking water-together with the tetravalent
species (Vinceti 2010). This study was a ‘natural experiment’, considered to be ‘the paradigm of non-experimental epidemiologic
research’, as in this type of study, ‘nature emulates the sort of experiment the investigator might have conducted, but for ethical and
cost constraints’ (p94, Rothman/Greenland/Lash 2008). Study authors assessed the potential for confounding by lifestyle by assessing
the socioeconomic status of exposed and unexposed cohorts, and labeling this study as a natural experiment was allowed only after the
similarity of the two populations was confirmed. Dr Brigelius-Flohé stated that Vinceti et al. admitted that their results are consistent
with “no effect”, as standardised mortality ratios were generally inconsistent between men and women at most sites, and most site-
specific estimates had limited precision. The citation in the original publication reads: “The results of our study are consistent with either
no effect or, particularly among the elderly, unfavourable effects of long-term exposure to inorganic selenium on cancer mortality”.
Then Vinceti et al. analyzed the strengths and limitations of their study, both for the melanoma association and more generally for the
effects on cancer risk. Excess melanoma risk, despite different study designs and strengths of association, has been documented to be
associated with selenium exposure in a number of studies (Garland 1995; Vinceti 1998; Duffield-Lillico 2002; Vinceti et al., in press)
and has been causally associated with administration of selenium in combination with zinc and vitamins in SU.VI.MAX (Hercberg
2007). In general, we would like to propose caution when dealing with the possible selenium-melanoma association.
In conclusion, we express our appreciation to our commentators for scrutinising our review, offering their criticisms and supporting the
scientific endeavour of enclosing epidemiological as well as intervention studies in a Cochrane review. We are hopeful that the review
and the commentary of our colleagues will contribute to the important and continuing discussion about the health effects of selenium
and selenium supplements globally and in diverse populations.
1. Aggett PJ. (2010). Toxicity due to excess and deficiency. J Toxicol Environ Health A: 73(2):175-80.
182Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Akbaraly TN, Arnaud J, Rayman MP, Hininger-Favier I, Roussel AM, Berr C, Fontbonne A. (2010). Plasma selenium and risk
of dysglycemia in an elderly French population: results from the prospective Epidemiology of Vascular Ageing Study. Nutr Metab 18:
21. Electronic publication: doi:10.1186/1743-7075-7-2.
3. Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, Fairweather-Tait SJ. (2009). Methods of assessment of selenium status in
humans: a systematic review. Am J Clin Nutr 89(6):2025S-39S.
4. Derumeaux H, Valeix P, Castetbon K, Bensimon M, Boutron-Ruault MC, Arnaud J, Hercberg S. (2003). Association of
selenium with thyroid volume and echostructure in 35- to 60-year-old French adults. Eur J Endocrinol 148(3):309-15.
5. Douron M. (2010). U-shaped dose-response curves: implications for risk characterization of essential elements and other
chemicals. J Toxicol Environ Health A 73(2):181-6.
6. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, et al. (2002). Baseline characteristics and
the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional
Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11(7):630-9.
7. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. (2003a). Selenium supplementation,
baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional
Prevention of Cancer Trial. BJU Int 91(7):608-12.
8. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. (2003b). Selenium supplementation
and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst Cancer Spectrum 95(19):1477-81.
9. Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D. (2010). Incidence of skin cancers during 5-
year follow-up after stopping antioxidant vitamins and mineral supplementation. Eur J Cancer 46(18):3316-22.
10. Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, et al. (1995). Prospective study of toenail selenium
levels and cancer among women. J Natl Cancer Inst 87(7):497-505.
11. Greenland S. (2011). Null misinterpretation in statistical testing and its impact on health risk assessment. Preventive Med 53:
225-228.
12. Haldimann M, Venner TY, Zimmerli B. (1996). Determination of selenium in the serum of healthy Swiss adults and correlation
to dietary intake. J Trace Elem Med Biol 10(1):31-45.
13. Hatfield DL, Berry MJ, Gladyshev VN (Editors). (2012). Selenium. Its Molecular Biology and Role in Human Health. 3rd
edition. Springer, New York, 2012, and springer ebooks: 10.1007/978-1-4614-1025-6.
14. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briançon S. (2004). The SU.VI.MAX
Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 164(21):
2335-42.
15. Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, Estaquio C, Briancon S, Favier A, Latreille J, Malvy D.
(2007). Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 137:2098-2105.
16. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano
JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr,
Baker LH. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
JAMA 306:1549-56.
17. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. (2009). Effect of selenium and vitamin E on
risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39-51.
18. Longnecker MP, Stram DO, Taylor PR, Levander OA, Howe M, Veillon C, et al. (1996). Use of selenium concentration in
whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 7(4):384-90.
19. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al. (2000). Prospective study of serum selenium levels and
incident esophageal and gastric cancers. J Natl Cancer Inst 92(21):1753-63.
20. Nogueira CW, Rocha JB. (2011). Toxicology and pharmacology of selenium: emphasis on synthetic organo-selenium
compounds. Arch Toxicol 85(11):1313-59.
21. Panter KE, Hartley WJ, James LF, Mayland HF, Stegelmeier BL, Kechele PO. (1996). Comparative toxicity of selenium from
seleno-DL-methionine, sodium selenate, and Astragalus bisulcatus in pigs. Appl Toxicol 32(2):217-23.
22. Renwick AG. (2006). Toxicology of micronutrients: adverse effects and uncertainty. J Nutr 136:493S-501S.
23. Renwick AG, Walker R. (2008). Risk assessment of micronutrients.Toxicol Lett 180(2):123-30.
24. Rothman KJ (1978). A show of confidence. N Engl J Med 299:1362-3.
25. Rothman KJ, Greenland S, Lash TL. (2008). Modern Epidemiology. Philadelphia: Lippincott Williams & Wilkins.
26. Schrauzer GN, White DA, Schneider CJ. (1977). Cancer mortality correlation studies-IV: associations with dietary intakes and
blood levels of certain trace elements, notably Se-antagonists. Bioinorg Chem 7(1):35-56.
183Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
27. Scientific Advisory Committee on Nutrition. (2011). Paper for discussion: Draft Selenium and Health position statement, 19/
10/11. http://www.sacn.gov.uk/pdfs/sacn1113˙sacn˙selenium˙and˙health˙position˙paper.pdf (accessed on 20 December 2011).
28. Stang A, Poole C, Kuss O. (2010). The ongoing tyranny of statistical significance testing in biomedical research. Eur J
Epidemiol 25:225-30.
29. Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. (2010). Selenium status and the risk of esophageal and gastric
cancer subtypes: the Netherlands cohort study. Gastroenterology 138(5):1704-13.
30. Steinbrenner H, Speckmann B, Pinto A, Sies H. (2011). High selenium intake and increased diabetes risk: experimental
evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr 48(1):40-5.
31. Sterne JA, Davey Smith G. (2001). Sifting the evidence-what’s wrong with significance tests? BMJ 322:226-31.
32. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. (2007). Effects of long-term selenium
supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147:217-23.
33. Stranges S, Sieri S, Vinceti M, Grioni S, Guallar E, Laclaustra M, Muti P, Berrino F, Krogh V. (2010). A prospective study of
dietary selenium intake and risk of type 2 diabetes. BMC Public Health 10:564. http://www.biomedcentral.com/1471-2458/10/564.
34. van den Brandt PA, Goldbohm RA, vant´ t Veer P, Bode P, Hermus RJ, Sturmans F. (1993). Predictors of toenail selenium levels
in men and women. Cancer Epidemiol Biomarkers Prev 2(2):107-112.
35. Vinceti M, Rothman KJ, Bergomi M, Borciani N, Serra L, Vivoli G. (1998). Excess melanoma incidence in a cohort exposed to
high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 7(10):853-6.
36. Vinceti M, Nacci G, Rocchi E, Cassinadri T, Vivoli R, Marchesi C, et al. (2000a). Mortality in a population with long-term
exposure to inorganic selenium via drinking water. J Clin Epidemiol 53(10):1062-8.
37. Vinceti M, Rovesti S, Bergomi M, Vivoli G. (2000b). The epidemiology of selenium and human cancer. Tumori 86(2):105-18.
38. Vinceti M, Maraldi T, Bergomi M, Malagoli C. (2009a). Risk of chronic low-dose selenium overexposure in humans: insights
from epidemiology and biochemistry. Rev Environ Health 24(3):231-48.
39. Vinceti M, Stranges S, Sieri S, Grioni S, Malagoli C, Muti P, Berrino F, Krogh V. (2009b). Association between high selenium
intake and subsequent increased risk of type 2 diabetes in an Italian population. ISEE 2009 Conference Abstracts Supplement;
Epidemiology: 20: S47.
40. Vinceti M, Bonvicini F, Rothman KJ, Vescovi L, Wang F. (2010). The relation between amyotrophic lateral sclerosis and
inorganic selenium in drinking water: a population-based case-control study. Environ Health 6:77. Electronic citation: doi 10.1186/
1476-069X-9-77.
41. Vinceti M, Crespi CM, Malagoli C, Bottecchi I, Ferrari A, Sieri S, Krogh V, Alber D, Bergomi M, Seidenari S, Pellacani G. (in
press). A case-control study of the risk of cutaneous melanoma associated with three selenium exposure indicators. Tumori.
42. Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Sun XD, et al. (2004). Prospective study of serum selenium
concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutri 79(1):80-5.
43. Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider K, Hames CG. (1983). Prediagnostic
serum selenium and risk of cancer. Lancet 2(8342):130-4.
44. World Cancer Research Fund International. (2007). Food, Nutrition, Physical Activity, and the Prevention of Cancer. A Global
Perspective. Washington, DC: AICR.
45. World Health Organization (WHO). (2004). Joint FAO/WHO Expert Consultation on Human Vitamin, Mineral
Requirements. (1998: Bangkok, Thailand). Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO
expert consultation, Bangkok, Thailand, 21-30 September 1998. http://whqlibdoc.who.int/publications/2004/9241546123.pdf
(accessed on 23 January 2011).
Contributors
Professor Regina Brigelius-Floh, Professor GF Combs Jr, Dr Cindy D Davis, Dr Fiona R Green, Professor John Hesketh, Professor
Josef Köhrle, Dr Alan Kristal, Fred Hutchinson, Professor Margaret P Rayman, Professor Lutz Schomburg, Phil Taylor, Piet van den
Brandt, Professor David J. Waters, Professor Phil Whanger.
Maree Brinkman, Gabriele Dennert and Marco Vinceti on behalf of the review authors.
184Selenium for preventing cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Further discussion on ’Selenium for preventing cancer’
Summary
We are pleased with your positive response to our concerns and the expressed willingness of the review authors to make changes as
appropriate. In particular, we welcome the following proposed modifications.
• A more accurate (and longer) abstract and plain language summary to take account of the concerns we specified in our letter and
in the first of our “General criticisms”.
• Modification of the review by ensuring that differences in baseline selenium exposure between trials are clarified and placed in
the proper context.
• More careful use of language in relation to statistical significance, as, for instance, in the two examples you cite in your letter.
The preferred form you quote is much better than the misleading use of “lower” or “higher” for “non-significant” effects, as occurred
frequently in the review.
• Removal of constraints on the use of section headings so that more appropriate headings can be used.
There is little point in revisiting all of our criticisms as they were clearly set out in our original letter and document, and most still
stand. We would like to see the review amended as soon as possible to take account of those criticisms and specifically to correct the
inaccuracies that we have noted. The review authors have replied with a number of points that we would like to challenge.
• p2: Re the suggestion of an upper safe limit of organic selenium of 20 µg/d by Vinceti et al., the authors now justify the original
inclusion of that statement on the basis of a study (ORDET) based on a semiquantitative FFQ at baseline and follow-up for
development of type 2 diabetes 16 years later. Based on that same study (p4), the authors refer to “Such a diabetogenic effect of
selenium….”. A prospective study, especially one with a very weak study design such as ORDET, can only show an association-
hardly a good basis for making such a statement in a Cochrane review. Furthermore, an upper safe limit of organic selenium of 20 µg/
d would be just above that at which Keshan disease is seen-11 µg/d in a Chinese man, which translates to 14 µg/d in a man of
Western body weight.[1]
• p2: The authors say, “The recent availability of new data about endocrine (Lippman 2009; Stranges 2007) and dermatologic
(Lippman 2009) toxicity of low doses of organic selenium adds new findings which support the recommendations by the WHO
group.” The authors seem still not to have taken on board the fact that Lippman et al. 2009 doesnot show any endocrine toxicity of
selenium. Furthermore, the dose given-200 µg/d-was not low.
• p4: Diminution of the effect on type 2 diabetes over time. Proper interpretation of SELECT is that there was a null result during
the trial (RR 1.07, P value 0.16) and a similarly null result with postintervention follow-up time included (RR 1.04, P value 0.34). If
trial-only data versus post-trial-only data were compared, it is probably unlikely that there would be any difference statistically.
However, we do understand the point the review authors make: Interpretation depends on how one thinks selenium acts. If we were
talking about an effect that occurred immediately after starting a drug (e.g. platelet effect of aspirin, blood pressure reduction from
antihypertensive) and stopped more or less immediately after cessation of the drug, then the review authors’ interpretation would
have better credibility.
• In contrast to the week or so that the effect of aspirin on platelets lasts, selenomethionine has a long half-life of 252 d [363 d
(turnover time) × 0.693 (from kinetic modelling)] (Swanson et al. AJCN 1991, 54:917-26). In medicine, when calculating dosing
intervals for drugs, it is typical to give doses every five to six half-lives. When first-order kinetics is applied, five half-lives for total
body selenium is 1260 days (3.45 years), and six half-lives is 1512 days (4.14 years). Although it is true that the amount of the
original dose still remaining is small after five (6.25%) or six (3.13%) half-lives, excess residual selenium remains from the
supplementation. So, on the basis of both observed effects with cancer and pharmacokinetic data, the events that occurred in the
post-trial period for SELECT participants (34 additional months) should still be considered a period of selenium exposure and
thereforeincompatible with the review authors’ hypothesis.
• p6: We hotly dispute the assertion of the review authors (none of whom is a nutritionist) that “The assessment of selenium
intake, despite the difficulties associated to its variability and the possible individual variability in absorption, in some cases might
even yield better estimates of actual exposure compared with biomarkers”.
• p7: Gender differences: The Schomburg references would have been preferable; Schomburg is the accepted authority in this area.
We very much hope that our original comments and those contained in this letter will help the review authors, guided by the editors,
to revise the review, so that it sits more comfortably with the opinion of experienced researchers in the selenium-cancer field.
Yours sincerely,
Professor Regina Brigelius-Flohé, University of Potsdam, German Institute of Human Nutrition
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Professor GF Combs Jr, Grand Forks Human Nutrition Research Center, ARS/USDA, USA
Dr Cindy D Davis, Office of Dietary Supplements, NIH, USA
Dr Fiona R Green, Reader in Functional Genomics, University of Surrey, UK
Professor John Hesketh, Institute for Cell & Molecular Biosciences, University of Newcastle, UK
Professor Josef Köhrle, Charité Universitätsmedizin Berlin, Germany
Dr Alan Kristal, Fred Hutchinson Cancer Research Center, Seattle, USA
Professor Margaret P Rayman, Faculty of Health and Medical Sciences, University of Surrey, UK
Professor Lutz Schomburg, Charité Universitätsmedizin Berlin, Germany
Dr Phil Taylor, Division of Cancer Epidemiology and Genetics, NCI, USA
Professor Piet van den Brandt, Department of Epidemiology, Maastricht University, The Netherlands
Professor David J Waters, Purdue University, USA
Professor Phil Whanger, Oregon State University, USA
[1] National Academy of Sciences, Institute ofMedicine’s Food and Nutrition Board, Dietary Reference Intakes for Vitamin C, Vitamin
E, Selenium and Carotenoids.
http://fnic.nal.usda.gov/nal˙display/index.php?info˙center=4&tax˙level=4&tax˙subject=256&topic˙id=1342&level3˙id=5141&
level4˙id=10591.
Reply
We would like to thank Drs Brigelius-Flohé and colleagues for their continuing interest in our research activity on selenium.
We decided to shortly respond to some of their discussion points (citations from Dr Brigelius-Flohé et al are provided in italics):
• “more careful use of language in relation to statistical significance as, for instance, in the two examples you cite in your letter. The
preferred form you quote is much better than the misleading use of “lower” or “higher” for “non-significant” effects as occurred frequently in
the review”
Dr Brigelius-Flohé and colleagues do not acknowledge the limitations of their approach based on ‘statistical significance’ (please refer to
the references provided in our previous reply). Their approach appears to have had major consequences for a number of considerations
and statements in their two letters. It is of interest to note that even the SELECT “Data and Safety Monitoring Committee” expressed
its concern “over a non-significant increase in diabetes mellitus associated with selenium (P = 0.08 per interim data of August 1, 2008)”
(cited from Lippman et al., JAMA 2009), which we consider a very correct approach given the decision-making responsibility of such
a Committee.
“The authors have replied with a number of points that we would like to challenge“
• p2: ”Re the suggestion of an upper safe limit of organic selenium of 20 µg/d by Vinceti et al., the authors now justify the original
inclusion of that statement on the basis of a study (ORDET) based on a semi-quantitative FFQ at baseline and follow-up for development of
type-2 diabetes 16 years later. Based on that same study (p4), the authors refer to “Such a diabetogenic effect of selenium….”. A prospective
study, especially one with a very weak study design such as ORDET, can only show an association-hardly a good basis for making such a
statement in a Cochrane review. Furthermore, an upper safe limit of organic selenium of 20 µg/d would be just above that at which Keshan
Disease is seen-11 mg/d in a Chinese man, which translates to 14 µg/d in a man of Western body weight.
As written in our original response, the suggestion of a safe upper limit of 20 µg/L was based on the ORDET study results already
availableand published as an abstract in Epidemiology in 2009. Stating that theORDET study, one of the first andmost methodologically
sound European prospective studies, started in the 1980s by the Italian National Cancer Institute in Milan, was ‘weak’ is unacceptable.
Its methodological value has been largely recognised in the scientific community and in the epidemiological literature.
Our review, however, never aimed at summarising the large epidemiological and laboratory literature addressing the issue of safe upper
limit of Se exposure in humans, particularly the most recent studies.
• p2: The authors say, “The recent availability of new data about endocrine (Stranges 2007; Lippman 2009) and dermatologic
(Lippman 2009) toxicity of low doses of organic selenium adds new findings which support the recommendations by the WHO group.” The
authors seem still not to have taken on board the fact that Lippman et al. 2009 shows no endocrine toxicity of selenium. Furthermore, the
dose given-200 mg/d-was not low.
The relation between selenium and excess diabetes risk is an extremely important issue that clearly would require extensive review, but
this was not the aim of our Cochrane review;therefore we would like to refer Dr Brigelius-Flohé and colleagues to themost recent studies
and reviews on the topic. It would also be useful to remind Dr Brigelius-Flohé and colleagues that the SELECT trial found an excess
risk of diabetes, which understandably caused concern for its “Data and safety monitoring Committee” (see above) and contributed to
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the anticipated ending of the trial. We took note that Dr Brigelius-Flohé and colleagues do not consider the SELECT supplemental
dose of 200 mg/Se/d to be a ‘low’ dose; actually, it was so high that it could be toxic.
• p6: “We hotly dispute the assertion of the authors (none of whom is a nutritionist) that “The assessment of selenium intake, despite the
difficulties associated to its variability and the possible individual variability in absorption, in some cases might even yield better estimates of
actual exposure compared with biomarkers”.
Different exposure assessment methods have different advantages and disadvantages. What we stated in our review was, “A concern,
which we cannot clarify to date, is that biomarkers do not adequately reflect intake of both organic and inorganic selenium species”.
We still think there is currently no way of clarifying this.
We were very surprised in reading comments such as ‘None of the authors is a nutritionist’, not just because this is incorrect (one of the
review authors, MB, is an accredited and practicing dietician and nutritionist), but also for the underlying and clearly ‘biased’ concept:
that the right to conduct independent research should be determined by subjective value judgements by one’s peers.
Despite the detailed comments made by Dr Brigelius-Flohé et al regarding key statements we have made and details of the studies we
have identified in preparing the review, we remain convinced that the conclusions drawn from the original version of the review remain
valid: We have not demonstrated a protective effect of selenium against cancer in men, women or children.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the previous Cochrane review, the risk of bias assessment for RCTs, which was introduced by The Cochrane Collaboration after
publication of our protocol, was adapted; the Jadad score and the Delphi list were also used to assess the quality of RCTs, but because
the results of these checklist assessments were of no relevance for this review, they have been omitted.
With respect to the protocol, in this updated review, we decided to perform meta-analysis of RCTs when at least two studies were
available, and to emphasise the analysis conducted for all RCTs and for RCTs at low risk of bias to highlight the most reliable and
recent evidence on the selenium and cancer relation, which comes from well-designed experimental studies. As in the previous version
of the review, we included in our analysis both primary and secondary outcomes of the RCTs.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Case-Control Studies; Neoplasms [∗prevention & control]; Odds Ratio; Randomized Controlled Trials as Topic; Selenium
[∗administration & dosage; adverse effects]; Sex Factors; Trace Elements [∗administration & dosage; adverse effects]
MeSH check words
Female; Humans; Male
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